Document:

Form of Research and Development Collaboration and License Agreement

 Exhibit 10.4 
 FORM OF RESEARCH AND DEVELOPMENT 
 COLLABORATION AND LICENSE AGREEMENT

 THIS RESEARCH AND DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT (the “Agreement”)
is made effective as of [—] (the “Effective Date”), by and between Pfizer Inc., a Delaware corporation having its principal place of business at 235 E. 42nd Street, New York, New York 10017 (“Pfizer”) and
Zoetis Inc., a Delaware corporation having its principal place of business at 235 E. 42nd Street, New York, New York 10017 (the “Company”). Pfizer and the Company are sometimes referred to herein individually as a “Party” and collectively as the
“Parties.” 
 RECITALS: 
 WHEREAS, the Company is in the business of researching, developing, and commercializing pharmaceutical products in the field of animal health; 

WHEREAS, Pfizer has a proprietary compound library and a system of related data and information as further described herein; and

 WHEREAS, in connection with that certain Global Separation Agreement by and between Pfizer and the Company, dated on or about
the date hereof (the “Global Separation Agreement”), the Parties are entering into this Agreement to grant the Company certain rights to access Pfizer’s compound library and systems to research, develop, and commercialize
pharmaceutical products in the field of animal health and to provide Pfizer with rights to the data and information generated by the Company for research, development and commercialization, subject to the terms and as further described herein.

 NOW, THEREFORE, in consideration of the mutual agreements, provisions and covenants contained in this Agreement, the Parties,
intending to be legally bound, hereby agree as follows: 
 1. DEFINITIONS 

 

	1.1	Definitions. For the purpose of this Agreement, the following terms shall have the following meanings: 

“AAA” has the meaning set forth in Section 21.4.1(b). 
 “Action” means any demand, action, suit, countersuit, arbitration, inquiry, proceeding or investigation by or before any federal, state, local, foreign or international Governmental
Authority or any arbitration or mediation tribunal. 
 “Affiliate” of any Person means a Person that controls, is controlled
by, or is under common control with such Person. As used herein, “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such entity, whether through ownership
of voting securities or other interests, by contract or otherwise. It is 

  
 1 

 
expressly agreed that, from and after the Effective Date, solely for purposes of this Agreement (a) no member of the Company Group shall be deemed to be an Affiliate of any member of the
Pfizer Group and (b) no member of the Pfizer Group shall be deemed to be an Affiliate of any member of the Company Group. 

“AIP” has the meaning set forth in Section 6.1. 
 “AIP Compound Series” has the meaning set forth in Section 6.3.2(a). 

“AIP Notice” has the meaning set forth in Section 6.3.2. 
 “AIP Request” has the meaning set forth in Section 6.2.1. 

“Alliance Manager” has the meaning set forth in Section 2.2. 
 “Alliance Manager Escalation Notice” has the meaning set forth in Section 2.1.7. 
 “Analog” means, with respect to a Compound, an analog, derivative, or modification thereof. 
 “Analog Plan” means a reasonably detailed plan that sets forth the Company’s plans to synthesize Analogs. 
 “Ancillary Agreements” has the meaning set forth in the Global Separation Agreement. 
 “Animal Health Company” means any Person that researches, develops, manufactures, markets, distributes, leases and/or sells vaccines, biologics, medicines, diagnostic products,
biodevices, genetic tests and services for the Field and has annual sales of pharmaceutical products in the Field of at least Five Hundred US Million Dollars (US$500,000,000). 
 “Annual Access Fee” has the meaning set forth in Section 9.1.1. 

“Applicable Laws” means all applicable laws, statutes, rules, regulations, and guidelines, including all applicable standards or
guidelines promulgated by any applicable Governmental Authority (including cGCP, cGMP, and cGLP). 
 “Assigned Patent Rights”
has the meaning set forth in Section 18.2.2(c)(ii). 
 “Bankruptcy Code” has the meaning set forth in
Section 20.2.2(a). 
 “Business Combination Transaction” has the meaning set forth in paragraph (b) of the definition
of “Change of Control.” 
 “Business Day” means any day other than a Saturday, Sunday or a day on which banking
institutions are authorized or obligated by Applicable Law to be closed in New York, New York. 
 “Calendar Quarter” means each
successive three (3) calendar month period commencing on January 1, April 1, July 1, and October 1. 

  
 2 

 “Calendar Year” means each successive period of twelve (12) months commencing on
January 1 and ending on December 31. 
 “Candidate Designation Activities” means all research and development
activities in the Field, except for the Restricted Development Activities. 
 “Candidate Designation Phase” has the meaning set
forth in Section 6.6. 
 “Candidate Designation Project” has the meaning set forth in Section 6.6. 

“Candidate Designation Project Team” has the meaning set forth in Section 6.8. 

“Candidate Designation Project Team Member” has the meaning set forth in Section 6.8. 

“Candidate Designee” has the meaning set forth in Section 6.7. 
 “cGCP” means the then current good clinical practice standards promulgated or endorsed by each applicable Regulatory Authority, including the guidelines promulgated by the VICH.

 “cGLP” means the then current good laboratory practice standards promulgated or endorsed by each applicable Regulatory
Authority, including the guidelines promulgated by the VICH. 
 “cGMP” means the then current good manufacturing practice
standards promulgated or endorsed by each applicable Regulatory Authority, including the guidelines promulgated by the VICH. 
 “Change
of Control” means with respect to the Company: 
  

	 	(a)	the acquisition by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended) (a
“Specified Person”) of beneficial ownership (within the meaning of Rule 13d–3 promulgated under the Securities Exchange Act of 1934, as amended); it being understood that “beneficial ownership” shall also include
any securities which any Person or any of such Person’s Affiliates has the right to acquire (whether such right is exercisable immediately or only after the passage of time, pursuant to any agreement, arrangement, understanding, or upon the
exercise of conversion right, exchange rights, warrants or options, or otherwise) of fifteen percent (15%) or more of either (i) the then outstanding common stock of the Company or (ii) the combined voting power of the then
outstanding voting securities of the Company; 

  

	 	(b)	 the entry into by the Company of a definitive agreement relating to, or the consummation by the Company of, any merger, consolidation, reorganization,
restructuring, liquidation, debt adjustment or readjustment or other business combination transaction involving the Company or one of its Subsidiaries (each, a “Business Combination Transaction”), whether or not in connection with a
bankruptcy or court proceeding, unless immediately following such Business Combination Transaction, the individuals and entities who were the beneficial owners of the outstanding common stock and outstanding voting securities of the Company
immediately prior to such Business Combination Transaction, 

  
 3 

	 	
respectively, beneficially own, directly or indirectly (including through one or more holding companies or subsidiaries), more than eighty-five percent (85%) of the outstanding common stock
and the combined voting power of the outstanding voting securities, as the case may be, of the corporation or other entity resulting from such Business Combination Transaction (including a corporation or other entity which as a result of such
transaction owns the then outstanding securities of the Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries); 

 

	 	(c)	the Company or any of its Subsidiaries assigns, sells, licenses or otherwise transfers to any Specified Person(s) (other than Pfizer or its Affiliates), in one or more
related transactions, all or a material portion of the properties or assets of the Company or its Subsidiaries; or 

  

	 	(d)	the individuals who, as of the date that Pfizer ceases to control at least fifty percent (50%) of the outstanding voting securities of the Company with respect to
the election of directors of the Company (the “Reference Date”), constitute the board of directors of the Company (the “Incumbent Board”) ceasing for any reason to constitute fifty percent (50%) or more of the
board of directors of the Company; provided that any individual becoming a director subsequent to the Reference Date whose election, or nomination for election by the Company’s stockholders, was approved by a vote of at least a
majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a
result of (i) an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Specified Person other than the board of
directors of the Company and (ii) any Business Combination Transaction; 

 provided that
notwithstanding anything to the contrary in the foregoing (a) through (d) or elsewhere herein, no Change of Control shall be deemed to have occurred solely by reason of Pfizer distributing to its stockholders any common stock owned by it
following the date of this Agreement pursuant to (x) a dividend or other distribution to Pfizer stockholders or (y) an exchange offer pursuant to which Pfizer exchanges shares of Company common stock for outstanding shares of Pfizer common
stock. 
 “Clinical Development Program” means the conduct of clinical development of a pharmaceutical product for which an IND
has been submitted to the applicable Regulatory Authority pursuant to such IND. 
 “Co-Chairpersons” has the meaning set forth
in Section 2.1.4. 
 “Collaboration” means all activities related to the research, development, manufacture and
commercialization of Compounds and Analogs and pharmaceutical products containing such Compounds and Analogs in the Field performed by or on behalf of Pfizer and its Affiliates and the Company, its Affiliates and its permitted sublicensees (as
applicable) in accordance with, and subject to the terms of, this Agreement and the License Agreements (if any). 

  
 4 

 “Collaboration Employees” means the Company’s JSC Members, the Leveragers, the Lead
Seekers, the Functional Line Senior Scientists, the Lead Seeking Project Team Members, the Candidate Designees, and the Candidate Designation Project Team Members. 
 “Collaboration Improvement” means any improvement or modification of, to or in the Collaboration IP claimed in a Patent Right, which improvement or modification is conceived, reduced to
practice or otherwise developed by or on behalf of the Company, its Affiliates and its permitted sublicensees in connection with exercising the license granted pursuant to Section 20.3.4(a) and such conception, reduction to practice or other
development occurs no later than five (5) years following the earlier of expiration or termination of this Agreement in its entirety; provided that in no event shall Collaboration Improvements include any Pfizer IP. 

“Collaboration IP” means the Collaboration Patent Rights and the Collaboration Know-How. 

“Collaboration Know-How” means all Know-How (whether or not patentable) that is conceived, reduced to practice or otherwise invented or
generated by or on behalf of the Company, its Affiliates or its permitted sublicensees (except to the extent otherwise expressly agreed upon by the JSC or set forth in the applicable notice granting Intent to Access or the AIP Notice) in connection
with the Collaboration; provided that Collaboration Know-How shall not include (a) the Collaboration Patent Rights or (b) any Know-How with respect to formulations of pharmaceutical products, screening methods, assays or
manufacturing processes to the extent solely directed to scale-up for commercial manufacturing (excluding any improvements of, to or in Know-How or Patent Rights licensed to the Company hereunder or under any of the License Agreements). 

“Collaboration Patent Rights” means all Patent Rights that are or may be filed on or that otherwise Cover Know-How that is conceived,
reduced to practice or otherwise invented or generated by or on behalf of the Company, its Affiliates or its permitted sublicensees (except to the extent otherwise expressly agreed upon by the JSC or set forth in the applicable notice granting
Intent to Access or the AIP Notice) in connection with the Collaboration; provided that Collaboration Patent Rights shall not include any Patent Rights that are or may be filed or that otherwise Cover Know-How with respect to
formulations of pharmaceutical products, screening methods, assays or manufacturing processes to the extent solely directed to scale-up for commercial manufacturing (excluding any improvements of, to or in Know-How or Patent Rights licensed to the
Company hereunder or pursuant to a License Agreement). 
 “Commercialization Phase” has the meaning set forth in the form
License Agreement attached as Exhibit 7.2.2. 
 “Commercially Reasonable Efforts” means, with respect to a Party, an activity,
and a country or other regulatory jurisdiction, the efforts, budget, head count, expertise, and resources normally used by such Party and its Affiliates (or if such Party or any of its Affiliates is acquired by, or assigns or delegates to, a Person
any of its applicable rights or obligations to conduct such activity to the extent expressly permitted hereunder, such Person; provided that, in no event shall such efforts, expertise, and resources be less than those normally used by
such Party and its 

  
 5 

 
Affiliates) in connection with such activity in such country or regulatory jurisdiction for a product or compound that is owned by it or its Affiliates or to which it or its Affiliates has rights
and that is of similar market potential and at a similar stage in its development or product life as the applicable product or compound related to the applicable activity and the fact that a Party is required to make any payments to the other Party
under this Agreement shall not reduce the level of efforts that such Party and its Affiliates shall be required to expend. 
 “Company
Competitor” means any Person that sells vaccines, biologics, molecular entities or medicines for the Field. 
 “Company
Formulation Technology” has the meaning set forth in Section 8.5. 
 “Company Group” means the Company, each
Transferred Entity, each other Subsidiary of the Company and each other Person that either (a) is controlled directly or indirectly by the Company immediately after the Effective Date or (b) becomes controlled by the Company following the
Effective Date. 
 “Company Indemnitees” has the meaning set forth in Section 14.2. 

“Company License Triggering Event” has the meaning set forth in Section 20.3.4(b). 

“Company Material Indebtedness” means any Indebtedness of the Company or of any Person whose indebtedness the Company has guaranteed or
for which the Company is otherwise obligated that is equal to or in excess of One Hundred Million U.S. Dollars ($100,000,000). 

“Company Non-Compliance Notice” has the meaning set forth in Section 12.9.5(b)(ii). 

“Company Security Procedures” has the meaning set forth in Section 12.9.3(a). 

“Company Technology Royalty Rate” has the meaning set forth in Schedule 8.5. 
 “Compound” means each compound (a) that is in the Pfizer Library and is identified by the Company in connection with the Collaboration, (b) for which data, results, or other
information in the Pfizer Database or the Pfizer Restricted Databases was accessed by or provided to the Company pursuant to the terms hereof, (c) that is included in the Pfizer Portfolio, or (d) that is not in the Pfizer Library and is
not an Analog of any of the foregoing (a) through (c) but that is researched or developed by or on behalf of the Company, its Affiliates or any of its permitted sublicensees using the Pfizer IP. 

“Compound Class” means a chemical class or group comprised of structurally related compounds which are homologs, isomers, analogs, or
derivatives of one another, as determined by the JSC. 
 “Compound Series” means a subset of compounds within a Compound Class
that possess similar chemical properties due to the presence of a common functional group, pharmacore or active substructure, as determined by the JSC. 
 “Confidential Information” has the meaning set forth in Section 12.1. 

  
 6 

 “Confidentiality Agreement” means the form confidentiality agreement attached as Exhibit
1.1. 
 “Control” and “Controlled” means (a) with respect to any Intellectual Property, possession by a
Party or its Affiliates of the right, whether directly or indirectly, to grant the right to use, or to grant a license or a sublicense under, such Intellectual Property as provided for herein and (b) with respect to any documents, tools or
other tangible materials (including Compounds and Analogs), the ability of a Party or its Affiliates to provide the other Party, with or with access to or rights to such documents, tools or other tangible materials as provided for herein, each of
the foregoing (a) and (b), without violating the terms of any agreement with a Third Party. For clarity, if a Party or its Affiliates can only grant a license, sublicense, or provide access or rights of limited scope, for a specific purpose or
under certain conditions (including as a result of any Encumbrance), “Control” or “Controlled” shall be construed to so limit such license, sublicense, provision of rights or access (as applicable). Notwithstanding anything to
the contrary herein, Persons that are not Affiliates of Pfizer as of the Effective Date shall not be Affiliates for purposes of this definition and Intellectual Property, documents, tools, and other tangible materials for which rights are acquired
from a Third Party by Pfizer or its Affiliates after the Effective Date shall not be “Controlled” by Pfizer or its Affiliates for purposes of this Agreement. 
 “Cover”, “Covered” and “Covering” means, with respect to a Patent Right, in the absence of a license to a Valid Claim thereof, the research, development,
manufacture, use, sale, offer for sale, or importation of the applicable invention, discovery, process, or product would infringe such Valid Claim (or, in the case of a Valid Claim that has not yet issued, would infringe such Valid Claim if it were
to issue). 
 “Curator” means the individual designated by Pfizer to whom (in accordance with the terms hereof): 

 

	 	(a)	the Lead Seekers, Leveragers, Functional Line Senior Scientists, and Candidate Designees shall direct all requests (i) to provide the Company with a copy of
information or data from the Pfizer Database, and (ii) for additional data and information (and/or a copy thereof) from the Pfizer Restricted Databases, and 

 

	 	(b)	the Company shall provide the results of any screening performed by the Company as part of the Collaboration in accordance with the terms hereof.

 The Curator as of the Effective Date shall be as set forth on Schedule 1.1(a) and Pfizer shall provide the
Company with prompt written notice if Pfizer replaces the Curator. 
 “Defense Action” has the meaning set forth in
Section 18.5.1. 
 “Development Activities” has the meaning set forth in the form License Agreement attached as Exhibit
7.2.2. 
 “Development Phase” has the meaning set forth in the form License Agreement attached as Exhibit 7.2.2. 

“Development Records” has the meaning set forth in Section 10.3. 

  
 7 

 “Development Status Compound” has the meaning set forth on Schedule 1.1(b). 

“Disclosing Party” has the meaning set forth in Section 12.1. 
 “Dispute” has the meaning set forth in Section 21.4.1. 
 “Effective
Date” has the meaning set forth in the Introduction. 
 “EMA” means the European Medicines Agency or any successor
agency thereto. 
 “Encumbrance” means any Third Party restrictions or limitations on Pfizer’s or its Affiliates’
ability to grant a license or other rights to the Company pursuant to this Agreement or any License Agreement, including (a) the terms of any licenses granted by or to Pfizer or any of its Affiliates, (b) the terms of any other agreements
that relate to the Pfizer IP and/or rights granted to the Company hereunder, and (c) ownership by, or other rights of, a Third Party. 

“European Union” means the member countries of the European Union as constituted from time to time. 

“Exclusive Patent Rights” has the meaning set forth in Section 18.2.2(a). 
 “Exhaustion Notice” has the meaning set forth in Section 11.1.1. 

“Expert Arbitrator” has the meaning set forth in Section 21.4.2(a). 
 “Expiration/Termination In Whole Triggering Events” has the meaning set forth in Section 20.3.4(b)(iv). 
 “Extension Period” has the meaning set forth in Section 20.2.5. 

“Fair Market Value” has the meaning set forth on, and shall be determined for each Compound and Analog for which the Reversion Right is
being exercised in accordance with, Schedule 1.1(c). 
 “FCPA” has the meaning set forth in Section 13.3.1. 

“FDA” means the United States Food and Drug Administration or any successor agency thereto. 

“Field” means the diagnosis, prevention, palliation, or treatment of any disease, disorder, syndrome, or condition solely in non-human
animals. 
 “Filing Notice” has the meaning set forth in Section 8.2.1. 

“Filing Phase” has the meaning set forth in the form License Agreement attached as Exhibit 7.2.2. 

“First Commercial Sale” has the meaning set forth in the form License Agreement attached as Exhibit 7.2.2. 

“FMV Notice” has the meaning set forth in Section 8.4.2. 

  
 8 

 “FTE” means the equivalent of a full-time individual’s work time for a twelve
(12) month period (consisting of eighteen hundred (1800) hours during such twelve (12) month period (excluding vacations and holidays)). For clarity, in the event that an individual works partially on an activity during a twelve
(12) month period, the related FTE shall be determined on a pro rata basis according to the total number of hours such individual spent on such activity during such period. 
 “FTE Rate” means, with respect to a particular task, the price of one (1) FTE per twelve (12) month period. The FTE Rate shall be as set forth on Schedule 1.1(d). 

“Functional Line Senior Scientists” has the meaning set forth in Section 4.2.4. 

“Global Separation Agreement” has the meaning set forth in the Recitals. 
 “Government” has the meaning set forth in Section 13.3.2. 

“Government Official” has the meaning set forth in Section 13.3.2. 
 “Governmental Authority” means any nation or government, any state, municipality, or other political subdivision thereof, and any entity, body, agency, commission, department, board,
bureau, court, tribunal, or other instrumentality, whether federal, state, local, regional, domestic, foreign, or multinational, exercising executive, legislative, judicial, regulatory, administrative, or other similar functions of, or pertaining
to, government and any executive official thereof. 
 “Grandfathered AIP Compounds” has the meaning set forth in
Section 6.5. 
 “Grandfathered Intent to Access Compounds” has the meaning set forth in Section 5.2.4. 

“Grandfathered Intent to Access Targets” has the meaning set forth in Section 5.2.4. 

“Group” has the meaning set forth in the Global Separation Agreement. 
 “Hit” has the meaning set forth in Section 5.4.2. 
 “Human Health
Company” means any Person that researches, develops, manufactures, markets, distributes, leases and/or sells vaccines, biologics, molecular entities, medicines, diagnostic products, biodevices, genetic tests or services for the diagnosis,
prevention, palliation, or treatment of any disease, disorder, syndrome, or condition in humans. 
 “Incumbent Board” has the
meaning set forth in paragraph (d) of the definition of “Change of Control.” 
 “IND” means (a) an
Investigational New Drug Application (as defined by Applicable Law) submitted to the FDA for authorization for clinical investigation of a pharmaceutical product outside the Field or (b) any foreign equivalent thereof that is submitted to
applicable Regulatory Authorities in other countries and regulatory jurisdictions in the Territory. 

  
 9 

 “Indebtedness” of any Person means (a) all obligations of such Person for borrowed
money, (b) all obligations of such Person evidenced by bonds, debentures, notes or similar instruments, (c) all obligations of such Person upon which interest charges are customarily paid, (d) all obligations of such Person under
conditional sale or other title retention agreements relating to property or assets purchased by such Person, (e) all obligations of such Person issued or assumed as the deferred purchase price of property or services, (f) all indebtedness
of others secured by (or for which the holder of such indebtedness has an existing right, contingent or otherwise, to be secured by) any mortgage, lien, pledge, or other encumbrance on property owned or acquired by such Person, whether or not the
obligations secured thereby have been assumed, (g) all guarantees by such Person of indebtedness of others, (h) all capital lease obligations of such Person and (i) all securities or other similar instruments convertible or
exchangeable into any of the foregoing, but excluding daily cash overdrafts associated with routine cash operations. 
 “Indemnifying
Party” has the meaning set forth in Section 14.3. 
 “Indemnitee” has the meaning set forth in Section 14.3.

 “Indemnity Payment” has the meaning set forth in Section 14.3. 

“Indications” has the meaning set forth in Section 6.3.2(c). 
 “Insurance Proceeds” means those monies: 
  

	 	(a)	received by an insured from a Third Party insurance carrier; 

  

	 	(b)	paid by a Third Party insurance carrier on behalf of the insured; or 

  

	 	(c)	received (including by way of setoff) from any Third Party in the nature of insurance, contribution or indemnification in respect of any Liability;

 in each such case net of any applicable premium adjustments (including reserves and retrospectively rated premium adjustments)
and net of any costs or expenses incurred in the collection thereof and excluding, for the avoidance of doubt, proceeds from any self-insurance, captive insurance or similar program. 
 “Intellectual Property” means all Patent Rights, Know-How, copyrights and copyrightable subject matter, Trademarks, and software. 
 “Intent to Access” has the meaning set forth in Section 5.1. 

“Intent to Access Other Restrictions” has the meaning set forth in Section 5.2.2(b)(iii). 

“Intent to Access Request” has the meaning set forth in Section 5.2.1(a). 
 “Invoiced Costs” means the costs and expenses set forth on Schedule 1.1(e). 

  
 10 

 “JSC” has the meaning set forth in Section 2.1.1. 

“JSC Members” has the meaning set forth in Section 2.1.1. 
 “Key Company Leadership” means the Persons set forth on Schedule 1.1(f). 

“Know-How” means all information and know-how, including clinical, technical, scientific, and medical information, practices,
techniques, methods, processes, inventions, developments, specifications, formulations, structures, trade secrets, analytical and quality control information and procedures, pharmacological, toxicological, and clinical test data and results,
stability data, studies and procedures, and regulatory information. 
 “Knowledge” means the actual knowledge of the Persons
set forth on Schedule 1.1(g). 
 “Lead Seeker” has the meaning set forth in Section 5.3.1. 

“Lead Seeking Activities” means the activities set forth on Schedule 1.1(h). 
 “Lead Seeking Phase” has the meaning set forth in Section 5.1. 

“Lead Seeking Project” has the meaning set forth in Section 5.2.2(c). 
 “Lead Seeking Project Team” has the meaning set forth in Section 5.3.2. 

“Lead Seeking Project Team Member” has the meaning set forth in Section 5.3.2. 

“Leveragers” has the meaning set forth in Section 4.2.1. 
 “Liabilities” means any and all indebtedness, claims, debts, Taxes, liabilities, demands, causes of actions, Actions and obligations, whether accrued, fixed or contingent, mature or
inchoate, known or unknown, reflected on a balance sheet or otherwise, including those arising under any Applicable Law, Action or any judgment of any court of any kind or any award of any arbitrator of any kind, and those arising under any
contract, commitment or undertaking. 
 “License Agreement” has the meaning set forth in Section 7.2.2. 

“License Subject Matter” has the meaning set forth in Section 7.2.2. 
 “Licensed Product” has the meaning set forth in the applicable License Agreement (if any). 
 “Lien” has the meaning set forth in the Global Separation Agreement. 

“Losses” means any and all damages, losses, deficiencies, Liabilities, Taxes, obligations, penalties, judgments, settlements, claims,
payments, fines, charges, interest, costs and expenses, whether or not resulting from Third Party Claims, including the costs and expenses of any and all Actions and demands, assessments, judgments, settlements and compromises relating thereto and
the costs and expenses of attorneys’, accountants’, consultants’ and other professionals’ fees and expenses incurred in the investigation or defense thereof or the enforcement of rights hereunder. 

  
 11 

 “Maintenance Costs” means the costs and expenses set forth on Schedule 1.1(i).

 “Major Market Country” means the United States, France, Germany, Italy, Spain, the United Kingdom, Japan, China,
Australia, or Brazil. 
 “Markush Structure” means a drawing containing defined variables used to describe a structurally
related set of compounds, examples of which are set forth on Schedule 1.1(j). 
 “Materials” has the meaning set forth
in Section 18.1.1(b)(i). 
 “Milestone Payment” means the milestone payment payable pursuant to each License Agreement.

 “New York Courts” has the meaning set forth in Section 21.4.3(c). 

“Opt-In” has the meaning set forth in Section 7.1.1. 
 “Opt-In Deadline” has the meaning set forth in Section 7.3.1. 

“Opt-In Notice” has the meaning set forth in Section 7.2.1. 
 “Other Restrictions” has the meaning set forth in Section 6.3.2(f). 

“Overpaying Party” has the meaning set forth in Section 9.9.3(b). 
 “Paragraph IV Certification” means any certification filed pursuant to 21 U.S.C. § 355(b)(2)(A)(iv), 21 U.S.C. § 355(j)(2)(A)(vii)(IV), or any comparable Applicable Law (or any
amendment or successor statute thereto) in any country or regulatory jurisdiction in the Territory. 
 “Patent Rights” means
all national, regional, and international patents, patent applications, invention disclosures, and all related continuations, continuations-in-part, divisionals, provisionals, renewals, reissues, re-examinations, additions, extensions (including all
supplementary protection certificates), and all foreign equivalents thereof. 
 “Person” means an individual, a general or
limited partnership, a corporation, a trust, a joint venture, an unincorporated organization, a limited liability entity, any other entity and any Governmental Authority. 
 “Pfizer Database” means, to the extent Controlled by Pfizer, the systems set forth on Schedule 1.1(k) (and any successors thereof) to the extent such systems store the types of data set
forth on Schedule 1.1(k). The contents of the Pfizer Database may be changed or updated from time to time by or on behalf of Pfizer or its Affiliates in the ordinary course. For clarity, any data or information to the extent (a) included in the
Pfizer Database and (b) assigned or licensed to the Company as of the Effective Date pursuant to the Global Separation Agreement or any Ancillary Agreement other than this Agreement, shall be deemed to not be in the Pfizer Database for the
purposes of this Agreement, and shall be subject to the Global Separation Agreement or the applicable other Ancillary Agreements, to the extent addressed in such agreements. 

  
 12 

 “Pfizer Group” means Pfizer, each other Subsidiary of Pfizer involved in the Transactions
and each other Person that either (x) is controlled directly or indirectly by Pfizer immediately after the Effective Date or (y) becomes controlled by Pfizer following the Effective Date; provided, however, that neither the
Company nor any other member of the Company Group shall be members of the Pfizer Group. 
 “Pfizer Indemnitees” has the meaning
set forth in Section 14.1. 
 “Pfizer IP” means the Pfizer Patent Rights and the Pfizer Know-How. 

“Pfizer Know-How” means, to the extent Controlled by Pfizer: 

 

	 	(a)	all Know-How that is (i) contained in the portions of the Pfizer Database accessed by the Company or (ii) provided to the Company by or on behalf of Pfizer or
its Affiliates in connection with the Collaboration (including any such Know-How provided from the Pfizer Restricted Databases and the Pfizer Portfolio); provided that, with respect to the foregoing (a)(i) and (a)(ii), such Know How
shall not include any Know-How with respect to formulations of pharmaceutical products, screening methods, assays or manufacturing processes to the extent solely directed to scale-up for commercial manufacturing (excluding any improvements of, to or
in Know-How or Patent Rights licensed to the Company hereunder or pursuant to a License Agreement) (unless otherwise specified by Pfizer in writing); and 

  

	 	(b)	Collaboration Know-How; 

provided that with respect to the foregoing (a) and (b), Pfizer Know-How shall not include any Pfizer Patent Rights.

 “Pfizer Library” means, to the extent Controlled by Pfizer, Pfizer’s and its Affiliates’ physical and virtual
compound library, the contents of which may change from time to time in the ordinary course. 
 “Pfizer Non-Compliance Notice”
has the meaning set forth in Section 12.9.5(a)(i). 
 “Pfizer Patent Rights” means, to the extent Controlled by Pfizer:

  

	 	(a)	all Patent Rights that are or may be filed on or otherwise Cover (i) Know-How (A) contained in the portions of the Pfizer Database accessed by the Company or
(B) provided to the Company by or on behalf of Pfizer or its Affiliates in connection with the Collaboration (including any Know-How provided from the Pfizer Restricted Databases and the Pfizer Portfolio), or (ii) Collaboration Know-How;
provided that, with respect to the foregoing (i), such Patent Rights shall not include any Patent Rights to the extent Covering formulations of pharmaceutical products, screening methods, assays or manufacturing processes to the extent
solely directed to scale-up for commercial manufacturing (excluding any improvements of, to or in Know-How or Patent Rights licensed to the Company hereunder or pursuant to a License Agreement) (unless otherwise specified by Pfizer in writing); and

  

	 	(b)	the Collaboration Patent Rights. 

  
 13 

 “Pfizer Portfolio” means the compounds and related pharmaceutical products for which Pfizer
or its Affiliates has an active or terminated program that has not reached the stage of being a Clinical Development Program that Pfizer decides in good faith at its sole discretion to disclose to the Company’s JSC Members hereunder.

 “Pfizer Protected Assets” has the meaning set forth in Section 12.9.3(a). 

“Pfizer Restricted Databases” means, to the extent Controlled by Pfizer, the systems set forth on Schedule 1.1(l) (and any successors
thereof). The contents of the Pfizer Restricted Databases may be changed or updated from time to time by or on behalf of Pfizer or its Affiliates in the ordinary course. For clarity, any data or information to the extent (a) included in the
Pfizer Restricted Databases and (b) assigned or licensed to the Company as of the Effective Date pursuant to the Global Separation Agreement or any Ancillary Agreement other than this Agreement, shall be deemed to not be in the Pfizer
Restricted Databases for the purposes of this Agreement, and shall be subject to the Global Separation Agreement or the applicable other Ancillary Agreements, to the extent addressed in such agreements. 

“Pfizer Software” means, to the extent necessary for the Company to exercise its rights hereunder, the software that is set forth on
Schedule 1.1(m) to the extent Controlled by Pfizer. 
 “Plan of Reorganization” has the meaning set forth in the Global
Separation Agreement. 
 “Pre-Made Plates” has the meaning set forth in Section 5.4.3. 

“Prime Rate” has the meaning set forth in the Global Separation Agreement. 
 “Prohibited Activities” has the meaning set forth in Section 3.3.2. 

“Proposed AIP Compound Series” has the meaning set forth in Section 6.2.1(a). 

“Prosecution Activities” has the meaning set forth in Section 18.2.1. 
 “Prosecution Request” has the meaning set forth in Section 18.2.2(a). 

“Receiving Party” has the meaning set forth in Section 12.1. 
 “Reference Date” has the meaning set forth in paragraph (d) of the definition of “Change of Control.” 
 “Regulatory Approval” means the approval, registration, license, or authorization of a Regulatory Authority necessary for the manufacture, distribution, use, promotion and sale of a
pharmaceutical product for one or more indications in a country or other regulatory jurisdiction in the Field, including approval of New Animal Drug Applications (as defined by Applicable Law) in the United States and Marketing Authorisations in the
European Union. 
 “Regulatory Approval Application” means an application that is submitted to a Regulatory Authority and the
approval of which is necessary to obtain Regulatory Approval, including New Animal Drug Applications in the United States and Marketing Authorisations in the European Union. 

  
 14 

 “Regulatory Authority” means any supranational, federal, national, regional, state,
provincial, or local regulatory agency, department, bureau, commission, council, or other government entity, that regulates or otherwise exercises authority with respect to manufacturing, research, development, or commercialization of pharmaceutical
products in any country or regulatory jurisdiction, including the FDA and EMA. 
 “Request” has the meaning set forth in
Section 21.4.1(a). 
 “Residuals” means Pfizer Know-How of a general nature, such as general knowledge, ideas, concepts,
know-how, or techniques, that is retained in the unaided memories of the Company’s employees who have had access to, or were provided, such information following the Effective Date. For clarity, an employee’s memory is unaided if the
employee has not intentionally memorized the applicable information for the purpose of retaining and subsequently using or disclosing it. 

“Restricted Compounds” has the meaning set forth in Section 20.3.4(c). 
 “Restricted Development Activities” means those activities set forth on Schedule 1.1(n). 
 “Reversion Expiration Date” has the meaning set forth in Section 8.3. 

“Reversion Notice” has the meaning set forth in Section 8.4.1. 
 “Reversion Right” has the meaning set forth in Section 8.1. 

“Rules” has the meaning set forth in Section 21.4.3(a). 
 “Screener” has the meaning set forth in Section 5.4.1. 
 “Screening
Services Agreement” has the meaning set forth in the Global Separation Agreement. 
 “Senior Executive Escalation
Notice” has the meaning set forth in Section 2.1.7. 
 “Senior Executives” has the meaning set forth in
Section 2.1.7. 
 “Species” has the meaning set forth in Section 6.3.2(c). 

“Specified Person” has the meaning set forth in paragraph (a) of the definition of “Change of Control.” 

“Subcommittee” has the meaning set forth in Section 2.1.8. 
 “Subsidiary” means, when used with respect to any Person, (a) a corporation in which such Person or one or more Subsidiaries of such Person, directly or indirectly, owns capital
stock 

  
 15 

 
having a majority of the total voting power in the election of directors of all outstanding shares of all classes and series of capital stock of such corporation entitled generally to vote in
such election; and (b) any other Person (other than a corporation) in which such Person or one or more Subsidiaries of such Person, directly or indirectly, has (i) a majority ownership interest or (ii) the power to elect or direct the
election of a majority of the members of the governing body of such first-named Person. 
 “Surviving Provisions” has the
meaning set forth in Section 20.3.11. 
 “Target” means a biologically active target. 

“Taxes” has the meaning set forth in the Global Separation Agreement. 
 “Term” has the meaning set forth in Section 20.1. 

“Territory” means worldwide. 

“Third Party” means a Person other than a Party or an Affiliate of a Party. 
 “Third Party Claim” has the meaning set forth in Section 14.4.1. 

“Third Party Infringement” has the meaning set forth in Section 18.3.1. 
 “Third Party Payments” has the meaning set forth in Section 9.4. 

“Trademarks” means all trademarks, service marks, names, corporate names, trade names, domain names, logos, slogans, trade dress, design
rights, and other similar designations of source or origin and all applications and registrations therefor, together with the goodwill symbolized by any of the foregoing. 
 “Transactions” has the meaning set forth in the Global Separation Agreement. 

“Transferred Entities” has the meaning set forth in the Global Separation Agreement. 

“Triggering Event” has the meaning set forth in Section 20.3.5. 
 “Upfront Payment” has the meaning set forth in Section 7.2.3. 

“Valid Claim” means (a) a claim of an issued and unexpired Patent Right that has not been permanently revoked or declared
unenforceable or invalid by a final and unappealable, or an unappealed within the time allowed for appeal, decision of a Governmental Authority of competent jurisdiction or (b) a good faith claim submitted to a patent office in the applicable
country or regulatory jurisdiction in a pending application for a Patent Right that has been pending for no more than seven (7) years from the earliest date from which such pending application claims priority in the applicable country or
regulatory jurisdiction and that has not been abandoned, disclaimed, denied, or admitted to be invalid or unenforceable through reissue or disclaimer or otherwise. 
 “VICH” means the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products. 

“Wind-Down Costs” means all reasonable out-of-pocket costs and expenses actually incurred by a Party and its Affiliates in connection
with early termination of the Collaboration, including 

  
 16 

 
relocation, reassignment and severance costs and expenses related to FTEs, and costs and expenses associated with disposing or redeploying assets owned, licensed or leased by such Party or its
Affiliates that were used in connection with the Collaboration or otherwise held by a Party or its Affiliates for purposes of the Collaboration. To the extent reasonably practicable, each Party shall seek to mitigate its and its Affiliates’
Wind-Down Costs. 
 “Withholding Tax Requirement” has the meaning set forth in Section 9.8.2. 

2. GOVERNANCE 
  

	2.1	Joint Steering Committee. 

  

	 	2.1.1	Formation and Purpose. The Parties hereby establish a joint steering committee (the “JSC”), which shall oversee and facilitate
communication regarding the Collaboration. Each Party shall appoint three (3) employees as JSC members (the “JSC Members”), who, collectively, shall have expertise in chemistry, biology, and safety and each JSC Member shall
have sufficient seniority within the applicable Party to make decisions within the scope of the JSC’s responsibilities. Each Party shall ensure that its JSC Members are subject to confidentiality obligations and use restrictions no less
restrictive than those set forth herein and the Company shall ensure that its JSC Members sign the Confidentiality Agreement prior to performing any JSC functions and Pfizer shall be provided with a copy of each such Confidentiality Agreement
entered into in accordance with this Section reasonably promptly following execution thereof. The initial JSC Members shall be as set forth on Schedule 2.1.1. A Party may replace any of its JSC Members at any time upon written notice to the other
Party; provided that the Company shall obtain Pfizer’s written consent prior to replacing any of its JSC Members (not to be unreasonably withheld and it shall not be unreasonable to withhold consent if the Company has replaced a
JSC Member position more than once during the prior twelve (12) months). A Party’s JSC Members may invite individuals who are not JSC Members to JSC meetings or portion thereof, subject to the other Party’s prior written consent (not
to be unreasonably withheld and it shall not be unreasonable to withhold consent to the extent the subject matter of such JSC meeting (i) does not relate to the subject matter for which the proposed individual has expertise and has been invited
to the JSC meeting, or (ii) relates to the Pfizer Portfolio or other sensitive (as determined by Pfizer in its sole discretion) Confidential Information of Pfizer or its Affiliates). Prior to attending any JSC meeting, the Party that invited
such individual shall ensure that such individual is subject to and complies with confidentiality obligations and use restrictions no less restrictive than those that apply to such Party’s JSC Members. 

 

	 	2.1.2	 JSC Meetings. The JSC shall meet at least quarterly (at regularly spaced intervals) or as otherwise agreed by the Parties in writing.
Each Party may call ad hoc meetings of the JSC upon at least ten (10) Business Days prior written notice if such Party reasonably believes that a significant matter must be addressed prior to the next scheduled meeting. The JSC may meet in
person, by teleconference, 

  
 17 

	 	
or by videoconference; provided that at least one meeting per year shall be in person (unless otherwise agreed by the Parties in writing). In-person JSC meetings shall alternate
between locations selected by Pfizer and by the Company. 

  

	 	2.1.3	JSC Minutes. The Parties shall alternate responsibility for preparing reasonably detailed draft minutes of each JSC meeting that reflect (without
limitation) material decisions made and discussions had at such meetings, subject to Section 2.1.6. The Party that is responsible for preparing the draft minutes shall circulate such minutes to the other Party’s JSC Members within thirty
(30) days of the applicable meeting. Minutes shall be deemed approved by a Party unless one or more of its JSC Members objects to the accuracy thereof within ten (10) Business Days of receipt thereof. 

 

	 	2.1.4	Chairperson. Each Party shall designate one of its JSC Members to serve as a co-chairperson of the JSC (together, the “Co-Chairpersons”).
The initial Co-Chairpersons of the JSC shall be as set forth on Schedule 2.1.4. The Co-Chairpersons shall be responsible for convening and presiding over JSC meetings and shall alternate responsibility for preparing and circulating agendas. The
Co-Chairpersons shall have no additional powers or rights beyond those held by the other JSC Members. 

  

	 	2.1.5	JSC Responsibilities. The JSC shall be responsible for: 

  

	 	(a)	discussing any Collaboration IP; 

  

	 	(b)	discussing the strategy for obtaining, maintaining, and enforcing the Pfizer IP; 

 

	 	(c)	forming additional Subcommittees in accordance with Section 2.1.8; 

  

	 	(d)	discussing Encumbrances applicable to the Company’s activities under the Collaboration; 

 

	 	(e)	reviewing and discussing the Pfizer Portfolio (subject to Section 2.1.6); 

 

	 	(f)	granting or denying AIP Requests in accordance with Sections 6.3 and 6.4; 

  

	 	(g)	granting or denying any request by the Company regarding its ability to sublicense or otherwise engage an Affiliate or Third Party in connection with the Collaboration,
and deciding upon any related rights and/or obligations of such Affiliate or Third Party; and 

  

	 	(h)	performing such other functions set forth herein for the JSC or that the Parties mutually agree upon in writing. 

  
 18 

	 	2.1.6	Pfizer Portfolio. 

  

	 	(a)	General. From time to time, and upon the Company’s reasonable written request, Pfizer may (in its sole discretion) disclose certain contents of the
Pfizer Portfolio to the Company’s JSC Members. 

  

	 	(b)	Disclosure. Notwithstanding anything to the contrary in this Agreement, the Company’s JSC Members shall not disclose the contents of the Pfizer
Portfolio to any Persons, except the Key Company Leadership to the extent (i) disclosure to the Key Company Leadership is necessary for the Company to determine whether to seek Intent to Access and (ii) such disclosure is in the form of a
written, high-level summary that has been approved by Pfizer’s JSC Members in writing in advance of such disclosure (subject to Pfizer’s JSC Members’ sole discretion) within ten (10) Business Days of Pfizer’s JSC
Members’ receipt of the applicable summary, unless otherwise agreed upon by the Parties in writing. Notwithstanding anything to the contrary, the Pfizer Portfolio is Pfizer’s Confidential Information. To the extent Pfizer’s JSC
Members do not approve any summary provided in accordance with this Section, or after the Key Company Leadership completes its review of any such summary that has been approved by Pfizer’s JSC Members, the Company shall promptly destroy such
written summary. 

  

	 	(c)	Use. The Company’s JSC Members and, to the extent permitted pursuant to Section 2.1.6(b), the Key Company Leadership shall use the contents of
the Pfizer Portfolio solely to determine whether to request Intent to Access (including to request additional information to determine whether to request Intent to Access, which request Pfizer may grant or deny in its sole discretion) for any
Compounds included in such request or Analogs thereof (subject to Pfizer’s written approval). 

  

	 	(d)	Minutes. Except as permitted pursuant to Section 2.1.6(b), in no event will any information from, or relating to, the Pfizer Portfolio be recorded by
the Company in any manner and for clarity, such information shall not be reflected in any JSC meeting minutes. 

  

	 	2.1.7	 Decision-Making. All decisions of the JSC shall be made by unanimous vote, with each Party having one (1) vote and with at least one
(1) JSC Member from each Party participating in each vote. Each Party shall cause its JSC Members to negotiate to resolve matters within the JSC’s authority as expeditiously as possible. In the event that the JSC fails to reach unanimous
agreement within thirty (30) days of the date that such a matter was first submitted to it in writing, either Party may, by written notice to the other Party (an “Alliance Manager Escalation Notice”), refer such matter to the
Alliance Managers. The Alliance Managers shall promptly meet and negotiate to develop and agree upon potential solutions to each matter referred to them in accordance with this Section 2.1.7. The Alliance Managers shall propose such solutions
(if any) to the JSC Members 

  
 19 

	 	
within fifteen (15) days of the date of the related Alliance Manager Escalation Notice. The JSC Members shall negotiate regarding any such potential solutions following receipt thereof. In
the event that the JSC fails to reach unanimous agreement, or the Alliance Managers fail to propose any agreed upon potential solutions, within thirty (30) days of the related Alliance Manager Escalation Notice, either Party may, by written
notice to the other Party (a “Senior Executive Escalation Notice”), refer such matter to those individuals set forth on Schedule 2.1.7 (or an employee currently occupying an equivalent, or more senior, position as such individual or
a successor position thereof), as such positions are understood by the Parties as of the Effective Date (the “Senior Executives”) for resolution. The Senior Executives shall promptly meet and negotiate to resolve each matter
referred to them in accordance with this Section 2.1.7. If the Senior Executives are unable to resolve a matter referred to them in accordance with this Section 2.1.7 within thirty (30) days of the date of the related Senior Executive
Escalation Notice, Pfizer shall have the authority to make the final decision in its sole discretion. 

  

	 	2.1.8	Subcommittees. From time to time, the JSC may establish subcommittees as it deems necessary or advisable (each such subcommittee, a
“Subcommittee”). Each Subcommittee shall consist of an equal number of members from each Party and shall meet with such frequency and according to such procedural rules as the JSC determines. 

 

	2.2	Alliance Managers. Promptly following the Effective Date, each Party shall appoint an employee to serve as an alliance manager (each, an “Alliance
Manager”) of the Collaboration. Each Alliance Manager shall have the qualifications necessary to fulfill its obligations hereunder and shall not be a JSC Member. Each Party shall ensure that its Alliance Manager is subject to
confidentiality obligations and use restrictions no less restrictive than those set forth herein, and the Company shall ensure that its Alliance Manager signs the Confidentiality Agreement prior to performing any Alliance Manager functions and
Pfizer shall be provided with a copy of each such Confidentiality Agreement entered into in accordance with this Section reasonably promptly following execution thereof. The Alliance Managers shall endeavor to assure clear and responsive
communication between the Parties with respect to the Collaboration and shall serve as a single point of contact for any matters arising under this Agreement. Alliance Managers may attend any JSC or Subcommittee meetings or portions thereof and
shall work together to resolve any deadlock between the Parties in accordance with the procedures set forth in Sections 2.1.7 and 21.4; provided that the Company Alliance Manager may not attend any portion of a JSC meeting that relates
to the Pfizer Portfolio or other sensitive (as determined by Pfizer in its sole discretion) Confidential Information of Pfizer or its Affiliates. Each Party shall be permitted to change its Alliance Manager at any time upon written notice to the
other Party; provided that the Company shall be required to obtain Pfizer’s prior written consent (not to be unreasonably withheld and it shall not be unreasonable to withhold consent if the Company has replaced its Alliance
Manager more than once during the prior twelve (12) month period). 

  
 20 

 3. LICENSES 

 

	3.1	Pfizer Licenses to the Company. 

  

	 	3.1.1	Lead Seeking Phase. During the Lead Seeking Phase, subject to the terms hereof, Pfizer hereby grants, and shall cause its Affiliates to grant, to the
Company a license in, to, and under the Pfizer IP (including the Collaboration IP) Controlled by Pfizer solely to the extent necessary for (a) the Leveragers, the Lead Seekers, the Key Company Leadership, the Functional Line Senior Scientists
and the JSC to determine whether to seek Intent to Access and (b) the Lead Seekers, the Lead Seeking Project Teams and the Functional Line Senior Scientists to conduct the Lead Seeking Activities with respect to the Compounds and Analogs for
which Intent to Access is granted in the Field throughout the Territory. Such license shall be (x) exclusive (except with respect to Pfizer and its Affiliates) with respect to the Collaboration IP and (y) non-exclusive with respect to all
other Pfizer IP. 

  

	 	3.1.2	Candidate Designation Phase. During the Candidate Designation Phase, subject to the terms hereof, Pfizer hereby grants, and shall cause its Affiliates to
grant, to the Company a license in, to, and, under the Pfizer IP (including the Collaboration IP) Controlled by Pfizer solely to the extent necessary for the Lead Seekers, the Candidate Designees, the Functional Line Senior Scientists and the
Candidate Designation Project Teams to conduct the Candidate Designation Activities with respect to the AIP Compound Series in the Field throughout the Territory. Such license shall be (a) exclusive (except with respect to Pfizer and its
Affiliates) as to the Collaboration IP and (b) non-exclusive with respect to all other Pfizer IP. 

  

	 	3.1.3	Software License. During the Lead Seeking Phase and the Candidate Designation Phase, subject to the terms hereof, Pfizer hereby grants, and shall cause
its Affiliates to grant, to the Company a non-exclusive license in, to, and under the Pfizer Software solely to the extent necessary to conduct the activities set forth on Schedule 1.1(m) to the extent expressly permitted under this Agreement.
Such license shall include rights to use, maintain, modify, enhance and create derivative works of the Pfizer Software. Notwithstanding anything to the contrary, Pfizer and its Affiliates shall not have any obligation to provide the Company with
any (a) support with respect to the Pfizer Software or (b) successor software systems. 

  

	3.2	Sublicensing and Third Party Contractors. 

  

	 	3.2.1	 General. The Company shall not sublicense any rights granted hereunder or otherwise engage a Third Party (including any contractors) or
any Affiliates to use the Pfizer IP or Pfizer Software or otherwise exercise its rights or perform its obligations hereunder, except to the extent expressly (a) specified (i) by Pfizer in a written notice granting an Intent to Access
Request pursuant to Section 5.2.2 or (ii) in an AIP Notice pursuant to Section 6.3.2 or (b) otherwise agreed upon by the JSC in writing (which the JSC may withhold in its good faith sole discretion). In the event that the Company
is permitted to sublicense the licenses granted 

  
 21 

	 	
hereunder, the Company shall not be relieved of any obligations hereunder and shall remain responsible and liable for its permitted sublicensees’ compliance with all of the terms of this
Agreement applicable to the Company. 

  

	 	3.2.2	Agreements. The Company shall enter into an agreement with any Person to whom it sublicenses rights granted hereunder or otherwise engages in connection
herewith. Except as otherwise expressly agreed upon by the JSC or set forth in the applicable notice granting Intent to Access or AIP Notice, all such agreements shall (a) be in writing if the applicable Person is a Third Party, (b) be
subject to, and consistent with, the terms of this Agreement (including all Encumbrances), (c) preclude assignment of such agreement without Pfizer’s prior written consent, (d) terminate upon termination of this Agreement in
accordance with the terms hereof, and (e) include Pfizer as an intended third party beneficiary with the right to enforce the terms of such sublicense agreement. For clarity, any permitted sublicensees hereunder may not grant further
sublicenses. 

  

	3.3	Encumbrances. 

  

	 	3.3.1	General. The Company hereby acknowledges and agrees that the licenses and other rights granted to the Company pursuant to this Agreement include rights to
Patent Rights, Know-How and software that may be subject to the Encumbrances and, accordingly, all of the terms of this Agreement shall be subject to such Encumbrances. To the extent that the Company is granted rights to any such Patent Rights,
Know-How or software, the Company shall, and shall ensure that its Affiliates and permitted sublicensees, comply with the Encumbrances. 

  

	 	3.3.2	Violations. In the event that either Party learns that the Company’s, its Affiliates’ or its permitted sublicensees’ activities may violate
an Encumbrance, Intent to Access Other Restriction, or Other Restriction (“Prohibited Activities”), (a) such Party shall notify the other Party as soon as reasonably practicable, and (b) the Company shall immediately
cease, and cause its Affiliates and permitted sublicensees to cease, the Prohibited Activities and destroy all related Pfizer Know-How and Materials in its and their possession in accordance with Pfizer’s instructions to the extent reasonably
required by such Encumbrances, Intent to Access Other Restriction, or Other Restriction (unless otherwise expressly agreed upon by the Parties). 

  

	3.4	No Implied Licenses. Each Party reserves its and its Affiliates’ rights in, to and under all Intellectual Property that is not expressly licensed
hereunder. Without limiting the foregoing, this Agreement and the licenses and rights granted herein do not and shall not be construed to confer any rights upon either Party or its Affiliates by implication, estoppel, or otherwise as to any of the
other Party’s or its Affiliates’ Intellectual Property, except as otherwise expressly set forth herein. 

  

	3.5	 Pfizer’s Good Faith. Notwithstanding anything to the contrary herein, for purposes of this Agreement, any decision or change that
Pfizer makes that is attributable (in part or in whole) to reasons (as determined by Pfizer in its sole discretion) relating to the conduct 

  
 22 

	 	
or performance of Pfizer’s or its Affiliates’ businesses (including (a) any potential or actual bona fide research, development, or commercialization on its or their own or by,
with or through a Third Party and (b) Pfizer’s investment in a Compound as compared to the compensation that Pfizer will be paid hereunder and pursuant to the applicable License Agreement) or any contemplated or existing Encumbrances shall
be deemed to have been made by Pfizer in good faith. For clarity, the Parties hereby acknowledge and agree that the foregoing are examples of, and shall not be construed to limit, the ways in which Pfizer may show that it has exercised good faith.

 4. COLLABORATION, GENERALLY AND THE PFIZER DATABASE 

 

	4.1	Collaboration, Generally. The Collaboration involves five (5) possible phases of research, development and commercialization with respect to each
Compound and Analog: (a) the Lead Seeking Phase, (b) the Candidate Designation Phase, (c) the Development Phase, (d) the Filing Phase, and (e) the Commercialization Phase, each as further set forth herein and in the License
Agreements (if any, as applicable). 

  

	4.2	Pfizer Database. 

  

	 	4.2.1	Access to the Pfizer Database. During the Term, no more than twelve (12) employees of the Company at any given time (such employees, the
“Leveragers”) shall have the right to access and view (but not download, print, transmit, copy, reproduce or export) the contents of the Pfizer Database solely to identify Targets, Compounds and Analogs for the Company to research,
develop and/or commercialize in connection with the Collaboration. The Leveragers shall not use the contents of the Pfizer Database for any other purpose and shall not disclose the contents of the Pfizer Database except as expressly set forth
herein. Without limiting any provision herein, and for clarity, in the event that a Leverager learns that his or her access to, or viewing of, any portions of the Pfizer Database may violate an Encumbrance, such Leverager shall (a) immediately
notify Pfizer, (b) immediately cease accessing and viewing such portions of the Pfizer Database, and (c) not use for any reason, or disclose to any Person other than Pfizer, such portions of the Pfizer Database. If, at any time, the
Company determines that additional Leveragers are necessary to exercise its rights under the Collaboration, the Company shall submit such request to the JSC (which the JSC may grant or deny in its sole discretion). 

 

	 	4.2.2	Leveragers. As of the Effective Date, the Leveragers shall be as set forth on Schedule 4.2.2(a). At all times, the Leveragers shall have the expertise and
qualifications set forth on Schedule 4.2.2(b), as such expertise and qualifications are generally understood in the veterinary pharmaceutical industry. The Company shall comply with Section 12.9.6 with respect to all Leveragers.

  

	 	4.2.3	 Disclosure of Information From The Pfizer Database. Prior to obtaining Intent to Access, the Leveragers shall be permitted to discuss the
contents of the Pfizer Database with the Lead Seekers and the Company’s JSC Members solely to 

  
 23 

	 	
determine whether to seek Intent to Access for a Target or Compound. In the event that the Company reasonably believes that it is necessary to discuss such information with any other Company
employees to determine whether to seek Intent to Access, the Company shall provide Pfizer with a written request therefor (which Pfizer may grant or deny in its sole discretion). 

 

	 	4.2.4	Functional Line Senior Scientists. During the Term, the Company shall have the right to designate up to seven (7) employees to serve as functional
line senior scientists in connection with the Collaboration (“Functional Line Senior Scientists”). As of the Effective Date, the Functional Line Senior Scientists shall be as set forth on Schedule 4.2.4(a). At all times, the
Functional Line Senior Scientists shall have the expertise and qualifications set forth on Schedule 4.2.4(b), as such expertise and qualifications are generally understood in the veterinary pharmaceutical industry. Each Functional Line Senior
Scientist shall be permitted to consult with the Company’s JSC Members, the Lead Seekers and the Candidate Designees with respect to his or her expertise set forth on Schedule 4.2.4(b) to the extent necessary for the Company to conduct the Lead
Seeking Activities and the Candidate Designation Activities. The Company shall comply with Section 12.9.6 with respect to all Functional Line Senior Scientists. 

 

	 	4.2.5	Information from the Pfizer Database and the Pfizer Restricted Databases. 

 

	 	(a)	Procedure. 

  

	 	(i)	Pfizer Database. Subject to Section 4.2.5(a)(iii), the Leveragers, Functional Line Senior Scientists, Candidate Designees and Lead Seekers may
request that Pfizer provide the Company with a copy of information and data that is in the Pfizer Database. For clarity, such information and data may be provided in an electronic or other form that may be downloaded, printed, copied, modified or
reproduced. 

  

	 	(ii)	Pfizer Restricted Databases. Subject to Section 4.2.5(a)(iii), the Leveragers, Functional Line Senior Scientists, Candidate Designees and Lead
Seekers may request that Pfizer provide the Company with access to, or a copy of, information and data that is in the Pfizer Restricted Databases. For clarity, such information and data may be provided in an electronic or other form that may be
downloaded, printed, copied, modified or reproduced. 

  

	 	(iii)	General Requirements. The Company shall ensure that the Leveragers, Functional Line Senior Scientists, Candidate Designees and Lead Seekers only submit
requests in accordance with Section 4.2.5(a)(i) or 4.2.5(a)(ii): 

  

	 	(1)	 if, with respect to a request by the Leveragers, Functional Line Senior Scientists and Lead Seekers, Intent to Access

  
 24 

	 	
has been granted with respect to the Target and/or Compound that relates to the requested information and data, 

 

	 	(2)	if, with respect to a request by the Candidate Designees and Functional Line Senior Scientists, AIP has been granted with respect to the Target and/or Compound that
relates to the requested information and data, and 

  

	 	(3)	to the extent necessary for the Leveragers, Functional Line Senior Scientists, Candidate Designees and Lead Seekers to perform their obligations hereunder.

 The Leveragers, Functional Line Senior Scientists, Candidate Designees and Lead Seekers shall submit each such
request in writing to the Curator. For clarity, the Curator shall be permitted to discuss each such request with Pfizer’s and its Affiliates’ employees and advisors. If Pfizer grants consent with respect to any request submitted pursuant
to Section 4.2.5(a)(i) or 4.2.5(a)(ii) (which Pfizer may withhold in its sole discretion), the Curator shall provide the Company with written notice of such consent, and, if applicable, the requested information or data, as soon as reasonably
practicable. 
  

	 	(b)	Number of Permitted Requests. Notwithstanding anything to the contrary herein, if the Company would like to submit requests described in this
Section 4.2.5 for more than (i) ten thousand (10,000) Compounds and Analogs thereof identified based on a single high throughput screen or (ii) fifty thousand (50,000) Compounds and Analogs thereof in the aggregate during a
twelve (12) month period, the Company shall provide the JSC with written notice thereof and the JSC shall decide (in its sole discretion) whether such additional requests shall be permitted. 

 

	 	(c)	Disclosures by Leveragers. Unless Pfizer grants prior written consent (which Pfizer may withhold in its sole discretion) or to the extent expressly set
forth herein, Leveragers shall only disclose information and data that Pfizer has provided to the Company pursuant to this Section 4.2.5 to (i) the Lead Seekers supervising the Lead Seeking Project to which such information and data
relates during the applicable Lead Seeking Phase and (ii) the JSC Members. 

  

	 	(d)	 Disclosures by the Functional Line Senior Scientists. Unless Pfizer grants prior written consent (which Pfizer may withhold in its sole
discretion) or to the extent expressly set forth herein, the Functional Line Senior Scientists shall only disclose information and data that Pfizer has disclosed pursuant to this Section 4.2.5 to (i) the Lead Seekers supervising the Lead
Seeking Project to which such information and data relates during the applicable Lead Seeking Phase, (ii) the Candidate Designees 

  
 25 

	 	
supervising the Candidate Designation Project to which such information and data relates during the applicable Candidate Designation Phase and (iii) the JSC Members.

  

	 	(e)	Disclosures by the Lead Seekers. Unless Pfizer grants prior written consent (which Pfizer may withhold in its sole discretion) or to the extent expressly
set forth herein, the Lead Seekers shall disclose information and data that Pfizer has disclosed pursuant to this Section 4.2.5 solely for the purpose of the applicable Lead Seeking Project and solely to (i) the Functional Line Senior
Scientists, (ii) the Lead Seeking Project Team Members assigned to such Lead Seeking Project and (iii) the JSC Members. 

  

	 	(f)	Disclosures by the Candidate Designees. Unless Pfizer grants prior written consent (which Pfizer may withhold in its sole discretion) or to the extent
expressly set forth herein, the Candidate Designees shall disclose information and data that Pfizer has disclosed pursuant to this Section 4.2.5 solely for the purpose of the applicable Candidate Designation Project and solely to (i) the
Functional Line Senior Scientists, (ii) the Candidate Designation Project Team Members assigned to such Candidate Designation Project and (iii) the JSC Members. 

 

	 	(g)	Disclosures to the Key Company Leadership. To the extent necessary to determine whether to seek Intent to Access or AIP, or to exercise the Opt-In, the
Leveragers, the Lead Seekers, the Candidate Designees and the Functional Line Senior Scientists shall be permitted to disclose information and data that Pfizer has disclosed pursuant to this Section 4.2.5 to the Key Company Leadership;
provided that such disclosure is in the form of a written, high-level summary that has been approved by Pfizer’s JSC Members in writing in advance of such disclosure (subject to Pfizer’s JSC Members’ sole discretion)
within ten (10) Business Days of Pfizer’s JSC Members’ receipt of the applicable summary. To the extent Pfizer’s JSC Members do not approve any such written summary, the Company shall promptly destroy such written summary.

  

	 	(h)	Intellectual Property. For clarity, neither Pfizer’s disclosure nor provision of any information or data to the Company pursuant to this
Section 4.2.5 shall transfer to, or create in, the Company any right, title, interest, or claim thereto or to any Intellectual Property to which Pfizer or its Affiliates have any rights, and all information and data that Pfizer discloses or
provides to the Company pursuant to this Section 4.2.5 shall be subject to the terms hereof (including Article 12 and Section 20.3). 

  
 26 

 5. LEAD SEEKING PHASE 

 

	5.1	Generally. The Company shall not have any rights hereunder to conduct research or development with respect to any Targets, Compounds or Analogs unless and
until Pfizer grants the Company intent to access (“Intent to Access”) as set forth in Section 5.2. If Pfizer grants Intent to Access, the initial phase of the Collaboration (the “Lead Seeking Phase”) shall
commence, and the Company shall be permitted to conduct the Lead Seeking Activities, solely with respect to the applicable Target, Compounds or Analogs as and to the extent set forth in this Article 5 (subject to any restrictions, limitations and
obligations set forth in this Agreement). 

  

	5.2	Intent to Access. 

  

	 	5.2.1	Intent to Access Request. 

  

	 	(a)	General. In order to be granted Intent to Access, the Company shall be required to provide Pfizer with a written request therefor in the form of Exhibit
5.2.1(a) hereto (each such request, an “Intent to Access Request”), which shall include: 

  

	 	(i)	the proposed Target or Compound(s), including any applicable Markush Structures, on which the Company would like to conduct the Lead Seeking Activities,

  

	 	(ii)	a brief, high-level summary of the Lead Seeking Activities that the Company expects to conduct during the Lead Seeking Phase with respect to the applicable Target,
Compound, or Analogs (including whether the Company plans to conduct any high-throughput screening using a Pre-Made Plate), 

  

	 	(iii)	if the Company requires the ability to sublicense any rights granted hereunder or otherwise engage a Third Party or any of its Affiliates to conduct any activities in
connection with the Lead Seeking Activities, (A) a list of such Persons, (B) a description of the activities proposed to be conducted by such Persons in connection with the Collaboration, (C) the proposed location where such
activities will be performed, and (D) any additional rights or obligations that the Company plans to grant or apply to such Persons, and 

  

	 	(iv)	any other information that the Company would like Pfizer to take into account in determining whether to grant Intent to Access. 

 

	 	(b)	 Requests for Additional Information. Following receipt of an Intent to Access Request, if Pfizer concludes that additional information
(which information may include an Analog Plan) is required for Pfizer to determine whether to grant Intent to Access, Pfizer shall provide the Company with written notice requesting such information. The Company

  
 27 

	 	
shall not be required to provide Pfizer with such additional information, but Pfizer shall have the right to take into account the Company’s failure to do so in determining whether to grant
the applicable Intent to Access Request and any denial thereof in such circumstances shall be deemed to have been made in good faith. 

  

	 	(c)	Good Faith Intention. Notwithstanding anything to the contrary, the Company shall only request Intent to Access for Targets, Compounds and Analogs for
which the Company has an ongoing, good faith intention to conduct bona fide research, development, and commercialization as part of the Collaboration, taking into account any anticipated budgetary and workforce limitations. 

 

	 	5.2.2	Granting Intent to Access. 

  

	 	(a)	Procedure. 

  

	 	(i)	Subject to Section 5.2.2(a)(ii), to the extent reasonably practicable, Pfizer shall provide the Company with written notice granting (in accordance with
Section 5.2.2(b)) or denying (in accordance with Section 5.2.3) the Company’s Intent to Access Request within thirty (30) days of the Company providing Pfizer with such Intent to Access Request. Pfizer may grant or deny each such
request in good faith at its sole discretion. 

  

	 	(ii)	If Pfizer does not provide the Company with written notice within thirty (30) days as set forth in Section 5.2.2(a)(i), the Parties shall discuss the
applicable Intent to Access Request at the first JSC meeting that is scheduled to occur after expiration of such thirty (30) day period. If, following such discussion, Pfizer decides to grant Intent to Access, Pfizer’s JSC Members shall
provide the Company with written notice thereof in accordance with Section 5.2.2(b). Notwithstanding anything to the contrary, whether to grant or deny Intent to Access in whole or in part shall be determined by Pfizer in good faith at its sole
discretion. 

  

	 	(b)	Scope of Intent to Access. For clarity, in the event that Pfizer decides to grant Intent to Access, the written notice granting Intent to Access shall be
in the form attached as Exhibit 5.2.2(b) and shall set forth: 

  

	 	(i)	the Target, Compound(s) and/or Analog(s) on which the Company may conduct the Lead Seeking Activities; 

 

	 	(ii)	whether the Company shall be permitted to sublicense or otherwise engage any Third Parties or Affiliates in connection with the Lead Seeking Activities and any
additional rights, obligations or restrictions in connection therewith (to the extent the Company included such a request in the applicable Intent to Access Request), and 

 

	 	(iii)	any other restrictions, limitations or obligations that apply to the Company’s rights during the Lead Seeking Phase (the “Intent to Access Other
Restrictions”). In the event that the Intent to Access Other Restrictions include any Compounds or Analogs on which the Company is precluded from conducting the Lead Seeking Activities in connection with the Collaboration, such Compounds
and Analogs shall be deemed Restricted Compounds. 

  
 28 

	 	(c)	Lead Seeking Activities. Subject to the terms hereof, if Pfizer grants Intent to Access with respect to a Target or any Compounds or Analogs, the Company
shall be permitted to conduct the Lead Seeking Activities solely with respect to such Target, Compounds or Analogs (as applicable) as and to the extent (and subject to any restrictions and obligations) set forth in the written notice granting Intent
to Access. Such Lead Seeking Activities with respect to such Target, Compounds or Analogs (as applicable) shall be deemed a “Lead Seeking Project.” 

 

	 	5.2.3	Denial of Intent to Access. If Pfizer does not grant Intent to Access (in part or in whole), Pfizer shall provide the Company with written notice thereof
setting forth the Targets, Compounds, or Analogs for which Intent to Access was denied (including, for clarity, any applicable Markush Structures) and this Agreement shall terminate with respect to such Targets, Compounds and Analogs (including for
clarity, any compounds encompassed by any applicable Markush Structures), as applicable, in accordance with Section 20.2.4(a). 

  

	 	5.2.4	Grandfathered Intent to Access Targets and Compounds. As of the Effective Date, subject to the terms hereof, Intent to Access shall be deemed to be
granted solely with respect to those (a) Compounds as and to the extent (and subject to the limitations) set forth on Schedule 5.2.4(a) (the “Grandfathered Intent to Access Compounds”) and (b) the Targets as and to the
extent (and subject to the limitations) set forth on Schedule 5.2.4(b) (the “Grandfathered Intent to Access Targets”). If, following the Effective Date, the Company identifies Targets or compounds on which it performed research
and/or development in the Field prior to the Effective Date (as evidenced by data in the Company’s possession), and the Company would like such Targets or compounds to be deemed Grandfathered Intent to Access Targets or Grandfathered Intent to
Access Compounds (as applicable), the Company shall provide Pfizer with a written request therefor. Pfizer shall discuss and consider any such request in good faith; provided that (x) the Company has not already submitted such a
request for the applicable Target or Compound to Pfizer and (y) Pfizer has sole discretion with respect thereto. 

  
 29 

	5.3	Lead Seekers and Lead Seeking Project Teams. 

  

	 	5.3.1	Lead Seekers. The Company shall designate up to fifteen (15) senior employees of the Company with the expertise and qualifications set forth on
Schedule 5.3.1(a) (as such expertise and qualifications are generally understood in the veterinary pharmaceutical field) (each such employee, a “Lead Seeker”) to conduct, supervise and direct one or more Lead Seeking Projects. The
Lead Seekers as of the Effective Date shall be as set forth on Schedule 5.3.1(b). The Company shall comply with Section 12.9.6 with respect to all Lead Seekers. 

 

	 	5.3.2	Lead Seeking Project Teams. Each Lead Seeker supervising a Lead Seeking Project shall be permitted to designate a reasonable number of employees of the
Company (each such employee, a “Lead Seeking Project Team Member” and collectively, a “Lead Seeking Project Team”) to conduct such Lead Seeking Project under his or her direction and supervision. Only employees that
have the expertise and qualifications set forth on Schedule 5.3.2 as such expertise and qualifications are generally understood in the veterinary pharmaceutical industry as of the Effective Date shall be appointed to a Lead Seeking Project Team
(unless the JSC otherwise agrees in writing). The Company shall comply with Section 12.9.6 with respect to all Lead Seeking Project Team Members. 

  

	5.4	Screening Activities. 

  

	 	5.4.1	Screeners. If the Lead Seeking Activities include screening the Pfizer Library (or portions thereof), the Company shall ensure that the Persons that
perform such screening are expressly authorized to conduct such screening under the Screening Services Agreement or otherwise authorized by Pfizer in writing in its sole discretion (each, a “Screener”). The Company shall ensure that
each Screener (a) performs such screening in accordance with the Lead Seekers’ instructions and the applicable notice granting Intent to Access and (b) is not provided with the structures of any Compounds identified through such
screening. 

  

	 	5.4.2	Results. After screening the Pfizer Library (or portions thereof), the Screeners shall provide the results to the applicable Lead Seeker, and if such Lead
Seeker would like information regarding any Compounds identified by such screening with selective and specific binding affinity for the applicable Target (each, a “Hit”) (including the structure thereof), such Lead Seeker shall
submit a request to the Curator in accordance with Section 4.2.5. Notwithstanding anything to the contrary, the Curator shall have no obligation to disclose the structure of, or any other information regarding, any Hits if Pfizer determines (in
its sole discretion) that doing so may violate an Encumbrance. Neither the Screeners, the Lead Seekers nor any other Collaboration Employee may discuss the screening results (including the identity of the Hits) with the Leveragers unless and until
the Curator consents thereto in writing. 

  

	 	5.4.3	 Process. The Company shall be solely responsible for preparing any and all screens to conduct screening activities during the Lead
Seeking Phase and, subject 

  
 30 

	 	
to the terms hereof, shall be permitted to use the 384-well plates that contain Compounds (the “Pre-Made Plates”), and any custom made plates that contain Compounds, in its
possession (in accordance with, and subject to, the terms of any written agreements between the Parties with respect thereto). 

  

	5.5	Diligence. During the Lead Seeking Phase, the Company shall exercise Commercially Reasonable Efforts to conduct the Lead Seeking Activities with respect
to each Lead Seeking Project. 

  

	5.6	Costs and Expenses. The Company shall be solely responsible for conducting the Lead Seeking Activities at its own cost and expense.

  

	5.7	License and Other Rights. For clarity, the Company’s license to the Pfizer IP during the Lead Seeking Phase shall be as set forth in
Section 3.1.1, and during the Lead Seeking Phase, the Company shall not be granted any rights hereunder to engage in any activities with respect to research, development, manufacture, or commercialization of any Compounds or Analogs, except the
Lead Seeking Activities. 

 6. AIP AND THE CANDIDATE DESIGNATION PHASE 

 

	6.1	Generally. To conduct the Candidate Designation Activities with respect to any Compounds or Analogs in a Compound Class involved in a Lead Seeking
Project, the Company shall be required to obtain approval in principle (“AIP”) from the JSC. 

  

	6.2	AIP Requests. 

  

	 	6.2.1	General. Requests for AIP must be made on a Compound Class-by-Compound Class basis and the Company may request AIP for one or more Compound Series in a
Compound Class by providing Pfizer’s JSC Members with written notice in the form of Exhibit 6.2.1 hereto (each such notice, an “AIP Request”) setting forth: 

 

	 	(a)	one (1) or more proposed Compound Series (including the applicable Markush Structures) for which AIP is being requested (collectively, the “Proposed AIP
Compound Series”) and related proposed Compound Class, 

  

	 	(b)	any Intellectual Property of Pfizer, any of its Affiliates or any Third Party of which the Company is aware that relates or may relate to the Company’s proposed
research, development, manufacture, or commercialization with respect to any Compounds or Analogs in the Proposed AIP Compound Series, 

  

	 	(c)	if the Company requires the ability to sublicense any rights granted hereunder or otherwise engage a Third Party or any of its Affiliates to exercise any of its rights
or perform any of its obligations in connection with the Candidate Designation Activities, (A) a list of such Persons, (B) a description of the activities proposed to be conducted by such Persons in connection with the Collaboration,
(C) the proposed location where such activities will be performed, and (D) any additional rights or obligations that the Company plans to grant or apply to such Persons. 

 

	 	(d)	any other information that the Company would like Pfizer to take into account in determining whether to grant AIP. 

  
 31 

	 	6.2.2	Species and Indication. Each AIP Request also shall set forth those therapeutic indications and target species for which the Company anticipates
researching, developing and commercializing the Proposed AIP Compound Series. For clarity, specifying such indications and target species shall not automatically limit the scope of AIP that is granted with respect to the applicable Proposed AIP
Compound Series. 

  

	 	6.2.3	Good Faith Intention. The Company shall only submit an AIP Request if it has an ongoing good faith intention to conduct bona fide research, development,
and commercialization as part of the Collaboration in connection with the Proposed AIP Compound Series, taking into account any anticipated budgetary and workforce limitations. If, at any time, the Company concludes that it will not request AIP for
any Compound Series that is the subject of a Lead Seeking Project, or no longer intends to conduct bona fide research, development or commercialization as part of the Collaboration, the Company shall inform the JSC in writing and this Agreement will
terminate with respect to such Compound Series in accordance with Section 20.2.3(a). 

  

	 	6.2.4	Requests for Additional Information. Following receipt of an AIP Request, if Pfizer concludes that additional information (which information may include
an Analog Plan) is required for Pfizer to determine whether to grant AIP, Pfizer shall provide the Company with written notice requesting such information. The Company shall not be required to provide Pfizer with such additional information, but
Pfizer (including its JSC Members) shall have the right to take into account the Company’s failure to do so in determining whether to grant the applicable AIP Request and any denial thereof in such circumstances shall be deemed to have been
made in good faith. 

  

	6.3	Grant of an AIP Request. 

  

	 	6.3.1	Generally. If the JSC decides to grant AIP in whole or in part, the JSC shall provide the Company with written notice thereof in accordance with
Section 6.3.2 within thirty (30) days of the Company providing the AIP Request to Pfizer’s JSC Members; provided that if the JSC is not able to agree regarding whether to grant AIP within such thirty (30) day period
for any reason, the JSC Members shall discuss such AIP Request at the next JSC meeting scheduled to occur after expiration of such thirty (30) day period. If, following such discussion, the JSC decides to grant AIP, the JSC Members shall notify
the Company in writing in accordance with Section 6.3.2. The JSC may grant or deny AIP (in part or in whole) using good faith in its sole discretion. Pfizer’s JSC Members shall have the right to discuss each AIP Request with Pfizer, its
Affiliates and its and their employees and advisors in connection with determining whether to grant such AIP Request. 

  
 32 

	 	6.3.2	Scope of AIP. For clarity, in the event that the JSC decides to grant AIP, the written notice granting AIP shall be in the form attached as Exhibit 6.3.2
(the “AIP Notice”) and shall set forth: 

  

	 	(a)	each Compound Series (including the applicable Markush Structure) for which AIP is granted, including any Compounds and Analogs excluded therefrom (which shall be
deemed Restricted Compounds) (the Compounds and Analogs in such Compound Series, collectively, the “AIP Compound Series”) and the related Compound Class, 

 

	 	(b)	the applicable Target, 

  

	 	(c)	the species (the “Species”) and indications (the “Indications”) in the Field for which AIP is granted (which, for clarity, may be
broader than the proposed Species and Indications set forth in the AIP Request), 

  

	 	(d)	any Encumbrances that apply to the Company’s rights with respect to the AIP Compound Series to the extent that Pfizer has Knowledge thereof,

  

	 	(e)	whether the Company shall be permitted to sublicense or otherwise engage any Third Parties or Affiliates in connection with the Candidate Designation Activities and any
additional rights, obligations or restrictions in connection therewith (to the extent the Company included such a request in the applicable AIP Request), and 

 

	 	(f)	any other restrictions, limitations or obligations that apply to the Company’s rights with respect to the AIP Compound Series (the “Other
Restrictions”). 

  

	 	(g)	In the AIP Notice, Pfizer shall have the right to designate as Restricted Compounds those compounds encompassed by Markush Structures within the same Compound Class (as
reasonably determined by Pfizer) as the AIP Compound Series (as set forth in the applicable AIP Notice) that are identified by Pfizer; provided that such Markush Structures encompass any compounds on which research, development or
commercialization has been conducted by or on behalf of Pfizer or its Affiliates (including by, through or with a Third Party). 

  

	6.4	 Denial of an AIP Request. In the event that the JSC does not grant AIP (in part or in whole), the JSC shall provide the Company with
written notice setting forth those Compounds and Analogs for which AIP was denied (including, for clarity, any related Markush Structures) and the related Compound Class. For clarity, Pfizer shall also be permitted to include in any such denial of
AIP those compounds encompassed by Markush Structures (a) within such related Compound Class (as reasonably determined by Pfizer) and (b) that encompass any compounds on which research, development or

  
 33 

	 	
commercialization has been conducted by or on behalf of Pfizer or its Affiliates (including by, with or through a Third Party) (regardless of whether the applicable AIP Request included such
compounds). This Agreement shall immediately terminate with respect to the Compounds and Analogs for which AIP was denied (including any compounds encompassed by any such Markush Structure) in accordance with Section 20.2.4(b).

  

	6.5	Grandfathered AIP Compounds. As of the Effective Date, subject to the terms hereof, AIP shall be deemed to be granted solely with respect to those
Targets, Compounds and Analogs (as applicable) as and to the extent (and subject to the limitations) set forth on Schedule 6.5 (collectively, the “Grandfathered AIP Compounds”). If, following the Effective Date, the Company
identifies additional compounds on which it performed research and/or development in the Field prior to the Effective Date (as evidenced by data in the Company’s possession with respect thereto), and the Company would like such compounds to be
deemed Grandfathered AIP Compounds, the Company shall provide Pfizer with a written request therefore. Pfizer shall discuss and consider any such request in good faith; provided that (x) the Company has not already submitted such
request to Pfizer and (y) Pfizer has sole discretion with respect thereto. 

  

	6.6	Candidate Designation Activities. Subject to the terms hereof, if the JSC grants AIP for any AIP Compound Series, the second phase of the Collaboration
(the “Candidate Designation Phase”) shall commence, and the Company shall have the right to conduct the Candidate Designation Activities, solely with respect to such AIP Compound Series as and to the extent (and subject to any
restrictions and obligations) set forth in the AIP Notice. The Candidate Designation Activities with respect to an AIP Compound Series shall be deemed a “Candidate Designation Project.” 

 

	6.7	Candidate Designees. The Company shall designate up to ten (10) senior employees of the Company with the expertise and qualifications set forth on
Schedule 6.7(a) (as such expertise and qualifications are generally understood in the veterinary pharmaceutical field) (each such employee, a “Candidate Designee”) to supervise and direct one or more Candidate Designation Projects.
The Candidate Designees as of the Effective Date shall be as set forth on Schedule 6.7(b). The Company shall comply with Section 12.9.6 with respect to all Candidate Designees. 

 

	6.8	Candidate Designation Project Teams. Each Candidate Designee supervising Candidate Designation Activities shall be permitted to designate a reasonable
number of employees of the Company (each such employee, a “Candidate Designation Project Team Member” and collectively, a “Candidate Designation Project Team”) to conduct such Candidate Designation Activities under
his or her direction and supervision. Only employees that have the expertise and qualifications set forth on Schedule 6.8 as such expertise and qualifications are generally understood in the veterinary pharmaceutical industry as of the Effective
Date shall be appointed to a Candidate Designation Project Team (unless the JSC otherwise agrees in writing). The Company shall comply with Section 12.9.6 with respect to all Candidate Designation Project Team Members. 

  
 34 

	6.9	Diligence. During the Candidate Designation Phase, the Company shall exercise Commercially Reasonable Efforts to conduct the Candidate Designation
Activities with respect to the AIP Compound Series. 

  

	6.10	Costs and Expenses. The Company shall be solely responsible for conducting the Candidate Designation Activities at its own cost and expense.

  

	6.11	License and Other Rights. For clarity, the Company’s license to the Pfizer IP during the Candidate Designation Phase shall be as set forth in
Section 3.1.2, and during the Candidate Designation Phase, the Company is not granted any rights hereunder to engage in any activities with respect to research, development, manufacture, or commercialization of any Compounds or any Analogs
thereof, except the Candidate Designation Activities. 

 7. OPT-IN 

 

	7.1	Generally. 

  

	 	7.1.1	The Opt-In. Subject to the terms hereof, Pfizer hereby grants the Company an option (the “Opt-In”) to be granted a license in the form
attached as Exhibit 7.2.2 with respect to each AIP Compound Series. 

  

	 	7.1.2	Certain Restrictions. Unless and until the Company exercises the Opt-In for an AIP Compound Series, the Company shall not conduct (a) any research or
development on such AIP Compound Series in connection with the Collaboration if any Compounds or Analogs in such AIP Compound Series have reached the stage of development at which the Company would designate such Compound or Analog (as applicable)
as a Development Status Compound or (b) the Restricted Development Activities with respect to any Compounds or Analogs in such AIP Compound Series in connection with the Collaboration. 

 

	7.2	Exercising the Opt-In. 

  

	 	7.2.1	The Opt-In Notice. In the event that the Company would like to exercise the Opt-In, the Company shall provide Pfizer with written notice in the form set
forth on Exhibit 7.2.1 hereto (the “Opt-In Notice”) that includes: 

  

	 	(a)	the AIP Notice, and 

  

	 	(b)	any Intellectual Property of Pfizer, any of its Affiliates or any Third Party of which the Company became aware following the grant of AIP that relates or may relate to
the Company’s proposed research, development, manufacture, or commercialization of any Compounds or Analogs in the Proposed AIP Compound Series. 

  

	 	7.2.2	 The License Agreement. Promptly following Pfizer’s receipt of an Opt-In Notice, Pfizer and the Company shall promptly meet to
finalize and execute a 

  
 35 

	 	
license agreement in the form attached as Exhibit 7.2.2 (each such license agreement, a “License Agreement”); provided that, before execution, each License
Agreement shall be updated to include: 

  

	 	(a)	the AIP Compound Series, Indications, Species, Encumbrances and Other Restrictions applicable to such AIP Compound Series (each, as set forth in the AIP Notice and with
respect to such Encumbrances, any additional Encumbrances about which Pfizer obtains Knowledge), 

  

	 	(b)	any Patent Rights Controlled by Pfizer or its Affiliates that Cover any Compounds or Analogs included in the AIP Compound Series that have been filed as of the
effective date of the License Agreement; provided that (i) AIP was granted with respect to the invention claimed in such Patent Rights and (ii) the Company reimburses Pfizer for the costs and expenses incurred by or on behalf
of Pfizer and its Affiliates during the Term in connection with the Prosecution Activities for such Pfizer Patent Rights. For clarity, the Company’s failure to reimburse Pfizer with respect to any applicable Patent Rights shall result in such
Patent Rights being excluded from the Patent Rights licensed to the Company under the applicable License Agreement, 

  

	 	(c)	the amount of the Milestone Payment and Royalties (which shall be Zero US Dollars (US$0.00) if the Compounds and Analogs in the AIP Compound Series are Grandfathered
Intent to Access Compounds or Grandfathered AIP Compounds), 

  

	 	(d)	the effective date of the License Agreement, and 

  

	 	(e)	the Company’s rights to present or publish under the License Agreement without Pfizer’s prior written consent (as determined by Pfizer in its good faith sole
discretion). 

 Notwithstanding anything to the contrary, the terms of this Agreement with respect to the AIP
Compound Series to which a License Agreement relates and the Intellectual Property licensed thereunder (the “License Subject Matter”) shall be subject to the terms of such License Agreement, and, in the event of a conflict, at any
time, and from time to time, between this Agreement and such License Agreement with respect to such License Subject Matter, the License Agreement shall control. Each License Agreement shall not be effective until execution thereof by both Parties.

  
 36 

	 	7.2.3	Upfront Payment. Upon execution of each License Agreement, the Company shall pay Pfizer a one-time, non-refundable, non-creditable upfront payment of one
million five hundred thousand US Dollars (US$1,500,000) (the “Upfront Payment”); provided that the Company shall not be required to pay Pfizer the Upfront Payment for any Grandfathered AIP Compounds or Grandfathered
Intent to Access Compounds. 

  

	 	7.2.4	Royalties and Milestone Payments. The royalties and Milestone Payments that are payable under the License Agreement shall be as set forth in the License
Agreement. For clarity, the Company shall not be required to pay any royalties or Milestone Payments with respect to the Grandfathered AIP Compounds or Grandfathered Intent to Access Compounds. 

 

	7.3	Opt-In Expiration and Consequences. 

  

	 	7.3.1	Timing for Exercising the Opt-In. Subject to the terms hereof, the Company shall have the right to exercise the Opt-In with respect to an AIP Compound
Series at any time beginning upon the date that the JSC grants AIP for such AIP Compound Series and ending upon the fifth (5th) anniversary of such date (the “Opt-In Deadline”). 

 

	 	7.3.2	Failure to Exercise the Opt-In. With respect to any Compounds or Analogs in an AIP Compound Series, if the Company does not exercise the applicable Opt-In
as of the Opt-In Deadline, this Agreement shall terminate with respect to the AIP Compound Series in accordance with Section 20.2.3(b). 

 8. REVERSION RIGHT 
  

	8.1	The Reversion Right. Subject to this Article 8, at any time beginning upon receipt of AIP for an AIP Compound Series, and from time to time thereafter,
Pfizer and its Affiliates shall have the right (the “Reversion Right”) to terminate this Agreement and any related License Agreement with respect to any Compounds and Analogs included in such AIP Compound Series so long as Pfizer
exercises good faith in connection therewith. Notwithstanding anything to the contrary herein, Pfizer and its Affiliates shall not have the Reversion Right with respect to the Grandfathered AIP Compounds (except those Grandfathered AIP Compounds set
forth on Schedule 8.1). 

  

	8.2	Regulatory Filing Notice. 

  

	 	8.2.1	Filing Notices. The Company shall be required to provide Pfizer with written notice no less than ninety (90) days prior to the date that the Company
reasonably believes that it will submit its first Regulatory Approval Application in a Major Market Country for each Compound or Analog in an AIP Compound Series, with such notice setting forth such proposed filing date (such notice, a
“Filing Notice”). If, at any time, the Company reasonably believes that submission of such a Regulatory Approval Application will be delayed for more than thirty (30) days after the proposed filing date set forth in its most
recent Filing Notice, the Company shall provide Pfizer with an additional Filing Notice, specifying the new proposed filing date. 

  
 37 

	 	8.2.2	Submission. Upon submission of its first Regulatory Approval Application in a Major Market Country for each Compound or Analog in an AIP Compound Series,
the Company shall provide Pfizer with written notice thereof. 

  

	8.3	Expiration of the Reversion Right. The Reversion Right with respect to a Compound or Analog in an AIP Compound Series shall expire upon the first
submission of the Regulatory Approval Application for such Compound or Analog (as applicable) in a Major Market Country; provided that if the most recent Filing Notice was provided to Pfizer less than thirty (30) days prior to
such submission, the Reversion Right shall expire upon the earlier of (a) thirty (30) days after the date of such Filing Notice and (b) thirty (30) days after such submission (the applicable expiration date, the
“Reversion Expiration Date”). Notwithstanding the foregoing, in the event that Pfizer is prevented by court order or Applicable Law from exercising the Reversion Right and the Reversion Expiration Date occurs while Pfizer continues
to be so prevented, the Reversion Expiration Date shall be tolled until twenty (20) days after such court order or Applicable Law no longer prevents Pfizer from exercising the Reversion Right. 

 

	8.4	Exercising the Reversion Right and Compensation to the Company. 

 

	 	8.4.1	Procedure for Exercising the Reversion Right. Pfizer may exercise the Reversion Right with respect to a Compound or Analog in an AIP Compound Series by
providing the Company with prior written notice (the “Reversion Notice”) no later than the applicable Reversion Expiration Date; provided that, subject to Sections 8.4.2 and 8.4.3, exercise of the Reversion Right shall
not be effective until Pfizer pays the Company the Fair Market Value of the applicable Compound or Analog. 

  

	 	8.4.2	Fair Market Value Determination. The Company shall provide Pfizer with written notice (the “FMV Notice”) within thirty (30) days of
Pfizer providing each Reversion Notice, which notice shall set forth the Fair Market Value of the Compound or Analog to which the Reversion Right applies as reasonably determined by the Company (and all supporting documentation thereof). The Parties
shall meet in person, by telephone, or by videoconference no later than sixty (60) days after the Company provides Pfizer with the FMV Notice to discuss and negotiate the amount of the Fair Market Value of the applicable Compound or Analog. If
the Parties agree in writing on the Fair Market Value for the applicable Compound or Analog, Pfizer shall pay the Company such amount within thirty (30) days of the date on which such amount is agreed. Notwithstanding the foregoing, if the
Parties fail to agree in writing on the Fair Market Value for the applicable Compound or Analog for any reason within ninety (90) days of the FMV Notice, either Party may submit such matter for resolution in accordance with Section 21.4.2.

  
 38 

	 	8.4.3	Exceptions to the Compensation Obligation. Pfizer shall not be required to pay any compensation (including the applicable Fair Market Value) to the
Company to exercise the Reversion Right of a Compound or Analog in an AIP Compound Series if the Company has not performed any material development activities designed to obtain Regulatory Approval during the twelve (12) month period prior to
the date on which Pfizer provides the Company with the applicable Reversion Notice. By way of example, and without expanding the foregoing, the Company shall be deemed to have performed such material development activities during such twelve
(12) month period if: 

  

	 	(a)	at least one (1) FTE of the Company has performed the Lead Seeking Activities, Candidate Designation Activities or the Development Activities (as applicable) on
the applicable Compound or Analog during such twelve (12) month period or 

  

	 	(b)	the Company has performed any analoguing, in vitro testing or in vivo testing with respect to the applicable Compound or Analog in
connection with the Collaboration during such twelve (12) month period. 

  

	8.5	 License to Company Formulation Technology. If the Company or any of its Affiliates Control any Patent Rights or Know-How with respect to
formulations that are necessary to research, develop, make, have made, use, sell, offer for sale, import or export the Compound or Analog for which the Reversion Right is being exercised and such Patent Rights and Know-How have been conceived,
reduced to practice or otherwise invented or generated by or on behalf of the Company, its Affiliates or its permitted sublicensees outside the scope of the Collaboration (such Patent Rights or Know-How, the “Company Formulation
Technology”), upon Pfizer’s written request in the applicable Reversion Notice, the Company hereby grants, and shall cause its Affiliates to grant, to Pfizer a world-wide, non-exclusive, sublicensable, royalty-bearing, perpetual
license to the Company Formulation Technology to research, develop, make, have made, use, sell, offer for sale, import and export such Compound or Analog for which the Reversion Right is being exercised, and any other compounds in the same compound
class (as reasonably determined by Pfizer) as such Compound or Analog (as applicable), and any related pharmaceutical products in the Territory outside the Field. Each such request shall set forth the Company Technology Royalty Rate with respect to
the applicable Company Formulation Technology as reasonably determined by Pfizer (and all supporting documentation thereof). The Parties shall discuss and negotiate regarding the amount of the applicable Company Technology Royalty Rate in connection
with the discussions and negotiations regarding the related Fair Market Value of the Compound or Analog for which the Reversion Right is being exercised. If the Parties agree in writing on the Company Technology Royalty Rate for the applicable
Company Formulation Technology, Pfizer shall pay to the Company royalties based on multiplying the aggregate Net Sales (as defined in Exhibit 7.2.2, applied mutatis mutandis) of the pharmaceutical products Covered by any Patents, or
that incorporate any Know-How, included in the Company Formulation Technology by the Company Technology Royalty Rate to the extent such Net Sales are invoiced as of or following the date of the Reversion Notice until expiration of the Royalty Term
(as defined in Exhibit 7.2.2, applied mutatis 

  
 39 

	 	
mutandis); provided that the Company Technology Royalty Rate with respect to a particular country or regulatory jurisdiction shall be reduced by fifty percent (50%) if
the Data Exclusivity Period (as defined in Exhibit 7.2.2, applied mutatis mutandis) with respect to the applicable pharmaceutical product has expired, and there is no Valid Claim Covering such product in such country or regulatory
jurisdiction. For clarity, if the First Commercial Sale of the applicable Licensed Product has not occurred as of the date of the Reversion Notice in a particular country or regulatory jurisdiction, such royalties shall not be payable in such
country or regulatory jurisdiction until the First Commercial Sale of such Licensed Product occurs in such country or regulatory jurisdiction. Notwithstanding the foregoing, if the Parties fail to agree in writing on the Company Technology Royalty
Rate for the applicable Company Formulation Technology for any reason within ninety (90) days of the FMV Notice, either Party may submit such matter for resolution in accordance with Section 21.4.2 and Pfizer shall pay to the Company
royalties as described in accordance with the foregoing sentence; provided that such royalties shall be payable (a) upon the later of (i) resolution of the Company Technology Royalty Rate in accordance with
Section 21.4.2 and (ii) the First Commercial Sale of each applicable product (b) until expiration of the Royalty Term (as defined in Exhibit 7.2.2, applied mutatis mutandis). 

 

	8.6	Good Faith. Notwithstanding anything to the contrary herein, the Company shall not oppose, or object to, Pfizer’s exercise or attempt to exercise its
Reversion Right (whether or not in connection with a judicial proceeding), except on the ground that Pfizer did not exercise good faith. 

 9. PAYMENTS AND TAX 
  

	9.1	Annual Access Fee. 

  

	 	9.1.1	Initial Annual Access Fee. During the Term, the Company shall pay on an annual basis the non-refundable annual access fee (the “Annual Access
Fee”). The amount of the first Annual Access Fee of One Million One Hundred Sixty-Two Thousand U.S. Dollars ($1,162,000) will be payable within forty-five (45) days of the Effective Date. The amount of each subsequent Annual Access Fee
shall be Seven Hundred Ninety-Six Thousand U.S. Dollars ($796,000) and shall be payable on each anniversary of payment of the initial Annual Access Fee, subject to adjustment as provided in Section 9.1.2 below. 

 

	 	9.1.2	 Changes to the Annual Access Fee. If Pfizer reasonably believes that the Maintenance Costs for a twelve (12) month period (excluding
costs in respect of maintaining the Pfizer Restricted Database) will exceed by five percent (5%) or more, the amount equal to (a) the Annual Access Fee for such twelve (12) month period, minus (b) the actual annual costs and
expenses incurred by or on behalf of Pfizer and its Affiliates in connection with maintaining the Pfizer Restricted Database as of the Effective Date, Pfizer shall have the right to provide the JSC with written notice thereof (including the amount
and reasonable supporting documentation of the anticipated Maintenance Costs) no later than sixty (60) days prior to the due date of such Annual Access Fee. Promptly after receipt of such notice,

  
 40 

	 	
the JSC shall meet to discuss and decide whether it reasonably agrees with Pfizer’s determination. If the JSC agrees with Pfizer (including regarding the amount of the anticipated
Maintenance Costs), the Annual Access Fee shall be increased to reflect such amount and the Company shall pay such increased Annual Access Fee for the remainder of the Term (unless and until the Annual Access Fee is further adjusted pursuant to this
Section). If the JSC does not agree with Pfizer (including with respect to the amount of the anticipated Maintenance Costs), such matter shall be resolved in accordance with Section 2.1.7. 

 

	9.2	Invoiced Costs. Pfizer shall invoice the Company for the Invoiced Costs incurred by Pfizer and/or Affiliates on a quarterly basis. The Company shall pay
Pfizer the amount set forth in each such invoice within forty-five (45) days of receipt thereof. 

  

	9.3	Disclaimer. The Parties hereby acknowledge and agree that payments to Pfizer pursuant to Sections 9.1 and 9.2 are solely intended to reimburse costs
incurred by and on behalf of Pfizer and its Affiliates in connection with the Collaboration and shall not be used as a measure of damages if this Agreement is terminated for any reason. 

 

	9.4	Third Party Payments. Any and all royalties, sublicense fees, milestones, and other fees payable to Third Parties attributable to or arising from
Pfizer’s grant of, or the Company’s exercise of, the licenses and other rights granted hereunder, including pursuant to Section 3.1 (“Third Party Payments”), shall be the Company’s sole responsibility. The
Company shall pay the Third Party Payments directly to such Third Parties; provided that, if the applicable Third Party does not permit the Company to pay such Third Party Payments to such Third Party directly (whether pursuant to the
applicable license agreement with Pfizer or otherwise), the Parties shall reasonably cooperate in good faith to ensure that such Third Party Payments are paid by the Company to Pfizer in such a manner that ensures Pfizer’s payment thereof in
compliance with the obligations to such Third Party. Such cooperation shall include the Company (a) providing Pfizer with reasonably detailed written reports reflecting calculation of the applicable Third Party Payments and any other reports
required by the applicable Third Party and (b) paying Pfizer the applicable Third Party Payments by wire transfer of immediately available funds to the bank account designated by Pfizer in writing no less than forty-five (45) days prior to
the due date of such payment to the applicable Third Party. 

  

	9.5	Other Amounts. The Company shall pay any other amounts due Pfizer under this Agreement within forty-five (45) days of Pfizer’s invoice therefor.

  

	9.6	Payment Method. All payments from the Company to Pfizer shall be made by wire transfer in US Dollars to the credit of such bank account as may be
designated in writing from time to time by Pfizer. Any payment which falls due on a date which is not a Business Day may be made on the next succeeding Business Day. 

  
 41 

	9.7	Late Payments. Except as expressly provided to the contrary in this Agreement, any amount not paid when due pursuant to this Agreement (and any amounts
billed or otherwise invoiced or demanded and properly payable that are not paid within thirty (30) days of such bill, invoice or other demand) shall accrue interest at a rate per annum equal to the Prime Rate. 

 

	9.8	Taxes. 

  

	 	9.8.1	It is understood and agreed between the Parties that any amounts payable by the Company to Pfizer hereunder are exclusive of any and all applicable sales, use, VAT,
GST, excise, property, and other taxes, levies, duties, or fees. 

  

	 	9.8.2	If the Company is required to make a payment to Pfizer subject to a deduction of tax or withholding tax (a “Withholding Tax Requirement”), then the sum
payable by the Company (in respect of which such deduction or withholding is required to be made) shall be increased to the extent necessary to ensure that Pfizer receives a sum equal to the sum which it would have received had no such Withholding
Tax Requirement been applicable, and the amount required to be deducted or withheld shall be remitted by the Company in accordance with Applicable Law. Any such withholding taxes required under Applicable Law to be paid or withheld shall be an
expense of, and borne solely by, the Company. 

  

	 	9.8.3	The Parties agree to cooperate and produce on a timely basis any tax forms or reports, including an IRS Form W-8BEN, reasonably requested by the other Party in
connection with any payment made by a Party to the other Party under this Agreement. 

  

	9.9	Financial Records, Audits. 

  

	 	9.9.1	 General. Each Party shall maintain complete and accurate records in sufficient detail to permit the other Party to confirm the accuracy
of any payments made or required to be made hereunder. Upon written notice to the other Party, each Party shall have the right, at its own expense, using an independent certified public accounting firm (that has been retained on an hourly or flat
fee basis and receives no contingency fee or other bounty or bonus fee) selected by such Party and reasonably acceptable to the other Party to audit the other Party’s books and records during normal business hours not more than once during any
Calendar Year, solely to verify the accuracy of any payments made or required to be made hereunder in respect of any Calendar Year ending not more than three (3) years prior to the date of such notice (provided that such
restriction on the number of permitted audits per Calendar Year shall not apply to the extent that (a) Pfizer has a reasonable, good faith belief that the Company or any of its Affiliates or permitted sublicensees failed to comply with any of
their obligations hereunder or (b) a prior audit demonstrates that the Company or any of its Affiliates or permitted sublicensees failed to comply with any of their obligations hereunder). The other Party shall reasonably cooperate with
such audit. The independent certified public accounting firm shall prepare a report based on each such audit, a 

  
 42 

	 	
copy of which shall be sent or otherwise provided to the audited Party at the same time that it is sent or otherwise provided to the auditing Party, and such report shall contain the conclusions
of such accounting firm and will specify that the amounts paid pursuant thereto were correct or, if incorrect, the amount of any underpayment or overpayment. The opinion of said independent accounting firm in connection therewith shall be binding on
the Parties, other than in the case of manifest error. 

  

	 	9.9.2	Audit Fees and Expenses. The auditing Party shall be responsible for any and all fees and expenses it incurs in connection with an audit conducted in
accordance with Section 9.9.1; provided that, in the event that such an audit reveals an underpayment by the Party being audited or an overpayment by the auditing Party of more than five percent (5%) as to the period subject
to such audit, the Party being audited shall reimburse the auditing Party for its reasonable and documented out-of-pocket costs and expenses of such audit within thirty (30) days of the auditing Party’s invoice therefor.

  

	 	9.9.3	Payment of Deficiency/Overpayments. 

  

	 	(a)	If any audit conducted in accordance with Section 9.9.1 establishes that a Party underpaid any amounts due to the other Party under this Agreement, the underpaying
Party shall pay the other Party any such deficiency within thirty (30) days of written notice thereof. For the avoidance of doubt, such payment shall be considered a late payment, subject to Section 9.7. 

 

	 	(b)	If any audit conducted in accordance with Section 9.9.1 establishes that a Party (the “Overpaying Party”) has overpaid any amounts due to the
other Party under this Agreement, such other Party shall, at the Overpaying Party’s sole discretion, (i) refund the excess payments to the Overpaying Party within thirty (30) days of receipt of written notice thereof or
(ii) offset all such excess payments against any outstanding and future amounts owed to the other Party hereunder. 

 10. REPORTS, RECORDS AND OPERATIONAL AUDIT RIGHTS 
  

	10.1	Progress Reports. On a quarterly basis or as the JSC otherwise reasonably requests, the Company shall provide the JSC with a written report summarizing
the Lead Seeking Activities and Candidate Designation Activities conducted and results achieved in connection therewith (as applicable) (including, for clarity, any Compounds and Analogs on which such activities were conducted) during the prior
Calendar Quarter and any Lead Seeking Activities and Candidate Designation Activities expected to be conducted during the next Calendar Quarter. 

  

	10.2	 Collaboration Know-How. Within forty-five (45) days of the first day of each Calendar Quarter, the Company shall, at its own
expense, provide Pfizer with a copy of the Collaboration Know-How generated during the previous Calendar Quarter. Such Collaboration Know-How shall be provided to Pfizer in the format set forth on Schedule 10.2

  
 43 

	 	
or such other format reasonably requested by Pfizer in writing at the Company’s cost and expense, unless such other format materially increases the Company’s costs and expenses, in
which case, the Parties shall meet to agree upon an appropriate format in writing. For clarity, Pfizer shall have the right (but not the obligation) to add the Collaboration Know-How to the Pfizer Database, the Pfizer Restricted Databases and any
other databases or systems that Pfizer or any of its Affiliates owns, controls or otherwise has access to (subject to Article 12). 

  

	10.3	Records. The Company shall maintain complete and accurate records (in the form of technical notebooks and/or electronic files where appropriate) of all
work conducted by or on behalf of the Company during, and in connection with, the Collaboration (the “Development Records”). The Development Records, including any and all electronic and physical files where such information is
contained, shall fully and properly reflect all work done and results achieved in the performance of the Lead Seeking Activities and Candidate Designation Activities (as applicable) in sufficient detail and in good scientific manner appropriate for
patent and regulatory purposes and in compliance with all Applicable Laws. Without limiting any other rights or remedies hereunder, during the Term and for three (3) years after final payments have been made under this Agreement, upon
Pfizer’s reasonable request to the Company, Pfizer shall have the right to (a) review and copy the Development Records during normal business hours and (b) obtain access to originals, with respect to each of the foregoing (a) and
(b), for patent or regulatory purposes or other legal proceedings or inquiries related to the Company’s compliance with the FCPA, its internal compliance policies or any “corporate integrity” or similar agreement with any Governmental
Authority to which it is a party. 

  

	10.4	Operational Audit Rights. At any time, during normal business hours and upon reasonable prior notice (which shall be no less than ten (10) Business
Days), Pfizer may send a reasonable number of qualified representatives of Pfizer, its Affiliates, and/or a Third Party reasonably acceptable to the Company to inspect the Company’s, its Affiliates’ and its permitted sublicensees’ (as
applicable) facilities used in connection with the Collaboration and review the records and operations related to the Company’s exercise of its rights and performance of its obligations hereunder to ensure compliance with the terms hereof. Such
audits shall occur no more than twice per Calendar Year, except to the extent that (a) Pfizer has a reasonable, good faith belief, or a prior audit demonstrated, that the Company or any of its Affiliates or its permitted sublicensees failed to
comply with any of their obligations hereunder or (b) such audit is being conducted in accordance with Section 12.9.5(a)(i). Pfizer shall be responsible for all costs associated with conducting an audit pursuant to this Section, except if
such audit demonstrates, or the audit immediately preceding such audit demonstrated, that the Company, its Affiliates or its permitted sublicensees failed to comply with any obligations hereunder (and in such circumstances, the Company shall be
responsible for all such costs and expenses). The Company shall, and shall cause its Affiliates and its permitted sublicensees to, reasonably cooperate with any representatives conducting any such audit. Such audits shall be conducted in a manner to
minimize interference with the Company’s performance of its businesses in this Section, the Company may require that, to the extent applicable, (x) any representatives conducting an audit pursuant to this Section be accompanied by the
Company’s representatives at all times during any such 

  
 44 

	 	
audit, (y) such representatives do not enter areas of any facility not involved in the Collaboration and (z) all such audits are conducted in accordance with the obligations set forth
in Article 12. 

 11. SUPPLY AND OTHER SERVICES 

 

	11.1	Supply. 

  

	 	11.1.1	From time to time, the Company may screen the Pre-Made Plates that are in the Company’s possession pursuant to the Screening Services Agreement solely to the
extent such screening is expressly permitted hereunder and subject to any restrictions, limitations or obligations set forth herein. Notwithstanding the foregoing, in the event that the Company uses sixty percent (60%) of the volume of the
solvent containing the Compounds in the wells on any Pre-Made Plate, the Company shall promptly provide Pfizer with written notice thereof (the “Exhaustion Notice”). Pfizer shall have the right to include the costs for replacing a
Pre-Made Plate used by the Company in the Invoiced Costs after providing the Company with an Exhaustion Notice for such Pre-Made Plate (unless this Agreement is expiring or terminating, in which case, Pfizer may provide such an invoice as soon as
reasonably practicable following the time of such expiration or termination). For clarity, any decision by Pfizer to not replace any such Compounds in a Pre-Made Plate shall not excuse the Company from reimbursing Pfizer for using such Pre-Made
Plates as described in this Section. The Company shall pay Pfizer the costs of each screen that it conducts in connection with the Collaboration as set forth on Schedule 1.1(e) and specified in an invoice as an Invoiced Cost.

  

	 	11.1.2	From time to time, the Company may submit to the Curator reasonable requests that Pfizer supply the Company with Compounds and Analogs to the extent the Company is
permitted to perform Lead Seeking Activities or Candidate Designation Activities on such Compounds or Analogs in accordance with the applicable notice granting Intent to Access or the AIP Notice. The Company may request such Compounds or Analogs as
solid (i.e., neat) samples, in solution in REMP tubes, or as part of custom-made plates or Pre-Made Plates to conduct research and development solely to the extent expressly permitted hereunder, and, for clarity, subject to any limitations
set forth herein. 

  

	 	11.1.3	 Pfizer may (using good faith and in its sole discretion) grant or deny any such request made by the Company pursuant to Section 11.1.2;
provided that, in no event, shall Pfizer be required to grant such a request (a) for greater than or equal to fifty-percent (50%) of Pfizer’s and its Affiliates’ readily-available inventory of the applicable
Compound or Analog, or (b) that would result in Pfizer’s and its Affiliates’ inventory of the applicable Compound or Analog being less than the quantities Pfizer reasonably believes (as determined by Pfizer in its sole discretion) are
necessary for the research and development conducted by or on behalf of Pfizer and its Affiliates (including in connection with any Third Parties) during 

  
 45 

	 	
the six (6) month period after the Company’s request. Notwithstanding the foregoing, in no event will the Company in connection with any such request be treated more favorably than
Pfizer’s or its Affiliates’ internal research units (or any successors thereof) would be treated if such research units had made such a request. Should Pfizer grant any Company request made pursuant to Section 11.1.2, the Company
shall pay Pfizer the cost of replacing any Compound or Analog as an Invoiced Cost, it being understood that such Invoiced Cost will include only the cost of such Compound or Analog, and the Company shall be solely responsible for payment of any
costs in respect of transfer (including shipping costs) of such Compound or Analog from Sigma-Aldridge or any other Third Party used to store such Compound or Analog, plus such pro rata portion of the facility fee from Sigma Aldridge or such Third
Party. 

  

	11.2	Delivery. Custom-made plates, solid samples, REMP tubes and Pre-Made Plates supplied by Pfizer hereunder shall be delivered in accordance with the
procedures established by Pfizer from time to time. For clarity, the Pre-Made Plates shall be in the Company’s possession pursuant to the Screening Services Agreement. Notwithstanding the foregoing, upon termination or expiration of the
Screening Services Agreement, the Parties shall meet to discuss supply of the Pre-Made Plates. 

  

	11.3	Restrictions. Without limiting any of the other provisions hereof, the Company shall use Compounds and Analogs supplied or provided pursuant to this
Article 11 (including as part of Pre-Made Plates or custom-made plates) solely for the purposes expressly specified, and subject to the restrictions, limitations and obligations set forth, in this Agreement and the Company shall not sell, transfer,
disclose, or otherwise provide access, to such Compounds and Analogs to any Third Party (except the Company’s permitted sublicensees to the extent expressly permitted in the notice granting Intent to access or the AIP Notice) without
Pfizer’s express written consent (which Pfizer may withhold in its sole discretion). 

  

	11.4	Intellectual Property. Pfizer’s and its Affiliates’ supply to the Company of the Compounds and Analogs as solid samples, in solution in REMP
tubes, as part of custom-made plates and on Pre-Made Plates pursuant to this Article 11 shall not transfer to, or create in, the Company any right, title, interest, or claim to any Intellectual Property to which Pfizer or any of its Affiliates have
any rights. 

  

	11.5	Consulting and Other Services. At any time during the Term, the Company shall be permitted to submit reasonable requests to Pfizer for Pfizer to perform
additional services for the Company in connection with the Collaboration, including consulting services. Following such a request, Pfizer may, in its sole discretion, negotiate with the Company the terms of an appropriate agreement to provide for
the applicable additional services. For clarity, neither Party shall be obligated to enter into an agreement with the other Party with respect to or to provide such additional services. 

  
 46 

 12. CONFIDENTIALITY AND SECURITY 

 

	12.1	Definition. “Confidential Information” shall mean all Know-How, business or financial information, research and development activities,
product and marketing plans, and customer and supplier information and all other confidential or proprietary information furnished by one Party or any of its Affiliates or its respective directors, officers, employees, agents, accountants, counsel
and other advisors and representatives (each, a “Disclosing Party”) to the other Party, any of its Affiliates or its respective directors, officers, employees, agents, accountants, counsel and other advisors and representatives
(each, a “Receiving Party”) in connection with this Agreement, whether disclosed or provided prior to or after the Effective Date and whether provided orally, visually, electronically, or in writing. Notwithstanding anything to the
contrary, Confidential Information included in the Collaboration IP shall be deemed Confidential Information of both Pfizer and the Company (and, for clarity, both Parties shall be a Receiving Party and a Disclosing Party with respect thereto)
unless and until this Agreement terminates pursuant to Section 20.2 or expires either in its entirety or with respect to the Compounds and/or Analogs to which such Collaboration IP relates (at which point, such Confidential Information shall be
deemed to be Confidential Information of Pfizer only), subject to the terms of any applicable License Agreement. Notwithstanding the foregoing, Confidential Information, with respect to a Disclosing Party, shall not include:

  

	 	12.1.1	information that is or becomes publicly known through no breach of this Agreement by the Receiving Party or any of its Affiliates, its respective directors, officers,
employees, agents, accountants, counsel and other advisors and representatives, 

  

	 	12.1.2	information that was independently developed following the Effective Date by employees or agents of the Receiving Party or any of its Affiliates, its respective
directors, officers, employees, agents, accountants, counsel and other advisors and representatives who have not accessed or otherwise received the applicable Confidential Information (before or after the Effective Date); provided that
such independent development can be demonstrated by competent, contemporaneous written records of the Receiving Party or any of its Affiliates; and 

  

	 	12.1.3	information that becomes available to the Receiving Party or its Affiliates following the Effective Date on a non-confidential basis from a Third Party who is not bound
directly or indirectly by a duty of confidentiality to the Disclosing Party; 

 provided that, in
each of the foregoing Sections 12.1.1 through 12.1.3, such information shall not be deemed to be within the foregoing exceptions merely because such information is embraced by more general knowledge that is publicly known or in the Receiving
Party’s possession, and no combination of features shall be deemed to be within the foregoing exceptions merely because individual features are publicly known or in the Receiving Party’s possession, unless the particular combination itself
and its principle of operations are in the public domain or in the Receiving Party’s possession without the use of or access to Confidential Information. 

  
 47 

	12.2	Pfizer Obligations. Except as otherwise expressly set forth herein, Pfizer shall not disclose business or financial information or customer or supplier
information included in the Company’s Confidential Information that is not Collaboration IP to any Third Parties without the Company’s prior written consent (which may be withheld by the Company in the Company’s good faith, sole
discretion) and Pfizer shall use such Confidential Information of the Company solely for the purposes expressly permitted hereunder. Pfizer shall protect all other Confidential Information of the Company against unauthorized uses and disclosures,
and disclose to Third Parties, using the same degree of care as Pfizer uses with respect to its own similar information (which in no event shall be less than a reasonable degree of care); provided that, notwithstanding anything to the
contrary in this Section 12.2, without the Company’s prior written consent (which may be withheld by the Company in the Company’s good faith, sole discretion), Pfizer shall not disclose any such Collaboration IP included in the
Company’s Confidential Information to any Company Competitor for such Company Competitor to use in the Field. 

  

	12.3	Company Obligations. Except as otherwise expressly set forth herein, the Company shall not disclose Pfizer’s Confidential Information (including the
Collaboration Know-How) to any Third Parties without Pfizer’s prior written consent (which may be withheld by Pfizer in Pfizer’s good faith, sole discretion) and the Company shall use Pfizer’s Confidential Information solely for the
purposes expressly permitted hereunder. 

  

	12.4	Disclosures to Sublicensees. The Company shall be permitted to disclose Pfizer’s Confidential Information to permitted sublicensees (subject to
Section 3.2) to the extent reasonably necessary for the Company to exercise any sublicense rights that it has been granted hereunder; provided that such sublicensees shall be subject to written obligations of confidentiality and
restrictions on permitted use at least equivalent in scope to those set forth in this Article 12 and the Company shall be liable for any failure by any such sublicensees to comply with the terms hereof. 

 

	12.5	Disclosure to Intellectual Property Offices, Regulatory Authorities. A Receiving Party may disclose Confidential Information of the Disclosing Party to
(a) patent authorities to obtain or maintain Patent Rights to the extent such Receiving Party is expressly permitted to obtain or maintain such Patent Rights under this Agreement and (b) Regulatory Authorities to obtain or maintain any
approval to conduct clinical trials or Regulatory Approvals with respect to a Compound or Analog or, with respect to Pfizer, pharmaceutical products that relate to such Confidential Information, to the extent expressly permitted hereunder;
provided that, with respect to the foregoing (a) and (b), such disclosure may be made only to the extent reasonably necessary to obtain or maintain such Patent Rights or obtain or maintain such approvals or Regulatory Approvals
(as applicable) and the Receiving Party shall provide the Disclosing Party with written notice of such disclosure. 

  

	12.6	 Disclosures Required By Law. In the event that the Receiving Party or any Person in its Group either determines on the advice of its
counsel that it is required to disclose any 

  
 48 

	 	
Confidential Information of the Disclosing Party pursuant to Applicable Law (including the rules and regulations of the Securities and Exchange Commission or any national securities exchange) or
receives any request or demand under lawful process or from any Governmental Authority to disclose or provide Confidential Information of the Disclosing Party (or any Person in the Disclosing Party’s Group) that is subject to the
confidentiality obligations hereof, the Receiving Party shall notify the Disclosing Party prior to disclosing or providing such Confidential Information and shall cooperate at the expense of the Disclosing Party in seeking any reasonable protective
arrangements (including by seeking confidential treatment of such Confidential Information) requested by the Disclosing Party. Subject to the foregoing, the Person that received such a request or determined that it is required to disclose
Confidential Information of the Disclosing Party may thereafter disclose or provide such Confidential Information to the extent required by such Applicable Law (as so advised by counsel) or requested or required by such Governmental Authority;
provided, however, that such Person provides the Disclosing Party, to the extent legally permissible, upon request with a copy of the Confidential Information so disclosed. 

 

	12.7	Terms of this Agreement. The terms of this Agreement are deemed to be Confidential Information of each Party and shall be subject to the confidentiality
obligations set forth in this Article 12; provided that each Party shall be permitted to disclose the terms of this Agreement to the extent reasonably necessary in connection with a potential or actual financing or assignment or sale
of the business or assets related to this Agreement to the extent permitted hereunder; provided further that such Persons shall be subject to obligations of confidentiality and non-use (whether in writing or by operation of law)
with respect thereto and the Receiving Party shall be liable for any failure by any such Persons to comply with the confidentiality provisions hereof. 

  

	12.8	Publications. The Company shall not be permitted to present or publish regarding Pfizer IP, any Compounds or Analogs being researched or developed by the
Company under the Collaboration or any other Confidential Information, unless Pfizer grants prior written consent (which Pfizer may withhold in its sole discretion). Pfizer shall respond to any such request made by the Company to present or publish
within forty-five (45) days of receipt of such request (which, for clarity, shall include the proposed presentation or publication). Pfizer’s and its Affiliates’ right to present or publish regarding any Compounds and Analogs included
in an AIP Compound Series during the Term after AIP is granted shall be limited to the following circumstances: (a) if Pfizer, any of its Affiliates, or the Company (to the extent expressly permitted hereunder) have filed any Patent Rights with
respect to the Collaboration Know-How disclosed in the applicable presentation or publication or (b) if the Company grants prior written consent. In the event that the Company reasonably believes that Pfizer’s proposed publication or
presentation will prevent Pfizer or its Affiliates from obtaining Patent Rights with respect to the applicable Pfizer IP related to the applicable AIP Compound Series, the Company shall promptly notify Pfizer thereof and Pfizer shall reasonably
consider whether to delay such presentation or publication (provided that Pfizer may decide such matter in its sole discretion). For clarity, nothing in this Section 12.8 shall be construed to restrict or otherwise limit Pfizer or
its Affiliates from filing, prosecuting or maintaining any Patent Rights, or except to the extent expressly set forth herein, from presenting or publishing. 

  
 49 

	12.9	Security. 

  

	 	12.9.1	Generally. The Company hereby acknowledges and agrees that the Pfizer IP and the Pfizer Software include proprietary and confidential information,
including trade secrets, of Pfizer, its Affiliates, and Third Parties, and such information is of substantial value to Pfizer and is only being provided to the Company for its use in the Collaboration to the extent expressly permitted and subject to
any limitations hereunder. Accordingly, the Company shall implement procedures and policies (including as specified herein) to ensure compliance with the use, access and disclosure restrictions specified herein and that the confidentiality of such
information is maintained. 

  

	 	12.9.2	Safeguarding the Pfizer IP. 

  

	 	(a)	General. The Company shall, and shall ensure that its Affiliates and its permitted sublicensees (as applicable), maintain technical and physical security
and administrative and other safeguards to protect against any use, loss or disclosure of any Pfizer IP and Pfizer Software in contravention of the terms hereof. 

 

	 	(b)	Location. When not in use, the Company shall store all paper files, documents, and records containing Pfizer IP, Compounds, Analogs and other Materials in
electronically and physically secure locations at the Company’s premises (including password-protected systems for electronic records and locked storage and file cabinets for tangible materials, as applicable), with access controlled and
limited to Collaboration Employees (e.g., by key, proximity card, or security number pad) solely to the extent reasonably required for each such employee to perform the tasks and obligations for which he or she is assigned. The Company shall
perform all research and development activities in connection with the Collaboration in rooms on the premises of the Company or as set forth in the notice granting Intent to Access or the AIP Notice (as applicable) or as otherwise agreed by the JSC.
Pfizer acknowledges that, to the extent reasonably necessary, such research and development activities may be conducted in the same room as research and development activities being conducted by Company employees outside the scope of the
Collaboration, except review of the Pfizer Database by the Leveragers (which shall only be conducted in rooms on the Company’s premises in the United States that are not accessible by Persons that are not Collaboration Employees). The Company
shall ensure that all Persons that may come into contact with Pfizer’s Confidential Information are informed of, and comply with, the Company’s obligations with respect to Pfizer’s Confidential Information. Notwithstanding anything to
the contrary in this Section 12.9.2(b), the Company shall remain responsible and liable for any breach by its employees of this Article 12. 

  
 50 

	 	(c)	Marking. The Company shall, and shall ensure that its Affiliates and its permitted sublicensees (as applicable), mark all Know-How and other Confidential
Information provided by or on behalf of Pfizer or its Affiliates to the Company, its Affiliates and its permitted sublicensees, and all other Pfizer IP (including all Collaboration IP) as the property of Pfizer and its Affiliates and as being
confidential. 

  

	 	(d)	Destruction/Modification of Collaboration Inventions. The Company shall not, and shall ensure that its Affiliates and permitted sublicensees (to the
extent permitted hereunder) do not, modify, delete or destroy any Collaboration Know-How or Materials prior to providing such Know-How or Materials to Pfizer in accordance with the terms hereof without Pfizer’s prior written consent, except as
expressly permitted hereunder. 

  

	 	12.9.3	System Security. 

  

	 	(a)	Company Security Measures. Prior to the Effective Date, the Parties hereby acknowledge and agree that the Company provided Pfizer with a copy of the
access, protection, and data/software security procedures that will be employed by the Company in connection with the Collaboration (the “Company Security Procedures”), which are attached as Schedule 12.9.3(a). The Company shall,
and shall ensure that its Affiliates and permitted sublicensees, comply with the Company Security Procedures in connection with the Collaboration and shall provide Pfizer with any material changes thereto (which shall be subject to the prior written
consent of Pfizer, which may be withheld in its sole discretion). Notwithstanding anything to the contrary herein, and without limiting this Article 12, in no event will any actions or inactions of the Company, its Affiliates or any of its permitted
sublicensees (as applicable) result in the Pfizer Database, the Pfizer Restricted Databases, the Pfizer Software, the Pfizer Library, the Pfizer Portfolio, any Compounds, Analogs, or other Materials or any other Pfizer IP or Confidential Information
(collectively, the “Pfizer Protected Assets”) being maintained at a level of security less than the level that the Company maintains with respect to its own sensitive or proprietary systems and data outside the Collaboration.

  

	 	(b)	Pfizer Security Measures. The Company shall not, and shall ensure that its Affiliates and permitted sublicensees do not, tamper with, compromise, or
circumvent any security or audit measures employed by Pfizer and its Affiliates in connection with the Pfizer Protected Assets. 

  

	 	12.9.4	Firewalls. 

  

	 	(a)	 General. The Parties hereby acknowledge that, except as expressly prohibited hereunder, the Company shall not be prohibited from
researching, developing or commercializing pharmaceutical products in the Field outside of the Collaboration; provided that the Company shall 

  
 51 

	 	
not be permitted to use any Pfizer IP and/or Pfizer Confidential Information or any other rights granted hereunder in connection therewith. Without limiting any other provision herein, the
Company shall, and shall ensure that its Affiliates and its permitted sublicensees (as applicable), establish and enforce appropriate firewall procedures between its activities in connection with the Collaboration and outside of the Collaboration to
ensure that no Pfizer IP is used in connection with its activities outside of the Collaboration. 

  

	 	(b)	Misuse of Pfizer IP. Without prejudice to any other rights or remedies available to Pfizer under this Agreement or otherwise, (a) in the event that
any Pfizer IP and/or Pfizer Confidential Information is used outside of the Collaboration in connection with the research, development or commercialization of any compounds or pharmaceutical products, Pfizer shall have all of the rights hereunder
with respect to such compounds and pharmaceutical products and the Company shall have all of the obligations hereunder with respect to such compounds or pharmaceutical products and (b) in the event that Pfizer reasonably believes that the
Company, its Affiliates or any of its permitted sublicensees has used any Pfizer IP and/or Pfizer Confidential Information outside of the Collaboration, Pfizer shall provide the Company with written notice thereof and the Company shall be required
to establish to Pfizer’s reasonable satisfaction by clear and convincing evidence that such use has not occurred or such use shall be deemed to have occurred. 

 

	 	12.9.5	Security Audits. 

  

	 	(a)	Pfizer Rights. 

  

	 	(i)	For clarity, Pfizer shall have audit rights in accordance with Section 10.4 to ensure compliance with this Article 12. In the event that Pfizer reasonably believes
following any such audit that the Company, its Affiliates or its permitted sublicensees has violated this Article 12 or otherwise poses a security concern with respect to the Pfizer Protected Assets, Pfizer shall provide the Company with written
notice thereof (a “Pfizer Non-Compliance Notice”) and may deny the Company and its Affiliates and permitted sublicensees (as applicable) access thereto. The Company shall, and shall ensure that its Affiliates and permitted
sublicensees, cooperate with Pfizer in investigating any apparent violations of this Article 12 and shall comply with Section 12.9.5(c) in the event that it receives such written notice from Pfizer. 

 

	 	(ii)	 Without limiting Section 12.9.5(a)(i), if, at any time, Pfizer determines or reasonably believes that the Company, any of its Affiliates or any of
its permitted sublicensees has engaged in activities that may lead to, or that has resulted in, any unauthorized 

  
 52 

	 	
access to or use of any Pfizer Protected Assets, Pfizer may provide the Company with written notice thereof and the Parties shall promptly meet to discuss the relevant activities and preventing
and/or addressing such potential or actual unauthorized use or access. Upon providing such written notice, the Company shall comply with Section 12.9.5(c) and Pfizer shall be permitted to immediately restrict the Company’s, its
Affiliates’ and its permitted sublicensees’ access to the Pfizer Protected Assets if Pfizer reasonably believes such unauthorized access has or may occur with respect thereto, and Pfizer may continue to restrict such access unless and
until Pfizer believes that the Company has instituted appropriate mechanisms to cease and/or prevent such unauthorized use or disclosure. 

  

	 	(b)	Company Obligations. 

  

	 	(i)	The Company shall maintain internal audit capabilities that comply with its internal audit policies and conduct regular audits of its, its Affiliates’ and its
permitted sublicensees’ systems and procedures to ensure compliance with this Article 12; provided that, during the first twelve (12) months following the Effective Date, in no event shall fewer than two (2) audits be
conducted. Upon Pfizer’s reasonable request, the Company shall provide Pfizer with a summary of such internal audits of the Company, its Affiliates and its permitted sublicensees. 

 

	 	(ii)	The Company shall immediately terminate any individual’s involvement in the Collaboration (including any access to Collaboration IP) if, at any time, the Company
determines or reasonably believes (whether pursuant to an audit conducted in accordance with this Section 12.9.5(b) or otherwise) that such individual (a) sought to circumvent, actually circumvented or breached the Company Security
Procedures or any other provision of this Article 12 or (b) engaged in activities that may lead to or that resulted in the unauthorized access, use, destruction, alteration, or loss of any Pfizer Protected Assets. If, at any time, the Company
determines or suspects that the foregoing has occurred or there has been any other unauthorized access to the Pfizer Protected Assets or other violation of this Article 12, the Company shall immediately notify Pfizer in writing with a description of
the relevant incident (a “Company Non-Compliance Notice”), take the actions specified in Section 12.9.5(c), and cooperate with Pfizer in connection therewith. 

 

	 	(c)	 Remediation. In the event that the Company receives a Pfizer Non-Compliance Notice or notice in accordance with
Section 12.9.5(a)(ii), or the Company provides Pfizer with a Company Non-Compliance Notice, 

  
 53 

	 	
the Company shall (a) immediately investigate and take actions directed at remedying the relevant violation or suspected violation, and (b) submit to the JSC within ten
(10) Business Days of the Company’s receipt or delivery (as applicable) of the applicable notice a remediation plan, setting forth in reasonable detail, its plans to remedy such violation or suspected violation and prevent similar
violations. The JSC may, in its sole discretion, determine whether any such remediation plan is sufficient to address the relevant violation or suspected violation (as applicable) and prevent similar violations, and require the Company to take any
reasonable additional measures if the JSC determines that such plan is insufficient. 

  

	 	(d)	General. Any exercise by Pfizer of its rights under this Section 12.9.5 shall be without prejudice to any other rights or remedies available to
Pfizer or its Affiliates under this Agreement or otherwise. 

  

	 	12.9.6	 Background Checks. The Company shall ensure that Pfizer and its Affiliates are permitted to conduct, and have Third Parties conduct,
background checks of the Leveragers, the Functional Line Senior Scientists, the Lead Seekers, the Lead Seeking Project Team Members, the Candidate Designees and the Candidate Designation Project Team Members from time to time and that each such
employee signs the Confidentiality Agreement prior to exercising any rights or performing any obligations in connection with the Collaboration (and the Company shall provide Pfizer with a copy of each such Confidentiality Agreement reasonably
promptly following execution thereof). The Company shall provide Pfizer with prompt written notice upon replacing any such employee. Upon Pfizer’s written request, the Company shall provide to Pfizer a complete and accurate list of such
employees as of the time of such request, and with respect to the Lead Seeking Project Team Members and Candidate Designation Project Team Members, such list shall be provided by the Company to Pfizer at each quarterly JSC meeting. In the event that
Pfizer believes (in good faith) that there are any issues pertaining to character, behavior or reputation that would render any such employee unfit to serve as a Collaboration Employee for any reason, including any adverse findings identified
through a background check, Pfizer shall provide the Company with written notice thereof and the Parties shall reasonably discuss Pfizer’s concern. If, following such discussion, Pfizer still believes that such employee is unfit to occupy the
applicable Collaboration Employee position, the Company shall remove such employee from such position. Notwithstanding anything to the contrary, in a twelve (12) month period, without Pfizer’s prior written consent (which may be withheld
in Pfizer’s sole discretion), the Company shall not be permitted to replace more than (i) four (4) Leveragers, (ii) four (4) Functional Line Senior Scientists, (iii) five (5) Lead Seekers, or (iv) two
(2) Candidate Designees. The Leveragers, the Functional Line Senior Scientists, the Lead Seekers, the Lead Seeking Project Team Members, the Candidate Designees and the Candidate Designation Project Team Members shall not be members of the JSC
and shall not attend JSC meetings; provided that such employees shall be permitted to attend JSC meetings or portions thereof solely to 

  
 54 

	 	
the extent the subject matter of the applicable JSC meeting (a) relates to the subject matter for which such employee has been invited to the JSC meeting, and (b) does not relate to the
Pfizer Portfolio or other sensitive (as determined by Pfizer in its sole discretion) Confidential Information of Pfizer or its Affiliates. 

  

	12.10	Change of Control. For clarity, and without limiting any other provision of this Agreement, the Company’s obligations pursuant to this Article 12
shall be deemed to be breached, and such breach shall be deemed material, in the event of a Change of Control of the Company to which Pfizer does not grant prior written consent (which, for clarity, may be withheld by Pfizer in its sole discretion).

 13. REPRESENTATIONS, WARRANTIES AND COVENANTS 

 

	13.1	Disclaimer of Representations and Warranties. 

  

	 	13.1.1	EXCEPT AS EXPRESSLY STATED IN THIS ARTICLE 13, NO PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE,
INCLUDING WARRANTIES OF TITLE, NON-INFRINGEMENT, VALIDITY, ENFORCEABILITY, ABSENCE OR SCOPE OF ANY ENCUMBRANCES, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE AND ALL SUCH REPRESENTATIONS AND WARRANTIES ARE HEREBY EXPRESSLY DISCLAIMED.

  

	 	13.1.2	THE COMPANY ACKNOWLEDGES AND AGREES THAT THE CONTENTS OF THE PFIZER LIBRARY AND THE COMPOUNDS, ANALOGS, AND OTHER MATERIALS ARE EXPERIMENTAL IN NATURE, ARE FOR RESEARCH
USE ONLY, MAY HAVE UNKNOWN CHARACTERISTICS, AND ARE NOT TO BE ADMINISTERED IN HUMANS IN ANY MANNER OR FORM. THE COMPANY SHALL USE PRUDENCE AND REASONABLE CARE IN THE USE, HANDLING, STORAGE, TRANSPORTATION, DISPOSITION, AND CONTAINMENT OF SUCH
MATERIALS AND ALL OTHER MATERIALS IN CONNECTION WITH THE COLLABORATION. ANY COMPOUNDS, ANALOGS, OTHER MATERIALS, INFORMATION AND DATA PROVIDED BY PFIZER OR ITS AFFILIATES TO THE COMPANY OR GENERATED BY THE COMPANY, ITS AFFILIATES OR ITS PERMITTED
SUBLICENSEES ARE MADE AVAILABLE FOR THE COMPANY, ITS AFFILIATES AND ITS PERMITTED SUBLICENSEES IN CONNECTION WITH THE COLLABORATION ON AN “AS IS” BASIS, WITHOUT WARRANTY WITH RESPECT TO COMPLETENESS, COMPLIANCE WITH REGULATORY STANDARDS,
REGULATIONS, OR ANY OTHER APPLICABLE LAW, OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER KIND OF WARRANTY WHETHER EXPRESS OR IMPLIED. 

  
 55 

	13.2	Compliance with Laws. Each Party shall comply, and shall cause its Affiliates and permitted sublicensees to comply, with all Applicable Laws in performing
its and their obligations or exercising its and their rights pursuant to this Agreement. Without limiting the foregoing, the Company shall conduct all Lead Seeking Activities and Candidate Designation Activities hereunder in good scientific manner
and in compliance with all requirements of cGLP, cGCP, and cGMP (as applicable). 

  

	13.3	FCPA. 

  

	 	13.3.1	With respect to the performance of its obligations hereunder and without limiting the generality of Section 13.2, each Party shall comply, and shall cause its
Affiliates and permitted sublicensees to comply, with the United States Foreign Corrupt Practices Act of 1977 (as modified or amended and equivalent laws through the world, including the UK Bribery Act 2010) (the “FCPA”). Each Party
represents and warrants (on behalf of itself and its Affiliates) to the other that, with respect to the performance of its and their respective obligations under this Agreement, it and they have not, and will not, directly or indirectly, offer or
pay, or authorize such offer or payment of, any money, or transfer anything of value, to improperly seek to influence any Government Official, nor offer, pay, request, or accept bribes on behalf of the other Party or any of its Affiliates in order
to gain an improper business advantage and will not accept in the future, such a payment or transfer. 

  

	 	13.3.2	Each Party shall ensure that no Government or Government Official is the beneficial owner of five percent (5%) or more of its or its Affiliates’ securities
and undertakes to inform the other Party in good faith (i) if the Party becomes aware, through an SEC Schedule 13D filing or otherwise, that a Government or Government Official has become the beneficial owner of five percent (5%) or more
of its or its Affiliates’ securities or (ii) if a Government or Government Official comes into a position of authority within its or its Affiliates’ structure that includes influence over decisions with respect to its or its
Affiliates’ business or any products, payments or services provided under this Agreement. As used in this Section 13.3, “Government Official” means: (a) any elected or appointed government official (e.g., a
member of a ministry of health), (b) any employee or person acting for or on behalf of a government official, agency, or enterprise performing a governmental function, (c) any political party officer, employee, or person acting for or on
behalf of a political party or candidate for public office, (d) an employee or person acting for or on behalf of a public international organization, or (e) any person otherwise categorized as a government official under local law.
“Government” is meant to include all levels and subdivisions of non-United States governments (i.e., local, regional, or national and administrative, legislative, or executive). 

  
 56 

 14. INDEMNIFICATION 

 

	14.1	Indemnification by the Company. Except as provided in Section 14.3, the Company shall indemnify, defend and hold harmless each member of the Pfizer
Group and each of their Affiliates and each member of the Pfizer Group’s and their respective Affiliates’ directors, officers, employees and agents, and each of the heirs, executors, successors and assigns of any of the foregoing
(collectively, the “Pfizer Indemnitees”) from and against any and all Losses of the Pfizer Indemnitees relating to, arising out of or resulting from any of the following items (without duplication and including any such Losses
arising by way of setoff, counterclaim or defense or enforcement of any Lien): (a) the Company’s exercise of its rights or performance of its obligations pursuant to the terms hereof (including, for clarity, Section 3.3), (b) any
personal injuries, death and/or property damages (including Losses associated with damage, disease or illness to livestock, or resulting from exposure or contact (through physical proximity, consumption or otherwise) to such livestock) resulting
from the use of any compound or product researched or developed by or on behalf of the Company, its Affiliates or its permitted sublicensees in connection with this Agreement, (c) the fraud, gross negligence, or willful misconduct or omissions
of the Company, its Affiliates or any Third Party performing obligations of, or exercising rights granted to, the Company hereunder, (d) breach by the Company of any provision of this Agreement, or (e) the research, development,
manufacture, use, sale, offer for sale, import or export of Compounds, Analogs or related compounds, analogs or pharmaceutical products by or on behalf of the Company, its Affiliates or its sublicensees except to the extent any of the foregoing
(a) through (e) was caused by any of the Pfizer Indemnitees’ fraud, gross negligence, or willful misconduct or any Action for which Pfizer has an obligation to indemnify the Company pursuant to Section 14.2.

  

	14.2	Indemnification by Pfizer. Except as provided in Section 14.3, Pfizer shall indemnify, defend and hold harmless each member of the Company Group and
each of their Affiliates and each member of the Company Group’s and their respective Affiliates’ respective directors, officers, employees and agents, and each of the permitted heirs, executors, successors and assigns of any of the
foregoing (collectively, the “Company Indemnitees”), from and against any and all Losses of the Company Indemnitees relating to, arising out of or resulting from any of the following items (without duplication and including any
Losses arising by way of setoff, counterclaim or defense or enforcement of any Lien): (a) the fraud, gross negligence, or willful misconduct of Pfizer or its Affiliates or (b) breach by Pfizer of any provision of this Agreement, except to
the extent any of the foregoing (a) and (b) was caused by any of the Company Indemnitees’ fraud, gross negligence, or willful misconduct or any Action for which the Company has an obligation to indemnify Pfizer and its Affiliates
pursuant to Section 14.1. 

  

	14.3	Indemnification Obligations Net of Insurance Proceeds and Other Amounts. 

 

	 	14.3.1	 The Parties intend that any Loss subject to indemnification or reimbursement pursuant to this Article 14 will be net of Insurance Proceeds that
actually reduce the amount of the Loss. Accordingly, the amount which any Party (an “Indemnifying Party”) is required to pay to any Person entitled to indemnification

  
 57 

	 	
hereunder (an “Indemnitee”) will be reduced by any Insurance Proceeds theretofore actually recovered by or on behalf of the Indemnitee in respect of the related Loss. If an
Indemnitee receives a payment (an “Indemnity Payment”) required by this Agreement from an Indemnifying Party in respect of any Loss and subsequently receives Insurance Proceeds, then the Indemnitee will pay to the Indemnifying Party
an amount equal to the excess of the Indemnity Payment received over the amount of the Indemnity Payment that would have been due if the Insurance Proceeds had been received, realized or recovered before the Indemnity Payment was made.

  

	 	14.3.2	An insurer who would otherwise be obligated to pay any claim shall not be relieved of the responsibility with respect thereto or, solely by virtue of the
indemnification provisions hereof, have any subrogation rights with respect thereto, it being expressly understood and agreed that no insurer or any other Third Party shall be entitled to a “wind-fall” (i.e., a benefit such insurer
or other Third Party would not be entitled to receive in the absence of the indemnification provisions) by virtue of the indemnification provisions hereof. Nothing contained in this Agreement or any Ancillary Agreement shall obligate any Person in
any Group to seek to collect or recover any Insurance Proceeds. 

  

	 	14.3.3	Any Indemnity Payment made by the Company shall be increased as necessary so that after making all payments in respect to Taxes imposed on or attributable to such
Indemnity Payment, each Pfizer Indemnitee receives an amount equal to the sum it would have received had no such Taxes been imposed. Any Indemnity Payment made by Pfizer shall be increased as necessary so that after making all payments in respect to
Taxes imposed on or attributable to such Indemnity Payment, each Company Indemnitee receives an amount equal to the sum it would have received had no such Taxes been imposed. 

 

	14.4	Procedures for Indemnification of Third Party Claims. 

  

	 	14.4.1	If an Indemnitee shall receive notice or otherwise learn of the assertion by a Third Party (including any Governmental Authority) of any claim or of the commencement by
any such Third Party of any Action with respect to which an Indemnifying Party may be obligated to provide indemnification to such Indemnitee pursuant to Sections 14.1 or 14.2, or any other Section of this Agreement (collectively, a “Third
Party Claim”), such Indemnitee shall give such Indemnifying Party written notice thereof as promptly as practicable (and in any event within forty-five (45) days) after becoming aware of such Third Party Claim. Any such notice shall
describe the Third Party Claim in reasonable detail. Notwithstanding the foregoing, the failure of any Indemnitee or other Person to give notice as provided in this Section 14.4 shall not relieve the related Indemnifying Party of its
obligations under this Article 14, except to the extent, and only to the extent, that such Indemnifying Party is materially prejudiced by such failure to give notice. 

  
 58 

	 	14.4.2	An Indemnifying Party may elect (but shall not be required) to defend, at such Indemnifying Party’s own expense and by such Indemnifying Party’s own counsel
(which counsel shall be reasonably satisfactory to the Indemnitee), any Third Party Claim; provided that the Indemnifying Party shall not be entitled to defend and shall pay the reasonable fees and expenses of one separate counsel for
all Indemnitees if the claim for indemnification relates to or arises in connection with any criminal action, indictment or allegation. Within forty-five (45) days after the receipt of notice from an Indemnitee in accordance with
Section 14.4.1 (or sooner, if the nature of such Third Party Claim so requires), the Indemnifying Party shall notify the Indemnitee of its election whether the Indemnifying Party will assume responsibility for defending such Third Party Claim,
which election shall specify any reservations or exceptions to its defense. After notice from an Indemnifying Party to an Indemnitee of its election to assume the defense of a Third Party Claim, such Indemnitee shall have the right to employ
separate counsel and to participate in (but not control) the defense, compromise, or settlement thereof, but the fees and expenses of such counsel shall be the expense of such Indemnitee; provided, however, in the event that
(a) the Indemnifying Party has elected to assume the defense of the Third Party Claim but has specified, and continues to assert, any reservations or exceptions in such notice or (b) the Third Party Claim involves injunctive or equitable
relief, then, in any such case, the reasonable fees and expenses of one separate counsel for all Indemnitees shall be borne by the Indemnifying Party. 

  

	 	14.4.3	If an Indemnifying Party elects not to assume responsibility for defending a Third Party Claim, or fails to notify an Indemnitee of its election as provided in
Section 14.4.2, such Indemnitee may defend such Third Party Claim at the cost and expense of the Indemnifying Party. Any legal fees and expenses incurred by the Indemnitee in connection with defending such claim shall be paid by the
Indemnifying Party at the then applicable regular rates charged by counsel, without regard to any flat fee or special fee arrangement otherwise in effect between such counsel and the Indemnitee. 

 

	 	14.4.4	Unless the Indemnifying Party has failed to assume the defense of the Third Party Claim in accordance with the terms of this Agreement, no Indemnitee may settle or
compromise any Third Party Claim without the consent of the Indemnifying Party. If an Indemnifying Party has failed to assume the defense of the Third Party Claim within the time period specified in Section 14.4.2 above, it shall not be a
defense to any obligation to pay any amount in respect of such Third Party Claim that the Indemnifying Party was not consulted in the defense thereof, that such Indemnifying Party’s views or opinions as to the conduct of such defense were not
accepted or adopted, that such Indemnifying Party does not approve of the quality or manner of the defense thereof or that such Third Party Claim was incurred by reason of a settlement rather than by a judgment or other determination of liability.

  

	 	14.4.5	 In the case of a Third Party Claim, no Indemnifying Party shall consent to entry of any judgment or enter into any settlement of the Third Party Claim
without the 

  
 59 

	 	
consent of the Indemnitee if the effect thereof is (a) to permit any injunction, declaratory judgment, other order or other non-monetary relief to be entered, directly or indirectly, against
any Indemnitee or (b) to ascribe any fault on any Indemnitee in connection with such defense. 

  

	 	14.4.6	Notwithstanding the foregoing, the Indemnifying Party shall not, without the prior written consent of the Indemnitee, settle or compromise any Third Party Claim or
consent to the entry of any judgment which does not include as an unconditional term thereof the delivery by the claimant or plaintiff to the Indemnitee of a written release from all Liability in respect of such Third Party Claim.

  

	14.5	Additional Matters. 

  

	 	14.5.1	Any claim on account of a Loss which does not result from a Third Party Claim shall be asserted by written notice given by the Indemnitee to the related Indemnifying
Party. Such Indemnifying Party shall have a period of thirty (30) days after the receipt of such notice within which to respond thereto. If such Indemnifying Party does not respond within such thirty (30) day period, such Indemnifying
Party shall be deemed to have refused to accept responsibility to make payment. If such Indemnifying Party does not respond within such thirty (30) day period or rejects such claim in whole or in part, such Indemnitee shall be free to pursue
such remedies as may be available to such Indemnitee as contemplated by this Agreement. 

  

	 	14.5.2	In the event of payment by or on behalf of any Indemnifying Party to any Indemnitee in connection with any Third Party Claim, such Indemnifying Party shall be
subrogated to and shall stand in the place of such Indemnitee as to any events or circumstances in respect of which such Indemnitee may have any right, defense or claim relating to such Third Party Claim against any claimant or plaintiff asserting
such Third Party Claim or against any other Person. Such Indemnitee shall cooperate with such Indemnifying Party in a reasonable manner, and at the cost and expense of such Indemnifying Party, in prosecuting any subrogated right, defense or claim.

  

	 	14.5.3	In the event of an Action in which the Indemnifying Party is not a named defendant, if either the Indemnitee or Indemnifying Party shall so request, the Parties shall
endeavor to substitute the Indemnifying Party for the named defendant or otherwise hold the Indemnifying Party as party thereto, if at all practicable. If such substitution or addition cannot be achieved for any reason or is not requested, the named
defendant shall allow the Indemnifying Party to manage the Action as set forth in this Section, and the Indemnifying Party shall fully indemnify the named defendant against all costs of defending the Action (including court costs, sanctions imposed
by a court, attorneys’ fees, experts’ fees and all other external expenses), the costs of any judgment or settlement, and the cost of any interest or penalties relating to any judgment or settlement with respect to such Third Party Claim.

  
 60 

	14.6	Remedies Cumulative. The remedies provided in this Article 14 shall be cumulative and, subject to the provisions of Article 12, shall not preclude
assertion by any Indemnitee of any other rights or the seeking of any and all other remedies against any Indemnifying Party. 

  

	14.7	Survival of Indemnities. The indemnity contained in this Article 14 shall remain operative and in full force and effect, regardless of (a) any
investigation made by or on behalf of any Indemnitee; and (b) the knowledge by the Indemnitee of Liabilities for which it might be entitled to indemnification or contribution hereunder. The rights and obligations of each Party and their
respective Indemnitees under this Article 14 shall survive the termination of any license granted hereunder. 

  

	14.8	Intellectual Property. Notwithstanding the foregoing Sections 14.1 through 14.7, in the event and to the extent that any Third Party Claim relates to or
may affect or otherwise impair either Party’s or a Third Party’s ownership of or rights in or the validity or enforceability of or rights to use Intellectual Property hereunder, the prosecution and defense of such aspects of such Third
Party Claim shall be governed by Article 18 to the extent that such Article addresses such prosecution or defense. 

15. LIMITATIONS ON LIABILITY 
  

	15.1	Consequential Damages Waiver. NOTWITHSTANDING ANY OTHER PROVISION OF THIS AGREEMENT TO THE CONTRARY, IN NO EVENT WILL EITHER PARTY OR ANY OF ITS
AFFILIATES BE LIABLE FOR ANY SPECIAL, INCIDENTAL, INDIRECT, COLLATERAL, CONSEQUENTIAL OR PUNITIVE DAMAGES OR LOSS OF PROFITS SUFFERED BY AN INDEMNITEE, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, IN CONNECTION WITH ANY DAMAGES ARISING HEREUNDER,
PROVIDED, HOWEVER, THAT TO THE EXTENT AN INDEMNITEE IS REQUIRED TO PAY ANY SPECIAL, INCIDENTAL, INDIRECT, COLLATERAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES OR LOSS OF BUSINESS PROFITS TO A PERSON WHO IS NOT THE OTHER PARTY OR AN AFFILIATE
OF THE OTHER PARTY IN CONNECTION WITH A THIRD PARTY CLAIM, SUCH DAMAGES WILL CONSTITUTE DIRECT DAMAGES AND NOT BE SUBJECT TO THE LIMITATION SET FORTH IN THIS ARTICLE 14. 

 

	15.2	Limitation on Liability. WITHOUT LIMITING SECTION 15.1, IN NO EVENT SHALL PFIZER’S AND ITS AFFILIATES’ LIABILITY IN THE AGGREGATE FOR ALL
LOSSES, DAMAGES, LIABILITIES, COSTS, AND EXPENSES IN CONNECTION WITH THIS AGREEMENT EXCEED THE LESSER OF (A) TWO MILLION US DOLLARS (US$2,000,000.00) OR (B) THE AGGREGATE AMOUNT OF PAYMENTS RECEIVED BY PFIZER AND ITS AFFILIATES FROM THE
COMPANY AND ITS AFFILIATES UNDER THIS AGREEMENT DURING THE TWENTY-FOUR (24) MONTHS IMMEDIATELY PRECEDING THE EVENT GIVING RISE TO THE CLAIM, REGARDLESS OF WHETHER PFIZER OR ITS AFFILIATES HAS BEEN INFORMED OF THE POSSIBILITY OR LIKELIHOOD OF
SUCH DAMAGES OR THE TYPE OF CLAIM, CONTRACT, OR TORT (INCLUDING NEGLIGENCE). 

  
 61 

 16. INSURANCE 

 

	16.1	Obligations to Maintain Insurance. The Company shall maintain during the Term and for five (5) years after termination or expiration of this
Agreement, commercial general liability insurance from a minimum “A-” AM Best rated insurance company, including contractual liability and product liability or clinical trials, if applicable, with coverage as set forth on Schedule 16.1.
The Company has the right to provide the total limits required by any combination of primary and umbrella/excess coverage. Each such insurance policy shall name Pfizer and its Affiliates as additional insured and provide a waiver of subrogation in
favor of Pfizer and its Affiliates. Such insurance policies shall be primary and non-contributing with respect to any other similar insurance policies available to Pfizer or its Affiliates. The Company shall be responsible for its own deductibles or
retentions. For clarity, the minimum level of insurance set forth herein shall not be construed to create a limit on the Company’s liability hereunder. 

 

	16.2	Policy Notification. The Company shall provide Pfizer with original certificates of insurance (which, for clarity, may be provided in electronic form)
evidencing the insurance requirements set forth in Section 16.1 (a) prior to execution by both Parties of this Agreement, and (b) on an annual basis. Pfizer shall be provided at least thirty (30) days (ten (10) days in the
case of cancellation for non-payment of premium) written notice prior to cancellation, termination, or any material change to restrict the coverage or reduce the limits afforded. 

17. REGULATORY AND SAFETY 
  

	17.1	Regulatory. The Company shall have the sole right (but not the obligation), at its own cost and expense, to control all regulatory matters with respect to
the Collaboration in the Field within the scope of the rights that it is granted hereunder, including the preparation, submission, and maintenance of all regulatory submissions; provided that if Pfizer is researching, developing or
commercializing the same compound that the Company is researching or developing under the Collaboration, upon Pfizer’s reasonable request, with respect to such compound (a) Pfizer shall have the right to participate in all meetings with
the Regulatory Authorities to the extent permitted by Applicable Law, and (b) the Company shall provide Pfizer with a copy of material communications from, and drafts of any material filings or responses to, any Regulatory Authorities
reasonably prior to submission to allow Pfizer an opportunity to review and comment thereon (and such material communications, filings and responses to the Regulatory Authorities shall be subject to Pfizer’s prior written approval, not to be
unreasonably withheld). Pfizer shall provide any comments with respect to such communications, filings and responses to the Company as soon as reasonably practicable and the Company shall incorporate all such comments. In the event of a dispute
between the Parties regarding such comments, Pfizer shall have final decision-making authority. All regulatory submissions made by or on behalf of the Company, its Affiliates and its permitted sublicensees in connection with the Collaboration (to
the extent expressly permitted) shall be made in the name of the Company, and the Company shall, and shall ensure that its Affiliates and permitted sublicensees (as applicable), permit Pfizer, its Affiliates and their sublicensees to cross-reference
and otherwise rely upon, and have access to, all such submissions made by or on behalf of the Company, its Affiliates or its permitted sublicensees in connection with the Collaboration in the manner reasonably requested by Pfizer for use outside the
Field. Following termination or expiration of this Agreement, upon the reasonable request of Pfizer, the Company shall ensure that all such regulatory submissions are transferred to Pfizer or its designated Affiliate or Third Party upon expiration
or termination of this Agreement, except to the extent that (x) Licensed Products for which the Company has exercised the Opt-In are the subject of such regulatory submissions or (y) such transfer is not permitted by the Regulatory Authorities, in
which case, rights for Pfizer, its Affiliates and its sublicensees to cross-reference and otherwise rely upon, and have access to such submissions, shall survive such expiration or termination (as applicable). For clarity this section shall be
subject to any notice granting Intent to Access and any AIP Notice and Pfizer’s obligations in Section 20.35. 

  
 62 

	17.2	Safety Notice. During the Term, each Party shall notify the other Party within forty-eight (48) hours, of any information that comes into such
Party’s possession, or action by, or notice that it receives (directly or indirectly) from, any Regulatory Authority or Third Party that (a) raises any material concerns regarding the safety or efficacy of any Compounds or Analogs that the
Company is researching or developing in accordance with the terms hereof, (b) indicates or suggests a potential investigation or formal inquiry by a Regulatory Authority in connection with any Compounds or Analogs that the Company is
researching or developing in accordance with the terms hereof, or (c) is reasonably likely to lead to a recall or market withdrawal of a product. 

 18. INTELLECTUAL PROPERTY 
  

	18.1	Ownership of Pfizer IP. 

  

	 	18.1.1	Pfizer Ownership. 

  

	 	(a)	Pfizer IP. As between the Parties, Pfizer shall own and retain all right, title, and interest in, to, and under all Pfizer IP and Pfizer Software
(including the Collaboration IP), including, for clarity, all preclinical, clinical, technical, chemical, safety, scientific and other data and information, know-how and other results generated by or resulting from or in connection with the conduct
of the Collaboration hereunder, including relevant laboratory notebook information and descriptions in any other form (whether physical, electronic or otherwise). 

 

	 	(b)	Materials. 

  

	 	(i)	As between the Parties, Pfizer shall own and retain all right, title and interest in, to and under all tangible embodiments of the Pfizer IP (including any and all
Analogs and Compounds synthesized by the Company) (the “Materials”) for all purposes without further obligation or payment to the Company. 

 

	 	(ii)	In the event that the Company conceives, reduces to practice, or otherwise develops any Materials hereunder, the Company shall provide Pfizer with written notice
thereof within forty-five (45) days of the beginning of each Calendar Quarter. The Company shall promptly provide Pfizer with the quantities of any such Materials that Pfizer reasonably requests (at Pfizer’s sole cost and expense) pursuant
to those procedures that are specified by Pfizer from time to time and in compliance with all Applicable Laws. For clarity, Pfizer shall have the right (but not the obligation) to add any Materials to the Pfizer Library and to add information
relating thereto to the Pfizer Database, the Pfizer Restricted Database and any other library, database or system to which Pfizer has rights (subject to Article 12). 

  
 63 

	 	(c)	Assignment. In the event that the Company or any of its Affiliates or sublicensees has been assigned or otherwise obtains or has ownership of any
Intellectual Property or Materials in contravention of Sections 18.1.1(a) or 18.1.1(b), the Company hereby assigns, and shall cause its Affiliates and permitted sublicensees (as applicable) to assign, to Pfizer its entire right, title, and interest
in, to, and under such Intellectual Property and Materials (as applicable) and hereby waives, and shall cause its Affiliates and permitted sublicensees to waive, any ownership in the foregoing if such assignment does not take effect immediately for
any reason. The Company shall, and shall cause its Affiliates and permitted sublicensees to, execute any and all assignments and other documents necessary to perfect or record Pfizer’s right, title, and interest in, to, and under such
Intellectual Property and Materials. The Company further agrees to execute, and cause its Affiliates and permitted sublicensees to execute, all further documents and assignments and do all such further things as may be necessary to perfect
Pfizer’s title to such Intellectual Property and Materials or to register Pfizer as the exclusive owner of any applicable registrable rights. 

  

	18.2	Patent Prosecution and Maintenance. 

  

	 	18.2.1	General. As between the Parties, subject to Section 18.2.2, Pfizer shall have the sole right and authority (but not the obligation) to prepare, file,
prosecute (including conduct any oppositions, interferences, reissue proceedings, reexaminations, and post-grant proceedings), and maintain (such activities, “Prosecution Activities”) the Pfizer Patent Rights in any country or
regulatory jurisdiction in the Territory. For purposes of this Agreement, the Prosecution Activities shall include the right to determine whether or not to file an application for Patent Rights on any Pfizer Know-How. Subject to Section 18.2.2,
Pfizer shall be solely responsible for the costs and expenses of the Prosecution Activities with respect to the Pfizer IP. 

  

	 	18.2.2	Collaboration Patent Rights and other Exclusive Patent Rights. 

 

	 	(a)	General. Pfizer shall reasonably consider any request (each, a “Prosecution Request”) by the Company that Pfizer or any of its Affiliates
files or continues to maintain any (a) Collaboration Patent Rights or (b) other Pfizer Patent Rights that relate to Compounds or Analogs for which AIP has been granted in a specific country or regulatory jurisdiction (the foregoing
(a) and (b), collectively, “Exclusive Patent Rights”). For clarity, whether to grant any Prosecution Request shall be determined by Pfizer in good faith at its sole discretion. The Patent Rights set forth on Schedule 18.2.2(a)
shall be deemed Exclusive Patent Rights for the countries and jurisdictions set forth on such Schedule as of the Effective Date. In the event that Pfizer agrees to a Prosecution Request and the Company complies with its obligations pursuant to this
Section 18.2.2, Pfizer shall (until the earlier of expiration or termination of this Agreement with respect to the applicable Compounds or Analogs, including due to expiration of the applicable Opt-In): 

 

	 	(i)	not abandon such Patent Right in the applicable country or regulatory jurisdiction, 

  
 64 

	 	(ii)	not grant any Third Parties any licenses or rights to such Patent Right in the Field if such licenses or rights would be granted to the Company pursuant to the
applicable License Agreement if and when the Company exercises the applicable Opt-In, and 

  

	 	(iii)	provide the Company with a copy of any material communications from patent authorities in the applicable countries and jurisdictions and drafts of any material filings
or responses to such patent authorities with respect to such Patent Right reasonably prior to submission thereof to allow the Company an opportunity to review and comment thereon. Pfizer shall reasonably consider any such comments made by or on
behalf of the Company (subject to Pfizer’s final decision-making authority). 

  

	 	(b)	Costs and Expenses. 

  

	 	(i)	Company Responsibility. Following the receipt of a Prosecution Request, the Company shall be responsible for all reasonable costs and expenses incurred by
or on behalf of Pfizer and its Affiliates in connection with the Prosecution Activities associated with the Exclusive Patent Rights that pertain to such Prosecution Request in the applicable country and regulatory jurisdictions.

  

	 	(ii)	Exceptions. Notwithstanding the foregoing Section 18.2.2(b)(i), in the event that a Clinical Development Program is being conducted by or on behalf
of Pfizer or any of its Affiliates with respect to, or Pfizer or any of its Affiliates is commercializing, any compound or product that is Covered by any Exclusive Patent Rights, Pfizer shall provide the Company with written notice thereof and,
beginning as of the date of such notice, the Company shall only be responsible for fifty percent (50%) of the costs and expenses incurred in connection with the Prosecution Activities for such Exclusive Patent Rights (and, for clarity, Pfizer
shall be responsible for the remaining fifty percent (50%) of such costs). 

  

	 	(c)	Delegation of Prosecution Activities and Assignment to the Company. 

 

	 	(i)	 Delegation of Prosecution Activities. Pfizer shall have the right to (in its sole discretion) delegate Pfizer’s rights to conduct
the Prosecution Activities with respect to any Collaboration Patent Rights and Exclusive Patent Rights to the Company and the Company shall perform such activities on Pfizer’s behalf

  
 65 

	 	
(including by using an in-house counsel or outside counsel reasonably acceptable to Pfizer). Following such delegation to the Company, the Company shall provide Pfizer with a copy of any material
communications from any applicable patent authorities and drafts of any material filings or responses to the applicable patent authorities with respect to such Patent Rights reasonably prior to submission to allow Pfizer an opportunity to review and
comment thereon. The Company shall incorporate all such comments. 

  

	 	(ii)	Assignment of Patent Rights. Subject to Section 18.2.2(c)(iii), Pfizer shall have the right to (in its sole discretion) assign any Collaboration
Patent Rights and Exclusive Patent Rights to the Company (any such assigned Patent Rights, the “Assigned Patent Rights”), in which case the rights and obligations of the Parties under this Agreement with respect to the Assigned
Patent Rights (except ownership thereof) shall remain as if such Patent Rights were not Assigned Patent Rights and the Prosecution Activities with respect thereto had been delegated to the Company in accordance with Section 18.2.2(c)(i). In the
event of such an assignment, the Company hereby grants, and shall cause its Affiliates to grant, to Pfizer a license to the Assigned Patent Rights, which license shall be exclusive (including as to the Company) with respect to all uses, except such
license shall be exclusive (except as to the Company) with respect to the scope of the license that would have been granted to the Company pursuant to Section 3.1.1 or 3.1.2, as applicable, if such Patent Right had not been assigned to the
Company. 

  

	 	(iii)	Reversion of Delegation/Assignment. In the event that (A) this Agreement expires or terminates with respect to a Collaboration Patent Right or
Exclusive Patent Right or (B) a Clinical Development Program is being conducted by or on behalf of Pfizer or its Affiliates (including by, with or through a Third Party) with respect to, or Pfizer or any of its Affiliates are commercializing
(including by, with or through a Third Party), any compound or product that relates to any Collaboration Patent Rights and/or Exclusive Patent Rights for which the related Prosecution Activities have been delegated, or that have been assigned, to
the Company in accordance with Section 18.2.2(c)(i) or 18.2.2(c)(ii), upon written request by Pfizer, the Company shall transfer such Prosecution Activities to Pfizer or its designee or assign to Pfizer or its designee all right, title and
interest in and to such Patent Rights (and the Company hereby assigns all such right, title and interest to Pfizer or its designee). 

  
 66 

	 	(d)	Effects of Failure to Pay, Prosecute and Accept Assignment. In the event that the Company does not pay for the portion of the Prosecution Activities as
set forth in Sections 18.2.2(b)(i) and 18.2.2(b)(ii) for specific Collaboration Patent Rights or Exclusive Patent Rights, Pfizer shall be permitted, during the period prior to the Company’s exercise of the Opt-In, to abandon such Patent Rights,
and/or grant Third Parties rights to such Patent Rights that would otherwise be granted to the Company pursuant to the applicable License Agreement if the Company exercised the applicable Opt-In. 

 

	 	18.2.3	Cooperation. Upon Pfizer’s request, the Company shall provide Pfizer with reasonable assistance and cooperation with respect to the Prosecution
Activities of the Pfizer IP, including providing any necessary powers of attorney, filings, and any other assignment documents or instruments for such prosecution. 

 

	18.3	Third Party Infringements. 

  

	 	18.3.1	Notice. The Company shall promptly notify Pfizer in writing upon learning of any actual or threatened infringement, misappropriation, or other violation
or challenge to the validity, scope, or enforceability of any Pfizer IP of which it becomes aware, including, for clarity, any Paragraph IV Certifications (“Third Party Infringement”). 

 

	 	18.3.2	Right of Enforcement. As between the Parties, Pfizer shall have the sole right and authority (but not the obligation) to control enforcement of the Pfizer
IP against any Third Party Infringement and Pfizer shall be solely responsible for all costs and expenses and may retain all recoveries in connection therewith. The Company shall reasonably cooperate (at its own cost and expense) with Pfizer to the
extent related to the Collaboration upon Pfizer’s reasonable request. 

  

	18.4	Liability. Neither Party nor, any of its Affiliates, or its or their employees, agents, or representatives, shall be liable to the other Party or any of
its Affiliates in respect of any act, omission, default, or neglect of such Party (or with respect to Pfizer, any of its Affiliates), or its (or with respect to Pfizer, its Affiliates’) employees’, agents’, or representatives’
part in connection with obligations pursuant to Sections 18.2 or 18.3 and that has not resulted from its (or with respect to Pfizer, its Affiliates’) or its (or with respect to Pfizer, its Affiliates’) directors’, employees’,
officers’, shareholders’, agents’, successors’, and assigns’ bad faith and each Party hereby waives any and all Actions that they may have against the other Party (and with respect to Pfizer, its Affiliates) and its (and
with respect to Pfizer, its Affiliates’) employees, agents, or representatives that may arise or result therefrom. 

  

	18.5	Defense Actions. 

  

	 	18.5.1	Notice. The Company shall promptly notify Pfizer in writing upon learning of any allegation that Intellectual Property Controlled by a Third Party is
infringed, misappropriated, or otherwise violated by either Party’s activities in connection with the Collaboration (each, a “Defense Action”). 

  
 67 

	 	18.5.2	Right of Enforcement. As between the Parties, if a Defense Action is brought against a Party or, with respect to Pfizer, any of its Affiliates, such Party
shall control such Defense Action against the applicable Third Party at its own cost and expense. The Party that controls a Defense Action in accordance with this Section 18.5.2 shall keep the other Party reasonably informed of the status of
such Defense Action and the other Party shall reasonably cooperate in connection therewith. The Party that controls a Defense Action may not settle, or stipulate to any facts, or make any admission with respect to, a Defense Action without the other
Party’s prior written consent; provided that, if Pfizer is controlling the Defense Action, Pfizer shall not be required to obtain the Company’s consent to the extent that the settlement does not give rise to liability of the
Company. 

  

	18.6	License Agreement and Encumbrances. Notwithstanding anything to the contrary, the Parties’ rights and obligations set forth in this Article 18 shall
be subject to (a) the terms of any agreements or contracts that relate to the Encumbrances and (b) License Agreements (if any). 

  

	18.7	CREATE Act. It is the intention of the Parties that this Agreement is a “joint research agreement” as that phrase is defined in 35 U.S.C. §
103(c)(3). In the event that the Company or any of its Affiliates intends to overcome a rejection of a claimed invention within the Pfizer Patent Rights pursuant to the provisions of 35 U.S.C. § 103(c)(2), the Company shall first obtain
Pfizer’s prior written consent. 

  

	18.8	Company Collaboration IP License. The Company, on behalf of itself and its Affiliates, hereby grants to Pfizer and its Affiliates a world-wide,
royalty-free, fully paid-up, sublicensable, perpetual, non-exclusive license under any and all Patent Rights and Know-How that are Controlled by the Company or any of its Affiliates and conceived, reduced to practice or otherwise invented or
generated by or on behalf of the Company, its Affiliates or its permitted sublicensees in connection with the Collaboration (but that are not Collaboration IP) to research, develop, make, have made, use, sell, offer for sale, import and export
compounds and pharmaceutical products in the Territory, outside the Field. 

 19. TRADEMARKS

  

	19.1	Trademarks. Subject to the terms hereof, the Company shall not use the Trademarks of Pfizer or Pfizer’s Affiliates in any product, packaging,
advertising, marketing, or other form of promotional disclosure without prior written consent of Pfizer or unless otherwise expressly permitted under the Global Separation Agreement or any other Ancillary Agreement. Pfizer hereby acknowledges that
it does not receive any right or license hereunder to any of the Trademarks of the Company, except as expressly set forth herein. 

  
 68 

 20. TERM AND TERMINATION 

 

	20.1	 Term. Unless earlier terminated in accordance with the terms hereof, this Agreement shall expire on the seventh (7th) anniversary of the Effective Date (the
“Term”), unless the Parties agree in writing to extend the Term (which agreement may be withheld by each Party in its sole discretion). 

 

	20.2	Termination Rights. 

  

	 	20.2.1	Termination for Material Breach. 

  

	 	(a)	General. Either Party shall have the right, without prejudice to any other remedies available to it at law or in equity, to terminate this Agreement in
its entirety in the event that the other Party is in material breach of this Agreement and fails to cure such material breach within sixty (60) days of duly given notice thereof (including because such breach is incapable of being cured);
provided that, (i) if such breach is capable of being cured, but cannot be cured within such sixty (60) day period, and the breaching Party initiates actions to cure such breach within such sixty (60) day period and
thereafter diligently pursues such actions, the breaching Party shall have such additional period as is reasonable to cure such breach and (ii) the breaching Party shall have ten (10) days (rather than sixty (60) days) to cure
breaches of payment obligations hereunder (and, for clarity, the foregoing (i) shall not apply). 

  

	 	(b)	Certain Material Breaches. In the event that (i) the Company is in material breach of any security measures, confidentiality or use restrictions with
respect to the Pfizer Protected Assets (including as specified in Article 12) and (ii) such breach is the result of bad faith, gross negligence or willful misconduct, such breach shall be deemed a material breach that is not capable of being
cured and Pfizer shall have the right to terminate this Agreement and all executed License Agreements upon ten (10) days written notice, except to the extent any such License Agreements grant rights to Compounds that are being commercialized in
the Field by the Company pursuant to terms of such License Agreement as of the date of such notice. 

  

	 	20.2.2	Immediate Termination Based on Certain Events. 

  

	 	(a)	 Certain Termination Events Relating to the Company. Except to the extent expressly waived or consented to in writing by Pfizer (in
its sole discretion), this Agreement shall terminate immediately and without any requirement for notice to the Company upon the event of: (i) the failure to pay when due and payable any principal, interest, or any other amount in excess of One
Million U.S. Dollars ($1,000,000) in respect of any Company Material Indebtedness; (ii) any event of default with respect to any Company Material Indebtedness; (iii) any other event or condition that results in any

  
 69 

	 	
Company Material Indebtedness becoming due prior to its scheduled maturity or that enables or permits (with or without the giving of notice, the lapse of time or both) the holder or holders of
any Company Material Indebtedness or any trustee or agent on its or their behalf to cause any Company Material Indebtedness to become due, or to require the prepayment, repurchase, redemption or defeasance thereof, prior to its scheduled maturity;
(iv) the Company being authorized (whether by its board of directors or such other Person having authority to direct the Company) to commence or institute any bankruptcy, receivership, insolvency, reorganization or other similar proceedings
under any bankruptcy, insolvency, or other similar law now or hereinafter in effect, including any section or chapter of the United States Bankruptcy Code (as may be amended, the “Bankruptcy Code”) or under any similar laws or
statutes of the United States or any state thereof or of any jurisdiction (whether or not in the United States) having authority or jurisdiction over the assets of the Company or in which the Company may operate or have assets; (v) the
commencement or institution of any bankruptcy, receivership, insolvency, reorganization or other similar proceedings by or against the Company under any bankruptcy, insolvency, or other similar law now or hereinafter in effect, including any section
or chapter of the Bankruptcy Code or under any similar laws or statutes of the United States or any state thereof or of any jurisdiction (whether or not in the United States) having authority or jurisdiction over the assets of the Company or in
which the Company may operate or have assets; (vi) the institution of any reorganization, restructuring, arrangement, or other readjustment of debt plan of the Company not involving the Bankruptcy Code; (vii) the appointment of a receiver,
trustee, or similar party for all or substantially all of the Company’s assets related to this Agreement or that are provided to the Company pursuant to the terms hereof; or (viii) any corporate action taken by the board of directors of
the Company or such other Person having authority to direct the Company in furtherance of any of the foregoing (i) through (vii). 

  

	 	(b)	 Certain Termination Events Relating to Pfizer. The Company shall have the right to terminate this Agreement immediately upon written
notice to Pfizer in the event of: (i) the commencement or institution of any bankruptcy, receivership, insolvency, reorganization or other similar proceedings by or against Pfizer under any bankruptcy, insolvency, or other similar law now or
hereinafter in effect, including any section or chapter of the Bankruptcy Code or under any similar laws or statutes of the United States or any state thereof or of any jurisdiction (whether or not in the United States) having authority or
jurisdiction over the assets of Pfizer or in which Pfizer may operate or have assets, where in the case of involuntary proceedings such proceedings have not been dismissed within sixty (60) days after they are instituted; (ii) the
institution of any reorganization, restructuring, arrangement, or other readjustment of debt plan of Pfizer not involving the Bankruptcy Code; (iii) the appointment of 

  
 70 

	 	
a receiver, trustee, or similar party for all or substantially all of Pfizer’s assets that relate to this Agreement; or (iv) any corporate action taken by the board of directors of
Pfizer or such other Person having authority to direct Pfizer in furtherance of any of the foregoing (i) through (iii); in each case of the foregoing (i) through (iv) if materially adversely affecting Pfizer’s ability to perform
hereunder. 

  

	 	(c)	Company Change of Control and Attempted Assignments. Except to the extent expressly consented to in writing by Pfizer (in its sole discretion), this
Agreement shall terminate automatically upon the occurrence of (i) a Change of Control of the Company or (ii) an attempted assignment or assumption of this Agreement by the Company in contravention of this Agreement (including
Section 21.2). 

  

	 	20.2.3	Company Termination Rights. 

  

	 	(a)	Termination Without Cause by the Company. Upon sixty (60) days written notice to Pfizer, the Company may terminate this Agreement on a
Compound-by-Compound and Analog-by-Analog basis or in its entirety without cause. 

  

	 	(b)	Termination for Failure to Exercise the Opt-In. In the event that the Company does not exercise the Opt-In as of the Opt-In Deadline for an AIP Compound
Series as set forth in Section 7.3.2, this Agreement shall terminate with respect to such AIP Compound Series (including, for clarity, those compounds encompassed by the applicable Markush Structure). 

 

	 	20.2.4	Pfizer/JSC-Related Termination Rights. 

  

	 	(a)	Termination Based on Failure to Grant Intent to Access. If Pfizer does not grant Intent to Access (in part or in whole) as set forth in
Section 5.2.3, this Agreement shall terminate with respect to those Targets, Compounds, and Analogs for which Intent to Access was denied (including, for clarity, those Compounds and Analogs encompassed by the applicable Markush Structure). For
clarity, this Agreement shall not terminate under this Section 20.2.4(a) with respect to those Targets, Compounds and Analogs for which Intent to Access has been granted. 

 

	 	(b)	Termination Based on Denial of AIP Request. If the JSC does not grant AIP (in part or in whole) as set forth in Section 6.4, this Agreement shall
terminate with respect to those Compounds and Analogs for which AIP was denied (including, for clarity, those compounds encompassed by the Markush Structures that are identified by the JSC or Pfizer in such denial of AIP). For clarity, this
Agreement shall not terminate under this Section 20.2.4(b) with respect to those Compounds and Analogs for which AIP was granted (including, for clarity, those Compounds and Analogs encompassed by the applicable Markush Structures identified in
the applicable AIP Notice). 

  
 71 

	 	(c)	Termination Based on Exercise of the Reversion Right. Pfizer may terminate this Agreement with respect to any Compounds and Analogs included in a given
AIP Compound Series in accordance with Section 8.1. 

  

	 	(d)	Termination by Pfizer for Certain Company Relationships. In the event that the Company or any of its Affiliates acquires (whether by merger, liquidation,
consolidation, reorganization, combination, transfer or otherwise) (i) ten percent (10%) or more of the outstanding equity interests or voting power of any Human Health Company or (ii) any assets (including equity securities of any
subsidiary), revenues, net income or earnings of any Human Health Company (other than assets, revenues, net income or earnings for which the Company’s and its Affiliates’ rights are limited to the Field), then the Company shall provide
Pfizer with written notice thereof within five (5) Business Days of the consummation of such acquisition and thereafter Pfizer shall have the right to terminate this Agreement as of a date that is at least ninety (90) days following
delivery of such written notice to Pfizer by providing the Company written notice thereof. Failure by the Company to provide any notice required by this Section 20.2.4(d) shall be deemed a material breach of this Agreement by the Company.

  

	 	20.2.5	Termination Based on Pfizer’s Acquisition of an Animal Health Company. In the event that (a) an Animal Health Company acquires (i) all or
substantially all of the businesses or assets of Pfizer and its Subsidiaries or a (ii) majority of the outstanding voting securities of Pfizer, (b) Pfizer or any of its Subsidiaries merges with or acquires all, or substantially all, of the
assets or business of a Person that is an Animal Health Company or (c) Pfizer becomes a controlled Affiliate of a Person that is an Animal Health Company, then, Pfizer shall provide the Company with written notice thereof as soon as reasonably
practicable following the consummation of such transaction and the Company and/or Pfizer shall have the right to terminate this Agreement within fifteen (15) days of such written notice. With respect to any AIP Compound Series designated as of
the effective date of termination pursuant to this Section 20.2.5 and for which the Opt-In Deadline has not occurred, the Company shall have the right to exercise the Opt-In until the earlier of (x) the Opt-In Deadline and (y) sixty
(60) days following the effective date of the termination pursuant to this Section 20.2.5 (the “Extension Period”); provided that during the Extension Period, the Company shall not perform any research or
development activities and shall not have access to the Pfizer Database or the Pfizer Library, except as otherwise required in order to comply with any requirements imposed by a Regulatory Authority with respect to any such AIP Compound Class in
connection with the Collaboration. 

  
 72 

	20.3	Effects of Expiration and Termination. 

  

	 	20.3.1	Termination of Licenses. 

  

	 	(a)	Expiration or Termination in Whole. Subject to this Section 20.3, upon any expiration or termination of this Agreement in whole, all licenses and
other rights granted by Pfizer and its Affiliates to the Company, and sublicenses granted by the Company, pursuant to this Agreement shall terminate. 

  

	 	(b)	Termination in Part. Subject to this Section 20.3, upon any termination of this Agreement in part, all licenses and other rights granted by Pfizer
and its Affiliates to the Company, and sublicenses granted by the Company, pursuant to this Agreement with respect to such termination shall terminate. 

  

	 	20.3.2	Transfer of Collaboration Know-How. Within forty-five (45) days of any expiration or termination of this Agreement in part or in whole, the Company
shall provide Pfizer with a copy of the Collaboration Know-How that relates to such expiration or termination that has not been provided to Pfizer as of such date. Such Collaboration Know-How shall be provided to Pfizer in the format set forth on
Schedule 10.2 or such other format reasonably requested by Pfizer in writing. For clarity, Pfizer shall have the right (but not the obligation) to add the Collaboration Know-How to the Pfizer Database, the Pfizer Restricted Databases and all other
databases or systems that Pfizer or any of its Affiliates owns, controls or has access to (subject to Article 12). 

  

	 	20.3.3	Return or Destruction of Confidential Information and Materials. Subject to Sections 20.3.4 and 20.3.6, upon expiration or termination of this Agreement
(in part or in whole), the Company shall within fifteen (15) Business Days of any request by Pfizer, (a) return to Pfizer, or (b) at Pfizer’s election, destroy in a manner that ensures that it is unrecoverable (and certify in
writing to Pfizer such destruction), (x) all Compounds, Analogs and other Materials that relate to the expiration or termination (which, for clarity, in the case of a termination or expiration of this entire Agreement, shall be all Compounds,
Analogs and other Materials) in its possession as of the date of such expiration or termination and (y) all Pfizer IP that is in the Company’s possession (including downloaded, or otherwise stored, on the Company’s computer systems)
as of the date of termination. Pfizer and its Affiliates shall be entitled to conduct, and have a Third Party that is reasonably acceptable to the Company conduct, an audit of the Company in order to ascertain compliance with this provision and the
Company agrees to allow reasonable access to Pfizer, its Affiliates and any such Third Parties for such purpose. Notwithstanding anything to the contrary in this Section 20.3.3, the Company shall not destroy any Collaboration Know-How prior to
providing such Know-How to Pfizer (unless Pfizer expressly states otherwise in writing). 

  
 73 

	 	20.3.4	Company License to Collaboration IP. 

  

	 	(a)	Company License. 

  

	 	(i)	Subject to Sections 20.3.4(a)(ii) and 20.3.4(a)(iii), in the event of a Company License Triggering Event, the Company shall be granted a non-exclusive research license
in, to and under the Collaboration IP and Residuals for which the licenses, other rights and sublicenses are terminating solely for the Field in the Territory; provided that such license shall not include any rights to conduct research
(including any analoguing of) or development on, or to make, use, sell, offer to sell, import or export, the Restricted Compounds. For clarity, and notwithstanding the foregoing, the Company shall be permitted to conduct research using the
Collaboration IP and Residuals with respect to any compounds if such compounds are not Restricted Compounds; provided that such compounds have not been created, designed or synthesized by conducting research with respect to (including
performing any analoguing of) the Restricted Compounds. 

  

	 	(ii)	Notwithstanding the foregoing Section 20.3.4(a)(i), subject to any Pfizer Patent Rights and the restrictions set forth in 20.3.4(a)(iv), if the structure of
a Restricted Compound and its activity with respect to the Target is or becomes publicly known through no breach of any obligation to Pfizer, its Affiliates, or any licensee or other Third Party to which Pfizer has granted rights or
that has granted rights to Pfizer, the license described in Section 20.3.4(a)(i) shall include a non-exclusive research license in, to and under the applicable Residuals solely to conduct internal research with respect to such Restricted
Compound. For clarity, the Company shall not be permitted to collaborate with any Third Parties with respect to the foregoing license. 

  

	 	(iii)	Notwithstanding the foregoing Section 20.3.4(a)(i), subject to any Pfizer Patent Rights and the restrictions of 20.3.4(a)(iv), if the structure of
a Restricted Compound and its activity with respect to the Target and any related Collaboration IP and Residuals become publicly known through no breach of any obligation to Pfizer, its Affiliates or any licensee or other Third Party to
which Pfizer has granted rights or that has granted rights to Pfizer, the Company shall be permitted to conduct research using such public Collaboration IP and Residuals with respect to such Restricted Compound (but not any other Restricted
Compounds). 

  

	 	(iv)	 The Company shall not have any rights to file or otherwise prosecute applications for Patent Rights Covering, or present or publish regarding,
(A) the Collaboration IP or Residuals licensed to the Company pursuant to this Section 20.3.4(a), or (B) prior to the date that the structure of a Restricted Compound and its

  
 74 

	 	
activity with respect to the Target has been made publicly known by Pfizer, the results of any research under the foregoing Section 20.3.4(a)(i) or (ii), in each case, without Pfizer’s
prior written consent (which may be withheld in Pfizer’s sole discretion). 

  

	 	(b)	Company License Triggering Events. For purposes of this Section 20.3.4, “Company License Triggering Events” means:

  

	 	(i)	expiration of this Agreement, 

  

	 	(ii)	termination of this Agreement by the Company in accordance with Section 20.2.1 (Termination For Material Breach), 

 

	 	(iii)	termination of this Agreement in accordance with Section 20.2.2(b) (Certain Termination Events Relating to Pfizer), 

 

	 	(iv)	termination of this Agreement in accordance with Section 20.2.5 (Termination Based on Pfizer’s Acquisition of an Animal Health Company), (the foregoing
(i) through (iv), “Expiration/Termination In Whole Triggering Events”) 

  

	 	(v)	termination of this Agreement in accordance with Section 20.2.3(b) (Termination for Failure to Exercise the Opt-In), 

 

	 	(vi)	termination of this Agreement in accordance with Section 20.2.4(b) (Termination Based on Denial of AIP Request), and 

 

	 	(vii)	termination of this Agreement in accordance with Section 20.2.4(c) (Termination Based on Exercise of the Reversion Right). 

 

	 	(c)	Restricted Compounds. For purposes of this Section 20.3.4, “Restricted Compounds” has the respective meaning set forth in this
Section 20.3.4(c): 

  

	 	(i)	Expiration/Termination In Whole Triggering Events. If the Company License Triggering Event is an Expiration/Termination In Whole Triggering Event, the
Restricted Compounds shall be: 

  

	 	(A)	the Compounds and Analogs in the Lead Seeking Phase as of the Expiration/Termination In Whole Triggering Event and on which the Company has conducted any Lead Seeking
Activities (including as set forth in the progress reports provided by the Company to the JSC in accordance with Section 10.1) (for clarity, a Leverager’s accessing of information from the Pfizer Database to determine whether to seek
Intent to Access does not constitute Lead Seeking Activities hereunder); 

  
 75 

	 	(B)	in the event that, as of such Expiration/Termination In Whole Triggering Event, any research, development or commercialization has been conducted by or on behalf of
Pfizer or any of its Affiliates (including by, with or through a Third Party) regarding any compounds in the same compound class (as determined by Pfizer in its good faith sole discretion) as the Compounds or Analogs specified in
Section 20.3.4(c)(i)(A), Pfizer shall have the right to include in the Restricted Compounds all compounds encompassed by Markush Structures that are identified by Pfizer; provided that such Markush Structures are in the same
compound class as any such compounds on which research, development or commercialization has been conducted by or on behalf of Pfizer or its Affiliates (including by, with or through a Third Party) (Pfizer shall designate such compounds in a writing
that it provides to the Company no later than thirty (30) days following such Company License Triggering Event); 

  

	 	(C)	with respect to the Compounds and Analogs that are in the Candidate Designation Phase as of the applicable Expiration/Termination In Whole Triggering Event, the related
AIP Compound Series (including any Compounds and Analogs encompassed by the Markush Structures identified in the applicable AIP Notice); and 

  

	 	(D)	Restricted Compounds that have been designated in the related notices granting Intent to Access and AIP Notices. 

 

	 	(ii)	Failure to Exercise the Opt-In Triggering Event. If the Company License Triggering Event is a termination in accordance with Section 20.2.3(b)
(Termination for Failure to Exercise the Opt-In), the Restricted Compounds shall be: 

  

	 	(A)	the related AIP Compound Series; and 

  

	 	(B)	any Restricted Compounds designated by Pfizer in the applicable notice granting Intent to Access or AIP Notice that relates to such AIP Compound Series.

  

	 	(iii)	Denial of AIP Request Triggering Event. If the Company License Triggering Event is a termination in accordance with Section 20.2.4(b) (Termination
Based on Denial of AIP Request), the Restricted Compounds shall be: 

  

	 	(A)	the Compounds and Analogs for which the AIP Request was denied (including, for clarity, those compounds encompassed by the applicable Markush Structures that are
identified by the JSC or Pfizer in such denial of AIP); 

  
 76 

	 	(B)	Restricted Compounds that have been designated by Pfizer in the notice granting Intent to Access that relates to such Intent to Access Request; and

  

	 	(C)	in the event that, as of such Company License Triggering Event, any research, development or commercialization has been conducted by or on behalf of Pfizer or any of
its Affiliates (including by, with or through a Third Party) regarding any compounds in the same Compound Class (as designated by the JSC in accordance with Section 6.4) as the Compounds or Analogs specified in Section 20.3.4(c)(iii)(A),
Pfizer shall have the right to include in the Restricted Compounds all compounds encompassed by Markush Structures that are identified by Pfizer; provided that such Markush Structures are in the same Compound Class as any such
compounds on which research, development or commercialization has been conducted by or on behalf of Pfizer or its Affiliates (including by, with or through a Third Party. Pfizer shall designate such compounds in a writing that it provides to the
Company no later than thirty (30) days following such Company License Triggering Event. For clarity, in the event of such a termination in accordance with Section 20.2.4(b) (Termination Based on Denial of AIP Request), any Compounds
and Analogs on which the Company may conduct the Lead Seeking Activities as specified in the Intent to Access Request but that are not Compounds or Analogs for which AIP was proposed and denied shall not be Restricted Compounds; provided
however that, for clarity, the Company shall not be permitted to use the Pfizer IP to conduct research, development or commercialization with respect thereto outside the scope of the Collaboration. 

 

	 	(iv)	Exercise of the Reversion Right Triggering Event. If the Company License Triggering Event is a termination in accordance with Section 20.2.4(c)
(Termination Based on Exercise of the Reversion Right), the Restricted Compounds shall be: 

  

	 	(A)	the Compound(s) or Analog(s) on which the Reversion Right is exercised, 

  
 77 

	 	(B)	any Restricted Compounds designated by Pfizer in the applicable notice granting Intent to Access or AIP Notice that relates to such AIP Compound Series, and

  

	 	(C)	in the event that, as of such Company License Triggering Event, any research, development or commercialization has been conducted by or on behalf of Pfizer or any of
its Affiliates (including by, with or through a Third Party) regarding any compounds in the same Compound Class (as designated by the JSC in accordance with Section 6.4) as the Compounds or Analogs specified in Section 20.3.4(c)(i), Pfizer
shall have the right to include in the Restricted Compounds all compounds encompassed by Markush Structures that are identified by Pfizer; provided that such Markush Structures are in the same Compound Class as any such compounds on
which research, development or commercialization has been conducted by or on behalf of Pfizer or its Affiliates (including by, with or through a Third Party). Pfizer shall designate such compounds in a writing that it provides to the Company no
later than thirty (30) days following such Company License Triggering Event. 

  

	 	(d)	Breach. In the event that the Company materially breaches a license granted by Pfizer pursuant to Section 20.3.4(a)(i), the Company hereby assigns,
and shall cause its Affiliates and all applicable Third Parties to assign, to Pfizer its entire right, title, and interest in, to, and under all Intellectual Property generated in connection with such breach. The Company shall, and shall cause its
Affiliates and all applicable Third Parties to, execute any and all assignments and other documents necessary to perfect or record Pfizer’s right, title, and interest in, to, and under such Intellectual Property. The Company further agrees to
execute, and cause its Affiliates and all applicable Third Parties to execute, all further documents and assignments and do all such further things as may be necessary to perfect Pfizer’s title to such Intellectual Property or to register
Pfizer as the exclusive owner of any applicable registrable rights. 

  

	 	(e)	Improvements. Subject to this Section 20.3.4, any Collaboration Improvements generated by or on behalf of the Company in connection with the licenses
granted pursuant to this Section 20.3.4 shall be owned by the Company, and the Company hereby grants to Pfizer a non-exclusive, royalty-free, worldwide license to use such Collaboration Improvements for any purpose outside of the Field.

  

	 	20.3.5	 Restriction on Pfizer. If this Agreement terminates in accordance with Sections 20.2.4(b) (Termination Based on Denial
of AIP Request), 20.2.4(c) (Termination Based on Exercise of Reversion Right), or 20.2.5 (Termination Based on Pfizer’s 

  
 78 

	 	
Acquisition of an Animal Health Company) (each, a “Triggering Event”), for the three (3) year period following the date of the applicable Triggering Event, Pfizer
shall not use the Collaboration IP, or any regulatory submission that it is assigned, or to which it is granted rights of reference, following expiration or termination of this Agreement in accordance with Section 17.1, to research, develop, or
commercialize the following compounds in the Field: 

  

	 	(a)	If the termination is pursuant to Section 20.2.4(b) (Denial of an AIP Request), the Compounds and Analogs on which the Company conducted the Lead Seeking
Activities for which AIP was denied, including all such compounds to the extent encompassed by the Markush Structure included in the applicable (i) notice granting Intent to Access and/or (ii) AIP Request, 

 

	 	(b)	If the termination is pursuant to Section 20.2.4(c) (Termination Based on Exercise of the Reversion Right), the Compound or Analog for which the Reversion
Right has been exercised, and 

  

	 	(c)	If the termination is pursuant to Section 20.2.5 (Termination Based on Pfizer’s Acquisition of an Animal Health Company), the AIP Compound Series on which
the Company is conducting the Candidate Designation Activities as of the date of such termination, including (i) all such compounds encompassed by the Markush Structure included within the AIP Notices that relate to such AIP Compound Series,
and (ii) the Compounds and Analogs in the Lead Seeking Phase on which the Company has conducted any Lead Seeking Activities (including as set forth in the progress reports provided by the Company to the JSC in accordance with
Section 10.1). 

  

	 	20.3.6	AIP Compound Series. Upon expiration of this Agreement or in the event of termination by the Company pursuant to Section 20.2.1 (Termination for
Material Breach) and 20.2.2(b) (Certain Termination Events Relating to Pfizer), as of the effective date of termination or expiration, the Company shall have the right to continue to conduct the Candidate Designation Activities for those
Compounds and Analogs in the AIP Compound Series for which AIP has been granted and the Opt-In Deadline has not occurred as of such date in accordance with the terms hereof; provided that, the Company shall not have access to the
Pfizer Database or the Pfizer Library during such time. In the event that the Company requires any additional information from the Pfizer Database to conduct the Candidate Designation Activities during such time, the Company shall have the right to
reasonably request such data and information from Pfizer and Pfizer shall reasonably consider each such request (but, for clarity, Pfizer shall have no obligation to provide the Company with any such additional data or information). For clarity, the
Company’s rights and the terms of this Agreement with respect to each such Compound and Analog shall expire three (3) years after AIP is granted with respect to such AIP Compound Series. 

 

	 	20.3.7	 License Agreements and Screening Services Agreement. For clarity, except as expressly set forth herein, termination of this Agreement
shall not in and of itself 

  
 79 

	 	
terminate (a) any of the License Agreements that are executed as of the date of such termination or (b) the Screening Services Agreement (to the extent such agreement is in effect as of
such date). 

  

	 	20.3.8	Payment. Within thirty (30) days of expiration or termination of this Agreement, in part or in whole (or such later date with respect to those costs
that are incurred but cannot be reported as of such date), the Company shall pay Pfizer all amounts due to Pfizer in connection with this Agreement (and, with respect to termination pursuant to Section 20.2.1(b), the License Agreements) as of
the effective date of such expiration or termination. 

  

	 	20.3.9	Wind-Down Costs. 

  

	 	(a)	Pfizer Responsibility. Pfizer shall be responsible for all of its and the Company’s reasonable out-of-pocket Wind-Down Costs in the event of
termination of this Agreement in its entirety (i) by the Company in accordance with Sections 20.2.1 (Termination for Material Breach), or 20.2.2(b) (Certain Termination Events Relating to Pfizer), or (ii) in accordance with
Section 20.2.5 (Termination Based on Pfizer’s Acquisition of an Animal Health Company). 

  

	 	(b)	Company Responsibility. The Company shall be responsible for all of its and Pfizer’s reasonable out-of-pocket Wind-Down Costs in the event of
termination of this Agreement in its entirety (i) by Pfizer in accordance with Sections 20.2.1 (Termination for Material Breach), 20.2.2(a) (Certain Termination Events Relating to the Company), or 20.2.4(d) (Termination by
Pfizer for Certain Company Relationships), (ii) by the Company in accordance with Section 20.2.3(a) (Termination Without Cause by the Company) or (iii) in accordance with Section 20.2.2(c) (Company Change of Control
and Attempted Assignments). 

  

	 	20.3.10	Exercise of Pfizer’s Reversion Right. For clarity, subject to Section 20.3.11, the effects of any termination pursuant to Section 20.2.4(c)
(Termination Based on Exercise of the Reversion Right) are as set forth in Section 8.1. 

  

	 	20.3.11	 Survival. Without limiting any other provisions in this Article 20, the following provisions (along with the provisions herein that
expressly specify survival terms or that would, by their nature, survive termination) shall survive expiration or termination of this Agreement for any reason (collectively, the “Surviving Provisions”): 3.3.1, 3.3.2, 3.4, 3.5, 4.2.1
(subsections (a) and (c) of the third sentence), 4.2.5(h), 7.2.2 (last paragraph), 8.1 through 8.4 (for so long as any License Agreements are in effect), 8.5, 8.6, 9.3, 9.9 (for the period of time set forth in such Section), 10.2 (last
sentence), 10.3 (for the period of time set forth in such Section), 10.4, 11.4, 12.1 through 12.9.5 (except to the extent such provisions reference provision of a remediation plan to the JSC), 12.9.5(d), 13.1, 14, 15, 16 (for the time period set
forth in such Section), 18.1.1(a), 18.1.1(b)(i), 18.1.1(b)(ii) (last sentence), 18.1.1(c), 18.4, 18.6 through 18.8, 19, 20.3 (subject to any time limitations set forth in such Section) 21. Without limiting any of

  
 80 

	 	
the rights or remedies otherwise available to either Party, each Party acknowledges and agrees that monetary damages would be an inadequate remedy for any breach of any of the Surviving
Provisions; that each of its obligations with respect to the Surviving Provisions shall continue, remain binding, and survive termination of this Agreement (and, without limiting the foregoing, shall not be dischargeable in any proceeding under the
Bankruptcy Code or similar proceeding); and that each of its obligations with respect to the Surviving Provisions is and shall be specifically enforceable under Applicable Law. 

21. MISCELLANEOUS 
  

	21.1	Compliance with Laws. Neither Party nor any of their Affiliates will be required by this Agreement to take or omit to take any action in contravention of
any Applicable Law, including any applicable national and international pharmaceutical industry codes of practices. Without limiting the foregoing, and notwithstanding any other provision of this Agreement, neither Party nor any of their Affiliates
shall be required to promote or otherwise commercialize a pharmaceutical product, or incur any expense in connection with any activity under this Agreement, that it reasonably believes, in good faith, may violate any Applicable Law (including any
applicable national and international pharmaceutical code of practice) or “corporate integrity” or similar agreement with any Governmental Authority to which it is a party. 

 

	21.2	 Assignability. For clarity, the rights, benefits, and obligations of the Company under (or relating to) this Agreement (including any
licenses or sublicenses granted pursuant to this Agreement) are personal to the Company. The Company may not assign (including in a bankruptcy or similar proceeding) or assume in a bankruptcy or similar proceeding this Agreement or any rights,
benefits, or obligations under or relating to this Agreement, in each case whether by operation of law or otherwise, without Pfizer’s prior written consent (which Pfizer may withhold in its sole discretion). For purposes of this Agreement, and
without limiting any other provision of this Agreement, a Change of Control of the Company constitutes an assignment hereunder. The Company acknowledges and agrees, on behalf of itself and any successors or assigns, that (a) Applicable Law
excuses Pfizer from accepting performance from, or rendering performance to, any entity other than the Company (whether or not such other entity is an assignee of the Company, a successor to the Company, a trustee in a bankruptcy or similar
proceeding, or the Company as a debtor or debtor in possession in a bankruptcy or similar proceeding); (b) Pfizer has not consented to any assignment or assumption of this Agreement (or of any licenses, sublicenses, rights, benefits, or
obligations under, or relating to, this Agreement), in each case whether by operation of law or otherwise; and (c) any future consent by Pfizer to an assignment or assumption of this Agreement (or any licenses, sublicenses, rights, benefits, or
obligations under, or related to, this Agreement) shall be limited to the specific assignment or assumption consented to, shall be personal to the assignee or the party assuming this Agreement (or any licenses, sublicenses, rights, benefits, or
obligations under, or related to, this Agreement) in such assignment or assumption, and shall not be (or be deemed to be) a consent to any other assignment or assumption. In the event of a permitted assignment or assumption hereunder, this Agreement
will be binding upon the 

  
 81 

	 	
Parties and their respective permitted successors and permitted assigns. Any attempted assignment or assumption without the prior written consent of Pfizer or that otherwise contravenes the terms
of this Agreement shall be void ab initio and of no force or effect; provided that, without limiting any provision of this Agreement (including this Section 21.2), in the event of an attempted assignment or assumption in
contravention of this Section 21.2, this Agreement (and any licenses or sublicenses granted hereunder) shall be subject to automatic termination in accordance with Section 20.2.2(c). 

 

	21.3	Governing Law. This Agreement shall be governed by and construed and interpreted in accordance with the laws of the State of New York, without regard to
the conflict of laws principles thereof that would result in the application of any law other than the laws of the State of New York, and, to the extent applicable to Intellectual Property, the applicable federal laws of the United States of America
(without regard to conflict of laws principles). 

  

	21.4	Dispute Resolution. 

  

	 	21.4.1	General. The following procedures shall be used to resolve any dispute, controversy or claim that may arise out of or relate to, or arise under or in
connection with this Agreement or the breach, termination, or validity thereof (each, a “Dispute”): 

  

	 	(a)	Promptly after the written request of either Party (“Request”), the Alliance Managers shall meet in person or by telephone to attempt to resolve any
Dispute. If, for any reason, the Alliance Managers do not resolve the Dispute within thirty (30) days of receipt by a Party of such Request, then the Senior Executives shall meet in person or by telephone to review and attempt to resolve the
Dispute. The Senior Executives shall have thirty (30) days to attempt to resolve the Dispute. 

  

	 	(b)	If, for any reason, the Senior Executives fail to resolve the Dispute within sixty (60) days of receipt by a Party of a Request in accordance with
Section 21.4.1(a), the Parties shall attempt to resolve the Dispute with the assistance of a mediator agreed upon by the Parties or, in default of such agreement, within seventy-five (75) days of receipt by a Party of a Request, at the
request of any Party, such mediator shall be appointed by the American Arbitration Association (“AAA”). The mediation shall be held in New York, New York and in accordance with the then-prevailing Commercial Mediation Rules of the
AAA. 

  

	 	(c)	All negotiations and mediation in connection with the Dispute shall be conducted in strict confidence and without prejudice to the rights of the Parties in any future
legal proceedings. Except for any Party’s right to seek interlocutory relief in the courts, no Party may commence any form of arbitration in accordance with Section 21.4.2 or 21.4.3 (as appropriate) until twenty (20) Business Days
after the appointment of a mediator or until one hundred twenty (120) days after the receipt by a Party of a Request, whichever occurs sooner. 

  

	 	(d)	If, with the assistance of the mediator, the Parties reach a settlement, such settlement shall be reduced to writing and, once signed by a duly authorized
representative of each of the Parties, shall be and remain binding on the Parties. The Parties shall bear their own legal costs of the mediation, but the costs and expenses of the mediator and the AAA shall be borne by the Parties equally.

  
 82 

	 	21.4.2	Fair Market Value and Company Technology Royalty Rate Disputes. All Disputes that for any reason are not timely resolved by the Parties in accordance with
Section 21.4.1(a) and that relate exclusively to determination of the amount of Fair Market Value and Company Technology Royalty Rate shall be resolved in accordance with this Section. 

 

	 	(a)	Upon written request by either Party to the other Party, the Parties shall promptly agree on the appointment of an appropriate valuation expert (the “Expert
Arbitrator”). If the Parties are not able to agree by mutual written agreement within fourteen (14) Business Days after the receipt by a Party of the written request in the immediately preceding sentence, either Party may request that
the AAA, or such other similar entity as the Parties may agree upon by mutual written agreement, appoint an Expert Arbitrator who shall have the qualifications set forth on Schedule 21.4.2(a), if practicable (such appointment to be made within
twenty (20) Business Days of such Request). The fees and costs of the Expert Arbitrator and the AAA shall be shared equally (50%/50%) by the Parties. 

 

	 	(b)	Within fifteen (15) Business Days after the designation of the Expert Arbitrator, each Party shall simultaneously submit to the Expert Arbitrator and one another a
written statement of its proposed amount for the applicable Fair Market Value or Company Technology Royalty Rate along with documents in support of such amount (and the Company shall include in its statement the amount that it initially proposed to
Pfizer for the applicable Fair Market Value or Company Technology Royalty Rate and its final offer made to Pfizer for the applicable Fair Market Value or Company Technology Royalty Rate prior to submission to the Expert Arbitrator in accordance with
this Section). Each Party shall have fifteen (15) Business Days from receipt of the other Party’s submission to submit to the Expert Arbitrator and the other Party a written response thereto, which shall include any scientific, financial,
technical, or other relevant information in support thereof. The Expert Arbitrator shall have the right to hold a hearing of no more than two (2) days for the Parties to present evidence regarding Fair Market Value or Company Technology Royalty
Rate. 

  
 83 

	 	(c)	No later than ten (10) days after the submission of all evidence or the close of the hearing or as soon thereafter as practicable, the Expert Arbitrator shall make
a determination by selecting the Fair Market Value or Company Technology Royalty Rate proposed by one of the Parties. In making his or her determination of Fair Market Value or Company Technology Royalty Rate (as applicable), the Expert Arbitrator
shall apply the principles set forth in Schedule 1.1(c) (with respect to Fair Market Value) and Schedule 8.5 (with respect to Company Technology Royalty Rate). The Expert Arbitrator shall provide the Parties with an award setting forth the Fair
Market Value or Company Technology Royalty Rate (as applicable) that was selected and a brief written statement setting forth the basis of the determination in connection therewith. The decision of the Expert Arbitrator shall be final and conclusive
and binding on the Parties and may be entered and enforced in any court having jurisdiction. The arbitration shall be held and the award shall be rendered in New York, New York. 

 

	 	21.4.3	Arbitration. 

  

	 	(a)	 All Disputes that for any reason are not timely resolved by the Parties in accordance with Section 21.4.1 (other than Disputes which are to be
resolved in accordance with Section 21.4.2) shall be finally and exclusively resolved by binding arbitration to be administered by the AAA in accordance with the then-prevailing Commercial Arbitration Rules of the AAA (the
“Rules”). The seat of the arbitration shall be in New York County, New York. The arbitration shall be held and the award shall be issued in the English language. If the amount in controversy is Three Million US Dollars
(US$3,000,000) or less (including all claims and counterclaims), there shall be one arbitrator who shall be agreed upon by the Parties within twenty (20) days of receipt by respondent of a copy of the demand for arbitration. If the amount in
controversy is more than Three Million US Dollars (US$3,000,000) (including all claims and counterclaims), there shall be three (3) neutral and impartial arbitrators, one of whom shall be appointed by each of the Parties within thirty
(30) days of receipt by respondent of the demand for arbitration, and the third (3rd) arbitrator, who shall chair the arbitral tribunal, shall be appointed by the Party appointed arbitrators within fifteen (15) days of the appointment of the second (2nd) arbitrator. If any arbitrator is not appointed within the time
limit provided herein, such arbitrator shall be appointed by the AAA in accordance with the listing, striking, and ranking procedures in the Rules. Any arbitrator appointed by the AAA shall be a retired judge or an attorney with no less than fifteen
(15) years of experience with commercial cases and an experienced arbitrator, who shall, if practicable, have experience with transactions or disputes related to the field of pharmaceutical development and technology and/or, if applicable,
intellectual property (including Patent Rights and trade secrets). 

  
 84 

	 	(b)	All arbitrators shall be neutral and impartial and shall not be officers or employees of either Party. The cost of the arbitration, including the fees and expenses of
the arbitrator(s), will be shared equally by the Parties. The arbitrator(s) shall have the right to award damages and other relief but will not have the authority to award any damages or remedies not available under the express terms of this
Agreement. The arbitration award will be presented to the Parties in writing and will include findings of fact and, where appropriate, conclusions of law. The award may be confirmed and enforced in any court of competent jurisdiction.
Notwithstanding anything to the contrary, in the event that the dispute concerns whether Pfizer exercised good faith, the Company shall be required to show by clear and convincing evidence that Pfizer did not exercise good faith.

  

	 	(c)	Prior to the appointment of the arbitral tribunal, either Party may seek injunctive relief from any court of competent jurisdiction in order to enforce compliance with
the provisions of this Section 21.4.3 or otherwise in aid of arbitration or to maintain the status quo or prevent irreparable harm. The Parties hereby submit to the non-exclusive jurisdiction of the Federal and State courts located in New York,
New York (the “New York Courts”) for such purpose. Without prejudice to such provisional remedies as may be available under the jurisdiction of the New York Courts, the arbitrator(s) shall have full authority to grant provisional
remedies and to direct the Parties to request that any New York Court modify or vacate any temporary or preliminary relief issued by any such New York Court, and to award damages for the failure of any Party to respect the arbitrator’s(s’)
orders to that effect. 

  

	21.5	Specific Performance. In the event of any actual or threatened default in, or breach of, any of the terms, conditions and provisions of this Agreement,
the Party or Parties who are or are to be thereby aggrieved shall have the right to specific performance and injunctive or other equitable relief of its rights under this Agreement, in addition to any and all other rights and remedies at law or in
equity, and all such rights and remedies shall be cumulative. The Parties agree that the remedies at law for any breach or threatened breach, including monetary damages, are inadequate compensation for any loss and that any defense in any Action for
specific performance that a remedy at law would be adequate is waived. Any requirements for the securing or posting of any bond with such remedy are waived. 

 

	21.6	Force Majeure. No Party shall be deemed in default of this Agreement to the extent that any delay or failure in the performance of its obligations under
this Agreement results from any cause beyond its reasonable control and without its fault or negligence, such as acts of God, acts of civil or military authority, embargoes, epidemics, war, riots, insurrections, fires, explosions, earthquakes,
floods, unusually severe weather conditions, labor problems or unavailability of parts, or, in the case of computer systems, any failure in electrical or air conditioning equipment. In the event of any such excused delay, the time for performance
shall be extended for a period equal to the time lost by reason of the delay. 

  
 85 

	21.7	Advisors. It is acknowledged and agreed by each of the Parties that Pfizer, on behalf of itself and the other members of the Pfizer Group, has retained
each of the Persons identified on Schedule 11.11 to the Global Separation Agreement to act as counsel in connection with this Agreement, the License Agreements, the Global Separation Agreement, the Ancillary Agreements, the Contribution and the
other transactions contemplated hereby and thereby and that the Persons listed on Schedule 11.11 to the Global Separation Agreement have not acted as counsel for the Company or any other member of the Company Group in connection with this Agreement,
the License Agreements, the Global Separation Agreement, the Ancillary Agreements, the Contribution and the other transactions contemplated hereby and thereby and that none of the Company or any member of the Company Group has the status of a client
of the Persons listed on Schedule 11.11 to the Global Separation Agreement for conflict of interest or any other purposes as a result thereof. The Company hereby agrees, on behalf of itself and each other member of the Company Group that, in the
event that a dispute arises after the Effective Date in connection with this Agreement, the License Agreements, the Global Separation Agreement, the Ancillary Agreements, the Contribution and the other transactions contemplated hereby and thereby
between Pfizer and the Company or any of the members of their respective Groups, each of the Persons listed on Schedule 11.11 to the Global Separation Agreement may represent any or all of the members of the Pfizer Group in such dispute even though
the interests of the Pfizer Group may be directly adverse to those of the Company Group. The Company further agrees, on behalf of itself and each other member of the Company Group that, with respect to this Agreement, the License Agreements, the
Global Separation Agreement, the other Ancillary Agreements, the Contribution and the other transactions contemplated hereby and thereby, the attorney-client privilege and the expectation of client confidence belongs to Pfizer or the applicable
member of the Pfizer Group and may be controlled by Pfizer or such member of the Pfizer Group and shall not pass to or be claimed by the Company or any member of the Company Group. Furthermore, the Company acknowledges and agrees that Skadden, Arps,
Slate, Meagher & Flom, LLP is representing Pfizer, and not the Company, in connection with the Transactions. 

  

	21.8	Notices. 

  

	 	21.8.1	All notices or other communications under this Agreement shall be in writing and shall be deemed to be duly given when (a) delivered in person or
(b) deposited in the United States mail or private express mail, postage prepaid, addressed as follows: 

 If
to Pfizer, to: 
 Pfizer Inc. 
 235 East 42nd Street 
 New York, NY 10017 

Attention: General Counsel 

  
 86 

 with a copy to: 
 If to the Company to: 
 with a copy to: 

Any Party may, by notice to the other Party, change the address to which such notices are to be given. 

 

	 	21.8.2	Notwithstanding the foregoing, each Party shall have the right to deliver to the other Party (as applicable) by email Intent to Access Requests, notices granting Intent
to Access, AIP Requests, AIP Notices, and Opt-In Notices and each of the foregoing shall be deemed to be duly given when received by the applicable other Party. 

 

	21.9	Waivers of Default. Waiver by any Party of any default by the other Party of any provision of this Agreement shall not be deemed a waiver by the waiving
Party of any subsequent or other default, nor shall it prejudice the rights of the other Party. 

  

	21.10	Amendments. No provisions of this Agreement shall be deemed waived, amended, supplemented, or modified by any Party, unless such waiver, amendment,
supplement or modification is in writing and signed by the authorized representative of the Party against whom it is sought to enforce such waiver, amendment, supplement or modification. 

 

	21.11	Severability. If any provision of this Agreement or the application thereof to any Person or circumstance is determined by a court of competent
jurisdiction to be invalid, void, or unenforceable, the remaining provisions hereof or the application of such provision to Persons or circumstances or in jurisdictions other than those as to which it has been held invalid or unenforceable, shall
remain in full force and effect and shall in no way be affected, impaired, or invalidated thereby, so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner adverse to any Party. Upon such
determination, the Parties shall negotiate in good faith in an effort to agree upon such a suitable and equitable provision to effect the original intent of the Parties. 

 

	21.12	Further Assurances. The Company and Pfizer hereby covenant and agree, without the necessity of any further consideration, to execute, acknowledge, and
deliver any and all such other documents and take any such other action as may be reasonably necessary or appropriate to implement this Agreement and carry out the intent and purposes of this Agreement. 

  
 87 

	21.13	Third Party Beneficiaries. Except for the indemnification rights under this Agreement of any Pfizer Indemnitee or Company Indemnitee in their respective
capacities as such (a) the provisions of this Agreement are solely for the benefit of the Parties and are not intended to confer upon any Person (including employees of the Parties) except the Parties any rights or remedies hereunder, and
(b) there are no third party beneficiaries of this Agreement and this Agreement shall not provide any third person (including employees of the Parties) with any remedy, claim, liability, reimbursement, claim of action, or other right in excess
of those existing without reference to this Agreement. 

  

	21.14	Relationship of the Parties. Nothing contained in this Agreement shall be deemed to constitute a partnership, joint venture, or legal entity of any type
between Pfizer and the Company, or to constitute one Party as the agent of the other. Moreover, each Party agrees not to construe this Agreement, or any of the transactions contemplated hereby, as a partnership for any tax purposes. Each Party shall
act solely as an independent contractor, and nothing in this Agreement shall be construed to give any Party the power or authority to act for, bind, or commit the other Party. 

 

	21.15	No Construction Against Drafter. The Parties acknowledge that this Agreement and all the terms and conditions contained herein have been fully reviewed
and negotiated by the Parties. Having acknowledged the foregoing, the Parties agree that any principle of construction or rule of law that provides that, in the event of any inconsistency or ambiguity, an agreement shall be construed against the
drafter of the agreement shall have no application to the terms and conditions of this Agreement. 

  

	21.16	Headings. The article, section, and paragraph headings contained in this Agreement are for reference purposes only and shall not affect in any way the
meaning or interpretation of this Agreement. 

  

	21.17	Interpretation. Words in the singular shall be held to include the plural and vice versa and words of one gender shall be held to include the other
genders as the context requires. The terms “hereof”, “herein” and “herewith” and words of similar import shall, unless otherwise stated, be construed to refer to this Agreement as a whole (including all of the
schedules, exhibits and appendices hereto) and not to any particular provision of this Agreement. Article, Section, Exhibit, Schedule and Appendix references are to the Articles, Sections, Exhibits, Schedules and Appendices to this Agreement unless
otherwise specified. The word “including” and words of similar import when used in this Agreement shall mean “including, without limitation”, unless the context otherwise requires or unless otherwise specified.

  

	21.18	Counterparts; Entire Agreement; Conflicting Agreements. 

  

	 	21.18.1	This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement, and shall become effective when one or more
counterparts have been signed by each of the Parties and delivered to the other Party. Execution of this Agreement or any other documents pursuant to this Agreement by facsimile or other electronic copy of a signature shall be deemed to be, and
shall have the same effect as, executed by an original signature. 

  
 88 

	 	21.18.2	This Agreement, the License Agreements, the Global Separation Agreement, the other Ancillary Agreements, the exhibits, the schedules and appendices hereto and thereto
contain the entire agreement between the Parties with respect to the subject matter hereof, supersede all previous agreements, negotiations, discussions, writings, understandings, commitments and conversations with respect to such subject matter and
there are no agreements or understandings between the Parties with respect to such subject matter other than those set forth or referred to herein or therein. 

 

	 	21.18.3	In the event of any inconsistency between this Agreement and any Schedule hereto, the Schedule shall prevail. In the event and to the extent that there shall be a
conflict between the provisions of this Agreement and the provisions of the Global Separation Agreement or any other Ancillary Agreement, this Agreement shall prevail. 

[Signature Page Follows] 

  
 89 

 IN WITNESS WHEREOF, the Parties have executed this Agreement in duplicate originals by their
proper officers. 
  

									
	PFIZER INC.	 		 	ZOETIS INC.
					
	By:	 	  
	 		 	By:	 	  

	Title:	 	  
	 		 	Title:	 	  

  
 90Pfizer Inc. 2004 Stock Plan, as Amended and Restated

 Exhibit 10.6 
 Pfizer Inc. 2004 Stock Plan, 
 As Amended and Restated 

(through February 23, 2012) 
 SECTION 1. PURPOSE 
 The purpose of the Pfizer Inc. 2004 Stock Plan (“the Plan”) is to
furnish a material incentive to employees and non-employee Directors of the Company and its Affiliates by making available to them the benefits of a larger common stock ownership in the Company through stock options and awards. It is believed that
these increased incentives stimulate the efforts of employees and non-employee Directors towards the continued success of the Company and its Affiliates, as well as assist in the recruitment of new employees and non-employee Directors. The Plan was
amended and restated as of January 1, 2008, to reflect the intended exemption from Section 409A (as defined below) for certain Awards, as well as continued compliance with Section 409A for certain other Awards, and further amended and
restated, as of April 23, 2009, to make certain other changes designed to promote the effective operation of the Plan and to replenish the number of Shares available for grant. 
 SECTION 2. DEFINITIONS 
 As used in the Plan, the following terms shall have the meanings set
forth below: 
  

	 	(a)	“Affiliate” shall mean (i) any Person that directly, or through one or more intermediaries, controls, or is controlled by, or is under common control
with, the Company or (ii) any entity in which the Company has a significant equity interest, as determined by the Committee. 

	 	(b)	“Award” shall mean any Option, Stock Appreciation Right, Restricted Stock Award, Performance Share, dividend equivalent, Other Stock Unit Award or any other
right, interest or option relating to Shares issued and delivered pursuant to the provisions of the Plan. 

	 	(c)	“Award Agreement” shall mean any written agreement, contract or other instrument or document evidencing any Award granted by the Committee hereunder, which in
the sole and absolute discretion of the Committee may, but need not, be signed or acknowledged by the Company or the Participant. 

	 	(d)	“Board” shall mean the Board of Directors of the Company. 

	 	(e)	“Cause” shall mean a willful breach of duty in the course of employment. No act or failure to act shall be deemed “willful” unless done, or omitted
to be done, not in good faith and without reasonable belief that the action or omission was in the best interest of the Company and its Affiliates. 

	 	(f)	 “Change in Control” shall mean the occurrence of any of the following events: (i) at any time during the initial two-year period
following the Effective Date or during each subsequent Renewal Term, as the case may be, at least a majority of the Board shall cease to consist of “Continuing Directors” (meaning directors of the Company who either were directors at the
beginning of such initial two-year period or subsequent Renewal Term, as the case may be, or who subsequently became directors and whose election, or nomination for election by the Company’s stockholders, was approved by a majority of the then
Continuing Directors); or (ii) any “person” or “group” (as determined for purposes of Section 13(d)(3) of the Exchange Act, except any majority-owned subsidiary of the Company or any employee benefit plan of the Company
or any trust thereunder, shall have acquired “beneficial ownership” (as determined for purposes of Securities and Exchange Commission (“SEC”) Regulation 13d-3) of Shares having 20% or more of the voting power of all

  
 1 

	 	
outstanding Shares, unless such acquisition is approved by a majority of the directors of the Company in office immediately preceding such acquisition; or (iii) a merger or consolidation
occurs to which the Company is a party, in which outstanding Shares are converted into shares of another company (other than a conversion into shares of voting common stock of the successor corporation or a holding company thereof representing 80%
of the voting power of all capital stock thereof outstanding immediately after the merger or consolidation) or other securities (of either the Company or another company) or cash or other property; or (iv) the sale of all, or substantially all,
of the Company’s assets occurs; or (v) the stockholders of the Company approve a plan of complete liquidation of the Company. 

	 	(g)	“Change in Control Price” means, with respect to a Share, the higher of (A) the highest reported sales price, regular way, of such Share in any
transaction reported on the New York Stock Exchange Composite Tape or other national exchange on which such Shares are listed or on the Nasdaq National Market during the 60-day period prior to and including the date of a Change in Control or Change
in Control Event or (B) if the Change in Control or Change in Control Event is the result of a tender or exchange offer or a corporate transaction, the highest price per such Share paid in such tender or exchange offer or corporate transaction;
provided, however, that in the case of an Award exempt from Section 409A, the Change in Control Price shall be the Fair Market Value of such Share on the date such Award is exercised or deemed exercised pursuant to Section 11. To the
extent the consideration paid in any such transaction described above consists in full or in part of securities or other noncash consideration, the value of such securities or other noncash consideration shall be determined in the sole discretion of
the Board. 

	 	(h)	“Code” shall mean the Internal Revenue Code of 1986, as amended from time to time, and any successor thereto. 

	 	(i)	“Committee” shall mean the Compensation Committee of the Board or such other persons or committee to whom it has delegated any authority, as may be
appropriate. A person may serve on the Compensation Committee only if he or she (i) is a “Non-employee Director” for purposes of Rule 16b-3 under the Exchange Act, and (ii) satisfies the requirements of an “outside
director” for purposes of Section 162(m) of the Code. 

	 	(j)	“Company” shall mean Pfizer Inc., a Delaware corporation. 

	 	(k)	“Covered Employee” shall mean a “covered employee” within the meaning of Section 162(m)(3) of the Code, or any successor provision thereto.

	 	(l)	“Director” shall mean a member of the Board. 

	 	(m)	“Effective Date” shall mean the date the Plan was last approved by the stockholders of the Company. 

	 	(n)	“Employee” shall mean any employee of the Company or any Affiliate. For any and all purposes under this Plan, the term “Employee” shall not include
a person hired as an independent contractor, leased employee, consultant or a person otherwise designated by the Committee, the Company or an Affiliate at the time of hire as not eligible to participate in or receive benefits under the Plan or not
on the payroll, even if such ineligible person is subsequently determined to be a common law employee of the Company or an Affiliate or otherwise an employee by any governmental or judicial authority. Unless otherwise determined by the Committee in
its sole discretion, for purposes of the Plan, an Employee shall be considered to have terminated employment or services and to have ceased to be an Employee if his or her employer ceases to be an Affiliate, even if he or she continues to be
employed by such employer. 

	 	(o)	“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended. 

	 	(p)	“Fair Market Value” shall mean, with respect to Shares, as of any date, the closing price for the Shares as reported on the New York Stock Exchange for that
date or, if no such price is reported for that date, the closing price on the next preceding date for which such price was reported, unless otherwise determined by the Committee, in a manner consistent with Section 409A.

  
 2 

	 	(q)	“Grandfathered Benefits” shall mean any Awards that were earned and vested as of December 31, 2004, within the meaning of Section 409A.
Grandfathered Benefits are subject to the distribution rules under the Plan that were in effect on October 3, 2004 and are summarized on Appendix A. 

	 	(r)	“Grant Date” shall mean the date on which an Award is granted. 

	 	(s)	“Incentive Stock Option” shall mean an Option granted under Section 6 that is intended to meet the requirements of Section 422 of the Code or any
successor provision thereto. 

	 	(t)	“Key Employee” means an Employee treated as a “specified employee” as of his or her Separation from Service under Code
Section 409A(a)(2)(B)(i), i.e., a key employee (as defined in Code Section 416(i) without regard to paragraph (5) thereof) of the Company or its Affiliates if the Company’s stock is publicly traded on an established securities
market or otherwise. Key Employees shall be determined under rules adopted by the Company in accordance with Section 409A. Key Employees shall also include those key employees who are eligible for the Company’s Executive Long-Term
Incentive Program as “specified employees” for the 12 month period following the specified employee effective date, if not already included pursuant to the foregoing. Key Employees shall be determined in accordance with Section 409A
using a December 31 identification date and the listing of Key Employees as of any such identification date shall be effective for the 12-month period beginning on the effective date following the identification date. Notwithstanding the
foregoing, the Committee may, under the alternative permissible methods allowable under Section 409A, adopt an alternative identification and effective date for purposes of determining which employees are Key Employees.

	 	(u)	“Nonqualified Stock Option” shall mean either an Option granted under Section 6 that is not intended to be an Incentive Stock Option or an Incentive
Stock Option that has been disqualified. 

	 	(v)	“Option” shall mean any right granted to a Participant under the Plan allowing such Participant to purchase Shares at such price or prices and during such
period or periods as the Committee shall determine. 

	 	(w)	“Other Stock Unit Award” shall mean any right granted to a Participant by the Committee pursuant to Section 10. 

	 	(x)	“Participant” shall mean an Employee or a non-employee member of the Board who is selected by the Committee or the Board from time to time in their sole
discretion to receive an Award under the Plan. 

	 	(y)	“Performance Award” shall mean any Award of Performance Shares granted pursuant to Section 9. 

	 	(z)	“Performance Period” shall mean a period of not less than one year, as established by the Committee at the time any Performance Award is granted or at any
time thereafter, during which any performance goals specified by the Committee with respect to such Award are to be measured. 

	 	(aa)	“Performance Share” shall mean any grant pursuant to Section 9 of a unit valued by reference to a designated number of Shares, which value may be paid to
the Participant by delivery of such property as the Committee shall determine, including, without limitation, cash, Shares, other property, or any combination thereof, upon achievement of such performance goals during the Performance Period as the
Committee shall establish at the time of such grant or earlier (but no later than ninety (90) days after the commencement of the Performance Period). 

	 	(bb)	“Person” shall mean any individual, corporation, partnership, association, limited liability company, joint-stock company, trust, unincorporated organization
or government or political subdivision thereof. 

	 	(cc)	“Renewal Term” shall mean the two-year period beginning on the second anniversary of the Effective Date and each successive two-year period thereafter.

	 	(dd)	“Restricted Stock” shall mean any Share issued with the restriction that the holder may not sell, transfer, pledge or assign such Share and with such other
restrictions as the Committee, in its sole discretion, may impose (including, without limitation, any restriction on the right to vote such Share, and the right to receive any cash dividends), which restrictions may lapse separately or in
combination at such time or times, in installments or otherwise, as the Committee may deem appropriate. 

  
 3 

	 	(ee)	“Restricted Stock Award” shall mean an award of Restricted Stock under Section 8. 

	 	(ff)	“Section 409A” shall mean Section 409A of the Code and the regulations and other guidance issued thereunder by the U.S. Treasury or Internal Revenue
Service. 

	 	(gg)	“Retirement” shall mean having attained a minimum age of 55 and a minimum of 10 years of service at the time of a Participant’s separation from the
Company, unless determined otherwise by the Committee, and which shall also constitute a Separation from Service. 

	 	(hh)	“Separation from Service” means a “separation from service” within the meaning of Section 409A. 

	 	(ii)	“Shares” shall mean the shares of common stock of the Company. 

	 	(jj)	“Stock Appreciation Right” shall mean any right granted to a Participant pursuant to Section 7 to receive, upon exercise by the Participant, the excess
of (i) the Fair Market Value of one Share on the date of exercise over (ii) the grant price of the right on the date of grant, or if granted in connection with an outstanding Option on the date of grant of the related Option, as specified
by the Committee in its sole discretion, which, except in connection with an adjustment provided in Section 4(c), shall not be less than the Fair Market Value of one Share on such date of grant of the right or the related Option, as the case
may be. Any payment by the Company in respect of such right may be made in cash, Shares, other property, or any combination thereof, as the Committee, in its sole discretion, shall determine. 

	 	(kk)	“Substitute Awards” shall mean Awards granted or Shares issued by the Company in assumption of, or in substitution or exchange for, awards previously granted,
or the right or obligation to make future awards, by a company acquired by the Company or an Affiliate or with which the Company or an Affiliate combines. 

	 	(ll)	“Total and Permanent Disability” shall mean total and permanent disability as determined in accordance with rules established by the Committee, and in
compliance with Section 409A. 

	 	(mm)	  “Vesting Period” shall mean the period of time before unrestricted shares become non-forfeitable and issuable to a Participant within the meaning
of Section 10. 

 SECTION 3. ADMINISTRATION 
 The Plan shall be administered by the Committee. The Committee shall have full power and authority, subject to such orders or resolutions not inconsistent with the provisions of the Plan as may from time
to time be adopted by the Board, to (a) select the Employees of the Company and its Affiliates to whom Awards may from time to time be granted hereunder; (b) determine the type or types of Award to be granted to each Participant hereunder;
(c) determine the number of Shares to be covered by or relating to each Award granted hereunder; (d) determine the terms and conditions, not inconsistent with the provisions of the Plan, of any Award granted hereunder; (e) determine
whether, to what extent and under what circumstances Awards may be settled in cash, Shares or other property or canceled or suspended, consistent with the terms of the Plan; (f) determine whether, to what extent, and under what circumstances
shares or cash paid to or gain realized by the Participant based on an Award shall be returned to the Company, consistent with the terms of the Plan; (g) determine whether, to what extent, and under what circumstances a Participant may be
ineligible to retain an Award; (h) determine whether, to what extent, and under what circumstances payment of cash, Shares, other property and other amounts payable with respect to an Award made under the Plan shall be deferred either
automatically or at the election of the Participant, consistent with the terms of the Plan; (i) interpret and administer the Plan and any instrument or agreement entered into under the Plan; (j) establish such rules and regulations and
appoint such agents as it shall deem appropriate for the proper administration of the Plan; and (k) make any other determination and take any other action that the Committee deems necessary or desirable for administration of the Plan. The
Committee may, in its sole and absolute discretion, and subject to the provisions of the Plan, from time to time delegate any or all of its authority to administer the Plan to any other persons or committee as it deems necessary or appropriate for

  
 4 

 
the proper administration of the Plan, except that no such delegation shall be made in the case of Awards intended to be qualified under Section 162(m) of the Code. The decisions of the
Committee shall be final, conclusive and binding with respect to the interpretation and administration of the Plan and any grant made under it. The Committee shall make, in its sole discretion, all determinations arising in the administration,
construction or interpretation of the Plan and Awards under the Plan, including the right to construe disputed or doubtful Plan or Award terms and provisions, and any such determination shall be conclusive and binding on all persons, except as
otherwise provided by law. A majority of the members of the Committee may determine its actions and fix the time and place of its meetings. 

Except as provided in Section 12, the Committee shall be authorized to make adjustments in Performance Award criteria or in the terms and conditions
of other Awards in recognition of unusual or nonrecurring events affecting the Company or its financial statements or changes in applicable laws, regulations or accounting principles. The Committee may correct any defect, supply any omission or
reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem desirable to carry it into effect. In the event that the Company shall assume outstanding employee benefit awards or the right or obligation to make
future such awards in connection with the acquisition of or combination with another corporation or business entity, the Committee may, in its discretion, make such adjustments in the terms of Awards under the Plan as it shall deem appropriate.

 SECTION 4. SHARES SUBJECT TO THE PLAN 
 (a)  Subject to adjustment as provided in Section 4(c), a total of four hundred twenty-five million (425,000,000) Shares shall be authorized for grant pursuant to Awards under the
Plan, plus any shares remaining available for grant under the Plan as of the Effective Date, provided that no more than four hundred twenty-five million (425,000,000) Shares may be granted as Incentive Stock Options. Any Shares granted in
connection with Options and Stock Appreciation Rights shall be counted against this limit as one (1) Share for every one (1) Option or Stock Appreciation Right awarded. Any Shares granted in connection with Awards other than Options and
Stock Appreciation Rights shall be counted against this limit as two (2) Shares for every one (1) Share granted in connection with such Award or by which the Award is valued by reference. No Participant under this Plan shall be granted
Options, Stock Appreciation Rights or other Awards (counted, as described above, as two (2) Shares awarded for every one Share issued in connection with such Award or by which the Award is valued by reference) in any consecutive 36-month period
covering more than eight million (8,000,000) Shares. The grant limit under the preceding sentence shall apply to an Award other than an Option or Stock Appreciation Right only if the Award is intended to be “performance-based” as that
term is used in Section 162(m) of the Code. No Award will be granted to any Participant who owns more than ten percent of the stock of the Company within the meaning of Section 422 of the Code. 

(b)  Any Shares issued hereunder may consist, in whole or in part, of authorized and unissued Shares, treasury Shares or Shares purchased in the
open market or otherwise. 
 (c)  In the event of any merger, reorganization, consolidation, recapitalization, stock dividend,
extraordinary cash dividend, stock split, reverse stock split, spin-off or similar transaction or other change in corporate structure affecting the Shares, such adjustments and other substitutions shall be made to the Plan and to Awards as the
Committee, in its sole discretion, deems equitable or appropriate, including, without limitation, such adjustments in the aggregate number, class and kind of securities that may be delivered under the Plan, in the aggregate or to any one
Participant, in the number, class, kind and option or exercise price of securities subject to outstanding Awards granted under the Plan (including, if the Committee deems appropriate, the substitution of similar options to purchase the shares of, or
other awards denominated in the shares of, another company) as the Committee may determine to be appropriate in its sole discretion; provided, however, that the number of Shares subject to any Award shall always be a whole number and further
provided that in no event may any change be made to an Incentive Stock Option which would constitute a modification within the meaning of Section 424(h)(3) of the Code. Moreover, notwithstanding

  
 5 

 
anything herein to the contrary, an adjustment to an Award under this Section 4(c) may not be made in a manner that would result in the grant of a new Option or Stock Appreciation Right
under Section 409A, unless the Committee specifically determines that such adjustment is desirable and will not cause the modified award to create adverse tax consequences under Section 409A. 

(d)  Any Shares subject to Awards that terminate, expire, or are forfeited, cancelled or settled in cash, either in whole or in part, may be
used for the further grant of Awards to the extent of such termination, forfeiture, cancellation or settlement. Any Shares that again become available for future grants pursuant to the preceding sentence shall be added back as one (1) Share if
such Shares were subject to Options or Stock Appreciation Rights, and as two (2) Shares if such Shares were subject to Awards other than Options or Stock Appreciation Rights. In addition, in the case of any Substitute Award, Shares delivered or
deliverable in connection with such assumed or Substitute Award shall not reduce the number of Shares authorized for grant in Section 4(a) above. Notwithstanding the foregoing, Shares subject to an Award under the Plan may not again be made
available for issuance or delivery under the Plan if such Shares are (i) Shares that were subject to a stock-settled Stock Appreciation Right and were not issued upon the net settlement or net exercise of such Stock Appreciation Right,
(ii) Shares delivered or withheld by the Company to pay the exercise price of an Option, (iii) Shares delivered to or withheld by the Company to pay the withholding taxes related to an Award, or (iv) Shares repurchased on the open
market with the proceeds of an Option exercise. 
 SECTION 5. ELIGIBILITY 
 Any Employee or non-employee Director shall be eligible to be selected as a Participant; provided, however, that Incentive Stock Options shall only be awarded to Employees of the Company, or a parent or
Affiliate, within the meaning of Section 422 of the Code. Notwithstanding any provision in this Plan to the contrary, the non-employee Directors, including a designated committee of the Board composed solely of non-employee Directors, shall
have the authority, in their sole and absolute discretion, to select non-employee Directors as Participants who are eligible to receive Awards other than Incentive Stock Options under the Plan. The non-employee Directors shall set the terms of any
such Awards in their sole and absolute discretion, and the non-employee Directors shall be responsible for administering and construing such Awards in substantially the same manner that the Committee administers and construes Awards to Employees.

 SECTION 6. STOCK OPTIONS 
 Options
may be granted hereunder to any Participant, either alone or in addition to other Awards granted under the Plan and shall be subject to the following terms and conditions: 
 (a)  Option Price. The option price per Share shall be not less than the Fair Market Value of the Shares on the date the Option is granted. 

(b)  Number of Shares. The Option shall state the number of Shares covered thereby. 
 (c)  Exercise of Option. Unless otherwise determined by the Committee, an Option will be deemed exercised by the optionee, or in the event of death, an option shall be deemed exercised by the
estate of the optionee, or by a person who acquired the right to exercise such option by bequest or inheritance or by reason of the death of the optionee, upon delivery of (i) a notice of exercise to the Company or its representative, or by
using other methods of notice as the Committee shall adopt, and (ii) accompanying payment of the option price or other methods of satisfying the option exercise prices as approved by the Committee and in accordance with any restrictions as the
Committee shall adopt. The notice of exercise, once delivered, shall be irrevocable. Notwithstanding the above, and unless the Committee determines otherwise, in the event that (i) an optionee dies, (ii) his representative has a right to
exercise an Option, (iii) the Option is not exercised 

  
 6 

 
by the last day on which it is exercisable, and (iv) the option price per share is below the Fair Market Value of a Share on such date, the Option shall be deemed exercised on such date via
a cashless exercise procedure and the resulting proceeds net of the option price and any required tax withholding shall be paid to the representative. 
 (d)  Term of Option. The Committee shall determine the option exercise period of each Option. The period for Incentive Stock Options shall not exceed ten years from the grant date. A
Nonqualified Stock Option may be exercisable for a period of up to ten years and six months so as to conform with or take advantage of governmental requirements, statutes or regulations. 
 (e)  First Exercisable Date. Except in the case of death, Total and Permanent Disability, Change in Control or the sale or restructuring of a business or plant closing, no Option may be
exercised during the first year of its term or such longer period as may be specified in the Option. 
 (f)  Termination of Option. All
Options shall terminate upon their expiration, their surrender, upon breach by the optionee of any provisions of the Option, or in accordance with any other rules and procedures incorporated into the terms and conditions governing the Options as the
Committee shall deem advisable or appropriate. 
 (g)  Incorporation by Reference. The Option shall contain a provision that all the
applicable terms and conditions of this Plan are incorporated by reference therein. 
 (h)  Other Provisions. The Option shall also be
subject to such other terms and conditions as the Committee shall deem advisable or appropriate, consistent with the provisions of the Plan as herein set forth. In addition, Incentive Stock Options shall contain such other provisions as may be
necessary to meet the requirements of the Code and the Treasury Department rulings and regulations issued thereunder with respect to Incentive Stock Options. 
 (i)  Exemption from Section 409A. It is intended that all Options granted under this Plan will be exempt from Section 409A. Nevertheless, the Company does not represent, covenant or
guarantee that any particular Award made under the Plan will qualify for favorable tax treatment (e.g., as in incentive stock options) or will avoid unfavorable tax consequences to the Participant (e.g., Section 409A penalties). 

SECTION 7. STOCK APPRECIATION RIGHTS 
 (a)
Grant of a Stock Appreciation Right. Stock Appreciation Rights may be granted hereunder to any Participant, either alone (“freestanding”) or in addition to other Awards granted under the Plan and may, but need not, relate to a specific
Option granted under Section 6. The provisions of Stock Appreciation Rights need not be the same with respect to each recipient. Any Stock Appreciation Right related to a Nonqualified Stock Option may be granted at the same time such Option is
granted or at any time thereafter before exercise or expiration of such Option. Any Stock Appreciation Right related to an Incentive Stock Option must be granted at the same time such Option is granted. In the case of any Stock Appreciation Right
related to any Option, the Stock Appreciation Right or applicable portion thereof shall terminate and no longer be exercisable upon the termination or exercise of the related Option, except that a Stock Appreciation Right granted with respect to
less than the full number of Shares covered by a related Option shall not be reduced until the exercise or termination of the related Option exceeds the number of Shares not covered by the Stock Appreciation Right. Any Option related to any Stock
Appreciation Right shall no longer be exercisable to the extent the related Stock Appreciation Right has been exercised. 
 (b) Terms. The
Committee may impose such terms and conditions or restrictions on the exercise of any Stock Appreciation Right, as it shall deem advisable or appropriate; provided that a Stock Appreciation Right shall not have an exercise price less than Fair
Market Value of a Share on the date of grant or a term of greater than ten years. 
 (c) Section 409A. Stock Appreciation Rights may be
granted hereunder by the Committee either (i) in a manner consistent with Section 409A such that the Stock Appreciation Right will not provide for a deferral of compensation under Section 409A, or (ii) in a manner that is
intended from grant to subject the Stock Appreciation Right to Section 409A. In the event Stock Appreciation Rights are granted to be so subject to 

  
 7 

 
Section 409A, then the Stock Appreciation Right shall be settled and paid in a single lump sum (i) as of a specified date, (ii) upon the Participant’s Separation from Service,
or (iii) the earlier of (i) or (ii) hereof, as specified and set forth by the Committee in an Award Agreement at the time of grant, and shall otherwise be granted, administered, settled and paid in accordance with Section 409A.
Notwithstanding the foregoing, any such settlement and payment may not be made to a Key Employee upon a Separation from Service before the date which is 6 months after the date of the Key Employee’s Separation from Service (or, if earlier, the
date of death of the Key Employee). 
 SECTION 8. RESTRICTED STOCK 
 (a)  Grant of Restricted Stock. A Restricted Stock Award shall be subject to restrictions imposed by the Committee at the time of grant for a period of time specified by the Committee (the
“Restriction Period”). Restricted Stock Awards may be issued hereunder to Participants for no cash consideration or for such minimum consideration as may be required by applicable law, either alone or in addition to other Awards granted
under the Plan. Any Award of Restricted Stock shall also be subject to such other terms and conditions as the Committee shall deem advisable or appropriate, consistent with the provisions of the Plan as herein set forth. Except in the event of a
termination of employment due to death, Retirement, Total and Permanent Disability, Change in Control or the sale or restructuring of a business or plant closing, Restricted Stock Awards shall have a Restriction Period of not less than three
(3) years from the date of grant, which may include pro-rata lapsing of restrictions thereon. In the event of a termination of employment due to death, Total and Permanent Disability or a Change in Control, awards of Restricted Stock
immediately and fully vest. In the event of a termination of employment due to Retirement or a sale or restructuring of a business or plant closing, awards of Restricted Stock vest pro-rata. Notwithstanding the above, Awards covering up to five
(5) percent of the total number of Shares that may be issued or delivered under the Plan (other than as Awards of Options or Stock Appreciation Rights) may contain no restrictions or be subject to a Restriction Period of less than three
(3) years. 
 (b)  Registration. Any Restricted Stock issued hereunder may be evidenced in such manner, as the Committee, in its
sole discretion, shall deem appropriate, including, without limitation, book entry registration or issuance of a stock certificate or certificates. In the event any stock certificates are issued in respect of Shares of Restricted Stock awarded under
the Plan, such certificates shall be registered in the name of the Participant and shall bear an appropriate legend referring to the terms, conditions and restrictions applicable to such Award. 

(c)  Section 409A. Restricted Stock Awards may be granted hereunder by the Committee either (i) in a manner consistent with
Section 409A such that the Restricted Stock Award not provide for a deferral of compensation under Section 409A, or (ii) in a manner that is intended from grant to subject the Restricted Stock Award to Section 409A. In the event
Restricted Stock Awards are subject to Section 409A, then the Restricted Stock Award shall be settled and paid in a single lump sum (i) as of a specified date, (ii) upon the Participant’s Separation from Service, or
(iii) the earlier of (i) or (ii) hereof, as specified and set forth by the Committee in an Award Agreement at the time of grant, and shall otherwise be granted, administered, settled and paid in accordance with Section 409A.
Notwithstanding the foregoing, any such settlement and payment may not be made to a Key Employee upon a Separation from Service before the date which is 6 months after the date of the Key Employee’s Separation from Service (or, if earlier, the
date of death of the Key Employee). 
 SECTION 9. PERFORMANCE AWARDS 
 Performance Awards may be paid in cash, Shares, other property, or any combination thereof, and may be subject to such other terms and conditions as the Committee shall deem advisable or appropriate,
consistent 

  
 8 

 
with the provisions of the Plan as set forth, in the sole discretion of the Committee at the time of payment. The performance levels to be achieved for each Performance Period and the amount of
the Award to be distributed shall be conclusively determined by the Committee. Performance Awards will be paid in a lump sum prior to the 15th day of the third month of the year immediately following the year in which the close of the Performance Period occurs
in accordance with the applicable short-term deferral exception provisions of Section 409A, or, in accordance with procedures established by the Committee and the applicable provisions of Section 409A, on a deferred basis pursuant to
Section 15 hereof, if applicable. All Performance Awards must satisfy the definition of “performance-based compensation” of Treasury Regulation Section 1.409A-1(e), but the Committee may designate whether any Performance Award,
either alone or in addition to other Awards granted under the Plan, being granted to any Employee is intended to be “performance-based compensation” as that term is used in Section 162(m) of the Code. Any such awards designated to be
“performance-based compensation” within the meaning of Code Section 162(m) shall be conditioned on the achievement of one or more performance measures, to the extent required by Code Section 162(m), and shall be issued in
accordance with Section 12. Except in the event of a Change in Control or Change in Control Event described in Section 11, in the event Performance Awards are subject to Section 409A, then the Performance Award shall be settled and
paid in a single lump sum (i) as of a specified date, (ii) upon the Participant’s Separation from Service, or (iii) the earlier of (i) or (ii) hereof, in accordance with rules established by the Committee at the time of
grant, and shall otherwise be granted, administered, settled and paid in accordance with Section 409A. Notwithstanding the foregoing, any such settlement and payment may not be made to a Key Employee upon a Separation from Service before the
date which is 6 months after the date of the Key Employee’s Separation from Service (or, if earlier, the date of death of the Key Employee). 
 SECTION 10. OTHER STOCK UNIT AWARDS 
 (a)  Stock and Administration. Awards that are
valued by reference to, or are otherwise based on, Shares (“Other Stock Unit Awards”) may be granted hereunder to Participants, either alone or in addition to other Awards granted under the Plan, and such Other Stock Unit Awards shall also
be available as a form of payment in the settlement of other Awards granted under the Plan. Other Stock Unit Awards may be paid in Shares, cash or any other form of property, as the Committee shall determine. Subject to the provisions of the Plan,
the Committee shall have sole and complete authority to determine the Employees to whom and the time or times at which such Awards shall be made, the number of Shares to be issued or delivered pursuant to such Awards, and all other conditions of the
Awards. Any Other Stock Unit Awards shall be subject to such other terms and conditions as the Committee shall deem advisable or appropriate, consistent with the provisions of the Plan as herein set forth. Except in the event of a termination of
employment due to death, Retirement, Total and Permanent Disability, Change in Control or the sale or restructuring of a business or plant closing, Other Stock Unit Awards shall have a Vesting Period of not less than three (3) years, which may
include pro-rata lapsing of restrictions thereon. In the event of a termination of employment due to death, Total and Permanent Disability or a Change in Control, Other Stock Awards immediately and fully vest. In the event of a termination of
employment due to Retirement or a sale or restructuring of a business or plant closing, Other Stock Awards vest pro-rata. Notwithstanding the above, Awards covering up to five (5) percent of the total number of Shares that may be issued or
delivered under the Plan (other than as Awards of Options or Stock Appreciation Rights) may contain no restrictions or be subject to a Vesting Period of less than three (3) years. 
 (b)  Other Provisions. Shares (including securities convertible into Shares) subject to Awards granted under this Section 10 may be issued for no cash consideration or for such minimum
consideration as may be required by applicable law. 
 (c)  Section 409A. Other Stock Unit Awards may be granted hereunder by the
Committee (i) in a manner consistent with Section 409A such that the Other Stock Unit Awards will not provide for a deferral of compensation under Section 409A, or (ii) in a manner that will subject the Other Stock Unit Award to

  
 9 

 
Section 409A. In the event Other Stock Unit Awards are granted to be so subject to Section 409A, then the Other Stock Unit Awards shall be settled and paid in a single lump sum
(i) as of a specified date, (ii) upon the Participant’s Separation from Service, or (iii) the earlier of (i) or (ii) hereof, as specified by the Committee at the time of grant or otherwise in a fashion which is
compliant with Section 409A, and shall otherwise be granted, administered, settled and paid in compliance with Section 409A. Notwithstanding the foregoing, any such settlement and payment may not be made to a Key Employee upon a Separation
from Service before the date which is 6 months after the date of the Key Employee’s Separation from Service (or, if earlier, the date of death of the Key Employee). 
 (d)  Section 162(m) Deferrals. Except for Other Stock Unit Awards which are subject to the satisfaction of performance goals, any outstanding Other Stock Unit Awards that are scheduled to
be settled or otherwise paid to a Participant during a taxable year in which such Participant is, or is likely to be, a Covered Employee, shall automatically be deferred into the Pfizer Inc Deferred Compensation Plan, as Amended and Restated,
effective January 1, 2008, in accordance with the terms of such plan and in compliance with the applicable provisions of Section 409A until the earlier of (i) the first day of the Participant’s first taxable year in which the
Company reasonably anticipates that if the payment is made during such year, the deduction of such payment by the Company will not be barred by the application of Code Section 162(m), or (ii) the Participant’s Separation from Service.
Notwithstanding the foregoing, any such payment may not be made to a Key Employee upon a Separation from Service before the date which is 6 months after the date of the Key Employee’s Separation from Service (or, if earlier, the date of death
of the Key Employee). 
 SECTION 11. CHANGE IN CONTROL PROVISIONS 
 (a)  Unless the Committee or Board shall determine otherwise at the time of grant with respect to a particular Award, and notwithstanding any other provision of the Plan to the contrary, in the
event a Participant’s employment or service is involuntarily terminated without Cause (as determined by the Committee or Board in its sole discretion) during the 24-month period following a Change in Control, and provided that, with respect to
any Awards that are considered deferred compensation under Section 409A, the Participant’s involuntary termination of employment or service also constitutes a Separation from Service: 

  (i) notwithstanding a provision in any Award Agreement to the contrary, any Options and Stock Appreciation Rights outstanding and which are
not then exercisable and vested shall upon such involuntary termination fully vest and become exercisable for their full term, and shall remain in effect for the respective terms of such award as set forth in the grant documents at the time of grant
notwithstanding such involuntary termination. 
   (ii) any vested Options and Stock Appreciation Rights outstanding shall remain in
effect and be exercisable for the respective terms of such award as set forth in the grant documents at the time of grant notwithstanding such involuntary termination; 
   (iii) the restrictions and deferral limitations applicable to any Restricted Stock shall lapse, and such Restricted Stock shall immediately become free of all restrictions and limitations and
become fully vested and transferable to the full extent of the original grant; 
   (iv) all Performance Awards shall be considered to
be earned and payable in full, based on the applicable performance criteria or, if not determinable, at the target level and any deferral or other restriction shall lapse and such Performance Awards shall be immediately settled and paid upon the
Participant’s Separation from Service (and the Participant shall have no discretion to choose the date of settlement and payment) provided, however, that any such settlement and payment may not be made to a Key Employee upon a Separation from
Service before the date which is 6 months after the date of the Key Employee’s Separation from Service (or, if earlier, the date of death of the Key Employee); and 
   (v) the restrictions and deferral limitations and other conditions applicable to any Other Stock Unit Awards or any other Awards shall immediately lapse, and any such Other Stock Unit Awards
or such other Awards shall become free of all restrictions, limitations or conditions and become fully vested and transferable to the full extent of the original grant; 

  
 10 

   (vi) notwithstanding any other provision of this Section 11(a), the proceeds, from exercise
or otherwise, of any Options, Stock Appreciation Rights, Restricted Stock, Performance Shares or Other Stock Unit Awards that are considered deferred compensation under Section 409A shall be paid (and if not exercised prior to the date of the
Participant’s Separation from Service, shall be deemed exercised and settled and paid) upon the Participant’s Separation from Service (and the Participant shall have no discretion to choose the date of payment) provided, however, that any
such payment may not be made to a Key Employee upon a Separation from Service before the date which is 6 months after the date of the Key Employee’s Separation from Service (or, if earlier, the date of death of the Key Employee). 

(b)  Change in Control Cash Out. Notwithstanding any other provision of the Plan, in the event of a Change in Control, or, with respect to
Options, Stock Appreciation Rights, Restricted Stock, Performance Shares or Other Stock Unit Awards that are considered deferred compensation under Section 409A, in the event of a Change in Control that is also a “Change in Control
Event” described in Section 409A(a)(2)(A)(v) or otherwise under Section 409A, (i) the Committee or Board may, in its discretion, provide in the terms of the Option, Stock Appreciation Right, Restricted Stock, Performance Share or
Other Stock Unit Award that is intended to be exempt from Section 409A, that such Option, Stock Appreciation Right, Restricted Stock, Performance Share or Other Stock Unit Award shall, upon the occurrence of a Change in Control, be cancelled in
exchange for a cash payment to be made within 60 days of the Change in Control (and the Participant shall have no discretion to choose the date of payment) in an amount equal to the amount by which the Fair Market Value per Share on the date of the
payment exceeds the purchase price per Share under the Option or Stock Appreciation Right multiplied by the number of Shares issued and delivered under the Option or Stock Appreciation Right, or in an amount equal to the Fair Market Value per Share
on the date of the payment for the Restricted Stock, Performance Share, or Other Stock Unit Award, or (ii) the Committee or Board may, in its discretion, provide in the terms of an Option, Stock Appreciation Right, Restricted Stock, Performance
Share, or Other Stock Unit Award that is deferred compensation under Section 409A, that such Option, Stock Appreciation Right, Restricted Stock, Performance Share or Other Stock Unit shall, upon the occurrence of a Change in Control Event, be
cancelled in exchange for a cash payment to be made within 60 days of the Change in Control Event (and the Participant shall have no discretion to choose the date of payment) in an amount equal to the amount by which the Change in Control Price per
Share exceeds the purchase price per Share under the Option or Stock Appreciation Right, multiplied by the number of Shares issued and delivered under the Option or Stock Appreciation Right, or in an amount equal to the Change in Control Price per
Share for the Restricted Stock, Performance Share or Other Stock Unit Award. 
 (c)  Notwithstanding the above, if the Change in
Control is the result of a transaction pursuant to Section 2(e)(iii) and the surviving entity does not assume, substitute or replace Awards, such Awards shall become fully vested and immediately exercisable or transferable to the full extent of
the original grant upon the Change in Control and shall be distributed, settled or paid in full within 90 days of the Change in Control as provided in Section 11(b) above. 
 SECTION 12. CODE SECTION 162(m) PROVISIONS 
 (a)  Notwithstanding any other provision of
the Plan if the Committee determines at the time, a Performance Award is granted to a Participant who is then an officer that such Participant is, or is likely to be as of the end of the tax year in which the Company would ordinarily claim a tax
deduction in connection with such Award, a Covered Employee, then the Committee may provide that this Section 12 is applicable to such Award. 

  
 11 

 (b)  If a Performance Award is subject to this Section 12, then the lapsing of restrictions
thereon and the distribution of cash, Shares or other property pursuant thereto, as applicable, shall be subject to the achievement of one or more objective performance goals established by the Committee, which shall be based on the attainment of
specified levels of one or any combination of the following: revenues, cost reductions, operating income, income before taxes, net income, adjusted net income, earnings per share, adjusted earnings per share, operating margins, working capital
measures, return on assets, return on equity, return on invested capital, cash flow measures, market share, shareholder return or economic value added of the Company or the Affiliate or division of the Company for or within which the Participant is
primarily employed. Such performance goals also may be based on the achievement of specified levels of Company performance (or performance of an applicable Affiliate or division of the Company) under one or more of the measures described above
relative to the performance of other corporations. Such performance goals shall be set by the Committee within the time period prescribed by, and shall otherwise comply with the requirements of, Section 162(m) of the Code, or any successor
provision thereto, and the regulations thereunder. 
 (c)  In setting performance goals, the Committee may provide in any such Award
Agreement that resulting from the following items shall be included or excluded: (i) asset write-downs; (ii) litigation or claim judgments or settlements; (iii) the effect of changes in tax laws, accounting principles or other laws or
provisions affecting reported results, (iv) charges for any reorganization and restructuring programs; (v) extraordinary nonrecurring charges or losses as described in Accounting Principles Board Opinion No. 30 and/or in
Management’s Discussion and Analysis of Financial Condition and Results of Operations appearing in the Company’s annual report to stockholders for the applicable year, (vi) the impact of acquisitions or divestitures;
(vii) foreign exchange gains and losses and (viii) gains or losses on asset sales. To the extent such inclusions or exclusions affect Awards to a Covered Employee, they shall be prescribed in a form that satisfies the requirements for
“performance-based compensation” within the meaning of Section 162(m) of the Code. 
 (d)  Notwithstanding any provision
of the Plan other than Section 11, with respect to any Performance Award that is subject to this Section 12, the Committee may adjust downwards, but not upwards, the amount payable pursuant to such Award, and the Committee may not waive
the achievement of the applicable performance goals except in the case of the death or Total and Permanent Disability of the Participant, or under such other conditions where such waiver will not jeopardize the treatment of other Awards under this
Section as “performance-based compensation” under Section 162(m) of the Code. 
 (e)  The Committee shall have the power
to impose such other restrictions on Awards subject to this Section 12 as it may deem necessary or appropriate to ensure that such Awards satisfy all requirements for “performance-based compensation” within the meaning of
Section 162(m)(4)(C) of the Code, or any successor provision thereto. 

  
 12 

 SECTION 13. AMENDMENTS AND TERMINATION 
 The Board may amend, alter, suspend, discontinue or terminate the Plan or any portion thereof at any time; provided, however, that no such amendment, alteration, suspension, discontinuation or termination
shall be made without (a) stockholder approval if such approval is necessary to qualify for or comply with any tax or regulatory requirement for which or with which the Board deems it necessary or desirable to qualify or comply, (b) the
consent of the affected Participant, if such action would materially impair the rights of such Participant under any outstanding Award or (c) approval of the holders of a majority of the outstanding Common Stock present or represented by proxy
and entitled to vote at a meeting of the Company’s stockholders with respect to any alteration or amendment to the Plan which increases the maximum number of shares of Common Stock which may be issued under the Plan or the number of shares of
such stock which may be issued to any one Participant, extends the term of the Plan or of options granted thereunder, changes the eligibility criteria in Section 5, or reduces the option price below that now provided for in the Plan. In
addition, notwithstanding the above, any termination of the Plan shall comply with all requirements under Section 409A that are necessary to be met to avoid adverse tax consequences to Participants under Section 409A. 

The Committee may delegate to another committee, as it may appoint, the authority to take any action consistent with the terms of the Plan, either before
or after an Award has been granted, which such other committee deems necessary or advisable to comply with any government laws or regulatory requirements of a foreign country, including but not limited to, modifying or amending the terms and
conditions governing any Awards, or establishing any local country plans as sub-plans to this Plan. In addition, under all circumstances, the Committee may make non-substantive administrative changes to the Plan as to conform with or take advantage
of governmental requirements, statutes or regulations. 
 The Committee may amend the terms of any Award theretofore granted, prospectively or
retroactively, but no such amendment shall (a) materially impair the rights of any Participant without his or her consent, (b) except for adjustments made pursuant to Section 4(c) or in connection with Substitute Awards, reduce the
exercise price of outstanding Options or Stock Appreciation Rights or cancel or amend outstanding Options or Stock Appreciation Rights for the purpose of repricing, replacing or regranting such Options or Stock Appreciation Rights with an exercise
price that is less than the exercise price of the original Options or Stock Appreciation Rights or cancel or amend outstanding Options or Stock Appreciation Rights with an exercise price that is greater than the Fair Market Value of a Share for the
purpose of exchanging such Options or Stock Appreciation Rights for cash or any other Awards without stockholder approval or (c) cause any Award intended to be exempt from Section 409A to become subject to Section 409A.
Notwithstanding the foregoing, the Committee may amend the terms of any award heretofore granted, prospectively or retroactively, in order to cure any potential defects under Section 409A, in a manner deemed appropriate by the Committee in its
sole discretion, without the consent of the Participant. Any change or adjustment to an outstanding Incentive Stock Option shall not, without the consent of the Participant, be made in a manner so as to constitute a “modification” that
would cause such Incentive Stock Option to fail to continue to qualify as an Incentive Stock Option. Notwithstanding the foregoing, any adjustments made pursuant to Section 4(c) shall not be subject to these restrictions. 

Notwithstanding the foregoing, no amendment of the Plan shall apply to amounts that were earned and vested (within the meaning of Section 409A)
under the Plan prior to 2005, unless the amendment specifically provides that it applies to such amounts. The purpose of this restriction is to prevent a Plan amendment from resulting in an inadvertent “material modification” to amounts
that are Grandfathered Benefits. 

  
 13 

 SECTION 14. DIVIDENDS 
 Subject to the provisions of the Plan and any Award Agreement, the recipient of an Award (including, without limitation, any deferred Award) may, if so determined by the Committee, be entitled to receive,
currently or on a deferred basis, cash or stock dividends, or cash payments in amounts equivalent to cash or stock dividends on Shares (“dividend equivalents”) with respect to the number of Shares covered by the Award, as determined by the
Committee, in its sole discretion, and the Committee may provide that such amounts (if any) shall be deemed to have been reinvested in additional Shares or otherwise reinvested. Provided however, that if the receipt of any such dividend equivalents
granted with respect to Options, Restricted Stock, Other Stock Unit Awards and Stock Appreciation Rights is contingent upon the exercise of the Options or Stock Appreciation Rights, or the vesting of the Restricted Stock or Other Stock Unit Awards,
then the Options, Restricted Stock, Other Stock Unit Awards, or Stock Appreciation Rights shall be granted and administered in accordance with all applicable provisions of Section 409A. 

 
 SECTION 15. DEFERRAL OF AWARDS UNDER THE COMPANY’S DEFERRED COMPENSATION PLAN

 Except as otherwise provided in this Plan, the Committee may provide upon the granting of an Award hereunder, other than an Award that is
intended to be a stock right which does not constitute a deferral of compensation within the meaning of Treasury Regulations Section 1.409A-1(a)(5) so that it is subject to the requirement that it not include any feature for the deferral of
compensation until an event enumerated in such provision, that it is eligible to be deferred under, and pursuant to the terms and conditions of, the Pfizer Inc Deferred Compensation Plan, as Amended and Restated, effective January 1, 2008. Any
such deferral shall be in accordance with the terms of such plan and in compliance with the applicable provisions of Section 409A. 

SECTION 16. GENERAL PROVISIONS 
 (a) An Award
may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution and may be exercised, during the lifetime of the Awardee, only by the Awardee; provided that the
Committee, in its sole discretion, may permit additional transferability, on a general or specific basis, other than to a third party for consideration, and may impose conditions and limitations on any permitted transferability. 

(b) No Employee shall have the right to be selected to receive an Option or other Award under this Plan or, having been so selected, to be selected to
receive a future Award grant or Option. Neither the Award nor any benefits arising out of this Plan shall constitute part of a Participant’s employment or service contract with the Company or any Affiliate and, accordingly, this Plan and the
benefits hereunder may be terminated at any time in the sole and exclusive discretion of the Company without giving rise to liability on the part of the Company or any Affiliate for severance payments. The Awards under this Plan are not intended to
be treated as compensation for any purpose under any other Company plan. 
 (c) No Employee shall have any claim to be granted any Award under
the Plan, and there is no obligation for uniformity of treatment of Employees or Participants under the Plan. 
 (d) The prospective recipient of
any Award under the Plan shall not, with respect to such Award, be deemed to have become a Participant, or to have any rights with respect to such Award until and unless such recipient shall have accepted any Award Agreement or other instrument
evidencing the Award. 
 (e) Nothing in the Plan or any Award granted under the Plan shall be deemed to constitute an employment or service
contract or confer or be deemed to confer on any Employee or Participant any right to continue in the employ or service of, or to continue any other relationship with, the Company or any Affiliate or limit in any way the right of the Company or any
Affiliate to terminate an Employee’s employment or Participant’s service at any time, with or without Cause. 

  
 14 

 (f) All Shares delivered under the Plan pursuant to any Award shall be subject to such stock transfer orders
and other restrictions as the Committee may deem advisable under the rules, regulations and other requirements of the Securities and Exchange Commission, any stock exchange upon which the Shares are then listed, and any applicable federal or state
securities law, and the Committee may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions. 
 (g) In appropriate circumstances, the Committee in its sole discretion may determine that an Award shall be cancelled, or the shares or cash paid or gain realized from an Award shall be returned to the
Company. 
 (h) No Award granted hereunder shall be construed as an offer to sell securities of the Company, and no such offer shall be
outstanding, unless and until the Committee in its sole discretion has determined that any such offer, if made, would comply with all applicable requirements of the U.S. federal securities laws and any other laws to which such offer, if made, would
be subject. 
 (i) Except as otherwise required in any applicable Award Agreement or by the terms of the Plan, recipients of Awards under the
Plan shall not be required to make any payment or provide consideration other than the rendering of services. 
 (j) The Company and its
Affiliates shall be authorized to withhold from any Award granted or payment due under the Plan, and/or to withhold from wages or other cash compensation paid to the Participant, the minimum statutory amount of withholding taxes due in respect of an
Award or payment hereunder and to take such other action as may be necessary in the opinion of the Company or Affiliate to satisfy all obligations for the payment of such taxes. Such other actions may include, without limitation, the requirement
that the Participant execute a market sale of Shares or other consideration received pursuant to the Award. The Committee shall be authorized to establish procedures for elections by Participants to satisfy such obligation for the payment of such
taxes by delivery of or transfer of Shares to the Company (in a manner limited so as to avoid adverse accounting treatment for the Company), or by directing the Company to retain Shares (up to the employee’s minimum statutory required tax
withholding rate) otherwise deliverable in connection with the Award. 
 (k) Nothing contained in the Plan shall prevent the Board from adopting
other or additional compensation arrangements, subject to stockholder approval if such approval is required; and such arrangements may be either generally applicable or applicable only in specific cases. 

(l) Any Award shall contain a provision that it may not be exercised at a time when the exercise thereof or the issuance of shares thereunder would
constitute a violation of any federal or state law or listing requirements of the New York Stock Exchange for such shares or a violation of any foreign jurisdiction where Awards are or will be granted under the Plan. The provisions of the Plan shall
be construed, regulated and administered according to the laws of the State of New York without giving effect to principles of conflicts of law, except to the extent superseded by any controlling Federal statute. Notwithstanding anything herein to
the contrary, the terms of the Plan are intended to, and shall be interpreted and applied so as to, comply in all respects with Section 409A. The Committee may amend the terms of any award heretofore granted, prospectively or retroactively, in
order to cure any potential defects under Section 409A, in a manner deemed appropriate by the Committee in its sole discretion, without the consent of the Participant. Nothing in this Section 16(l) shall be construed as an admission that
any of the compensation and/or benefits payable under this Plan constitutes “deferred compensation” subject to Section 409A. 

(m) If any provision of the Plan is or becomes or is deemed invalid, illegal or unenforceable in any jurisdiction, or would disqualify the Plan or any
Award under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to applicable laws or if it cannot be construed or deemed amended without, in the determination of the Committee, materially
altering the intent of the Plan, it shall be stricken and the remainder of the Plan shall remain in full force and effect. 
 (n) Awards may be
granted to Participants who are foreign nationals or employed outside the United States, or both, on such terms and conditions different from those applicable to Awards to Employees employed in the United States as may, in the judgment of the
Committee, be necessary or desirable in order to recognize 

  
 15 

 
differences in local law or tax policy. The Committee also may impose conditions on the exercise or vesting of Awards in order to minimize the Company’s obligation with respect to tax
equalization for Employees on assignments outside their home country. 
 (o) If approved by the Committee in its sole discretion, an
Employee’s absence or leave because of military or governmental service, Total and Permanent Disability or other reason shall not be considered an interruption of employment for any purpose under the Plan; provided, however, that to the extent
an Award under this Plan is subject to Section 409A, such absence or leave shall be considered a Separation from Service to the extent provided by Section 409A. 
 SECTION 17. TERM OF PLAN 
 The Plan shall terminate on the tenth anniversary of the Effective
Date, unless sooner terminated by the Board pursuant to Section 13. 
 SECTION 18. COMPLIANCE WITH SECTION 16 

With respect to Participants subject to Section 16 of the Exchange Act (“Members”), transactions under the Plan are intended to comply
with all applicable conditions of Rule 16b-3 or its successors under the Exchange Act. To the extent that compliance with any Plan provision applicable solely to such Members that is included solely for purposes of complying with Rule 16b-3 is not
required in order to bring a transaction by such Member in compliance with Rule 16b-3, it shall be deemed null and void as to such transaction, to the extent permitted by law and deemed advisable by the Committee. To the extent any provision in the
Plan or action by the Committee involving such Members is deemed not to comply with an applicable condition of Rule 16b-3, it shall be deemed null and void as to such Members, to the extent permitted by law and deemed advisable by the Committee.

  
 16 

 APPENDIX A 
 GRANDFATHERED BENEFITS 
 Distribution, settlement or payment of amounts
that were earned and vested (within the meaning of Section 409A) under the Plan prior to 2005 (and earnings thereon) and are exempt from the requirements of Section 409A shall be made in accordance with certain Plan terms as in effect on
December 31, 2004, and as set forth in this Appendix A. Unless otherwise specified in this Appendix A, Grandfathered Benefits shall be governed by the terms of the Plan. 

 
 SECTION 2. DEFINITIONS 
 As used in this Appendix A, all terms have the same meaning as defined in Section 2 of the Plan, except as set forth below: 
 (a)  “Fair Market Value” shall mean, with respect to Shares, as of any date, the average of the high and low trading prices for the Shares as reported on the New York Stock Exchange
for that date or, if no such prices are reported for that date, the average of the high and low trading prices on the next preceding date for which such prices were reported, unless otherwise determined by the Committee. 

SECTION 6. STOCK OPTIONS 
 Options may be
granted hereunder to any Participant, either alone or in addition to other Awards granted under the Plan and shall be subject to the following terms and conditions: 
 (a)  Option Price. The option price per Share shall be not less than the Fair Market Value of the Shares on the date the Option is granted. 

(b)  Number of Shares. The Option shall state the number of Shares covered thereby. 
 (c)  Exercise of Option. Unless otherwise determined by the Committee, an Option will be deemed exercised by the optionee, or in the event of death, an option shall be deemed exercised by the
estate of the optionee, or by a person who acquired the right to exercise such option by bequest or inheritance or by reason of the death of the optionee, upon delivery of (i) a notice of exercise to the Company or its representative, or by
using other methods of notice as the Committee shall adopt, and (ii) accompanying payment of the option price in accordance with any restrictions as the Committee shall adopt. The notice of exercise, once delivered, shall be irrevocable.
Notwithstanding the above, and unless the Committee determines otherwise, in the event that (i) an optionee dies, (ii) his representative has a right to exercise an Option, (iii) the Option is not exercised by the last day on which it
is exercisable, and (iv) the option price per share is below the Fair Market Value of a Share on such date, the Option shall be deemed exercised on such date via a cashless exercise procedure and the resulting proceeds net of any required tax
withholding shall be paid to the representative. 
 (d)  Other Provisions. The Option shall also be subject to such other terms and
conditions as the Committee shall deem advisable or appropriate, consistent with the provisions of the Plan as herein set forth. In addition, Incentive Stock Options shall contain such other provisions as may be necessary to meet the requirements of
the Code and the Treasury Department rulings and regulations issued thereunder with respect to Incentive Stock Options. 

  
 17 

 SECTION 9. PERFORMANCE AWARDS 
 Performance Awards may be paid in cash, Shares, other property, or any combination thereof, and may be subject to such other terms and conditions as the Committee shall deem advisable or appropriate,
consistent with the provisions of the Plan as set forth, in the sole discretion of the Committee at the time of payment. The performance levels to be achieved for each Performance Period and the amount of the Award to be distributed shall be
conclusively determined by the Committee. Performance Awards may be paid in a lump sum or in installments following the close of the Performance Period or, in accordance with procedures established by the Committee, on a deferred basis. 

SECTION 10. OTHER STOCK UNIT AWARDS 

(a)  Stock and Administration. Awards that are valued by reference to, or are otherwise based on, Shares (“Other Stock Unit Awards”)
may be granted hereunder to Participants, either alone or in addition to other Awards granted under the Plan, and such Other Stock Unit Awards shall also be available as a form of payment in the settlement of other Awards granted under the Plan.
Other Stock Unit Awards may be paid in Shares, cash or any other form of property, as the Committee shall determine. Subject to the provisions of the Plan, the Committee shall have sole and complete authority to determine the Employees to whom and
the time or times at which such Awards shall be made, the number of Shares to be granted pursuant to such Awards, and all other conditions of the Awards. Any Other Stock Unit Awards shall be subject to such other terms and conditions as the
Committee shall deem advisable or appropriate, consistent with the provisions of the Plan as herein set forth. Unless the Committee determines otherwise to address specific considerations, Other Stock Unit Awards granted to Employees shall have a
vesting period of not less than one year. 
 (b)  Other Provisions. Shares (including securities convertible into Shares) subject to
Awards granted under this Section 10 may be issued for no cash consideration or for such minimum consideration as may be required by applicable law. 
 SECTION 11. CHANGE IN CONTROL PROVISIONS 
 (a)  Unless the Committee or Board shall
determine otherwise at the time of grant with respect to a particular Award, and notwithstanding any other provision of the Plan to the contrary, in the event a Participant’s employment or service is involuntarily terminated without cause (as
determined by the Committee or Board in its sole discretion) during the 24-month period following a Change in Control: 
   (i) any
Options and Stock Appreciation Rights outstanding, and which are not then exercisable and vested, shall become immediately fully vested and exercisable; 
   (ii) the restrictions and deferral limitations applicable to any Restricted Stock shall lapse, and such Restricted Stock shall immediately become free of all restrictions and limitations and
become fully vested and transferable to the full extent of the original grant; 
   (iii) all Performance Awards shall be considered to
be earned and payable in full, based on the applicable performance criteria or, if not determinable, at the target level and any deferral or other restriction shall lapse and such Performance Awards shall be immediately settled or distributed; and

   (iv) the restrictions and deferral limitations and other conditions applicable to any other Stock Unit Awards or any other Awards
shall immediately lapse, and any such Other Stock Unit Awards or such other Awards shall become free of all restrictions, limitations or conditions and become fully vested and transferable to the full extent of the original grant. 

(b) Change in Control Cash Out. Notwithstanding any other provision of the Plan, in the event of a Change in Control the Committee or Board may, in its
discretion, provide that each Option or Stock Appreciation 

  
 18 

 
Right shall, upon the occurrence of a Change in Control, be cancelled in exchange for a cash payment to be made within 60 days of the Change in Control in an amount equal to the amount by which
the Change in Control Price per Share exceeds the purchase price per Share under the Option or Stock Appreciation Right (the “spread”) multiplied by the number of Shares granted under the Option or Stock Appreciation Right. 

  
 19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}]]